# Guillermo Garcia-Manero

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4134359/publications.pdf

Version: 2024-02-01

| 1,556 | 64,023 | 668 122 | 1745 212 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 1567 | 1567 | 1567 | 43310 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. American Journal of Hematology, 2023, 98, . | 2.0 | 11 |
| 2 | Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia, 2022, 36, 257-262. | 3.3 | 19 |
| 3 | Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia and Lymphoma, 2022, 63, 199-204. | 0.6 | 3 |
| 4 | SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 1-16. | 0.2 | 20 |
| 5 | Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 236-250. | 0.2 | 10 |
| 6 | The cure of leukemia through the optimist's prism. Cancer, 2022, 128, 240-259. | 2.0 | 17 |
| 7 | Prediction of early (4â€week) mortality in acute myeloid leukemia with intensive chemotherapy. American Journal of Hematology, 2022, 97, 68-78. | 2.0 | 25 |
| 8 | Dr. Elihu H. Estey (1946â€“2021). American Journal of Hematology, 2022, 97, 166-167. | 2.0 | 0 |
| 9 | Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia, 2022, 36, 1189-1192. | 3.3 | 5 |
| 10 | Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. Journal of Hematology and Oncology, 2022, 15, 12. | 6.9 | 13 |
| 11 | Improved outcomes among newly diagnosed patients with <scp>FMSâ€like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. American Journal of Hematology, 2022, 97, 329-337. | 2.0 | 15 |
| 12 | Time to blur the blast boundaries. Cancer, 2022, 128, 1568-1570. | 2.0 | 11 |
| 13 | NCCN GuidelinesÂ® Insights: Myelodysplastic Syndromes, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 106-117. | 2.3 | 54 |
| 14 | Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2022, 97, 574-582. | 2.0 | 9 |
| 15 | Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia, 2022, 36, 1253-1260. | 3.3 | 9 |
| 16 | Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia, 2022, 36, 1432-1435. | 3.3 | 5 |
| 17 | Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study. Leukemia and Lymphoma, 2022, 63, 1660-1668. | 0.6 | 10 |
| 18 | Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567. | 15.2 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | <scp>Treatmentâ€free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American Journal of Hematology, 2022, 97, 856-864. | 2.0 | 33 |
| 20 | Prediction of survival with intensive chemotherapy in acute myeloid leukemia. American Journal of Hematology, 2022, 97, 865-876. | 2.0 | 12 |
| 21 | Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022, 13, 1970. | 5.8 | 34 |
| 22 | Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases. Annals of Diagnostic Pathology, 2022, 59, 151951. | 0.6 | 1 |
| 23 | Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American Journal of Hematology, 2022, 97, 885-894. | 2.0 | 4 |
| 24 | A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 2161-2170. | 0.6 | 12 |
| 25 | Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study. Cancer, 2022, 128, 2736-2745. | 2.0 | 8 |
| 26 | Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematology,the, 2022, 9, e350-e360. | 2.2 | 26 |
| 27 | Hypomethylating agent and venetoclax with FLT3 inhibitor â€œtripletâ€•therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer Journal, 2022, 12, 77. | 2.8 | 33 |
| 28 | Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Modern Pathology, 2022, 35, 1212-1219. | 2.9 | 10 |
| 29 | Venetoclax combined with <scp>FLAGâ€IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, 1035-1043. | 2.0 | 31 |
| 30 | Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia, 2022, 36, 2097-2107. | 3.3 | 2 |
| 31 | Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2022, 40, 3848-3857. | 0.8 | 41 |
| 32 | Treating Leukemia in the Time of COVID-19. Acta Haematologica, 2021, 144, 132-145. | 0.7 | 57 |
| 33 | The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia, 2021, 35, 691-700. | 3.3 | 37 |
| 34 | Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica, 2021, 106, 894-898. | 1.7 | 80 |
| 35 | Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53. | 2.0 | 8 |
| 36 | Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia â€“ a distinct subtype with favorable prognosis. Leukemia and Lymphoma, 2021, 62, 224-228. | 0.6 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatmentâ€related mortality. American Journal of Hematology, 2021, 96, 282-291. | 2.0 | 59 |
| 38 | Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery, 2021, 2, 125-134. | 2.6 | 50 |
| 39 | The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. American Journal of Hematology, 2021, 96, 241-250. | 2.0 | 19 |
| 40 | Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience. Leukemia and Lymphoma, 2021, 62, 909-917. | 0.6 | 11 |
| 41 | Validation of International Working Group response criteria in higherâ€risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. Cancer Medicine, 2021, 10, 447-453. | 1.3 | 24 |
| 42 | Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 â€ITD and IDH mutations. Cancer, 2021, 127, 381-390. | 2.0 | 10 |
| 43 | Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics, 2021, 16, 567-576. | 1.3 | 9 |
| 44 | Phase 2 study of lenalidomide maintenance for patients with highâ€risk acute myeloid leukemia in remission. Cancer, 2021, 127, 1894-1900. | 2.0 | 5 |
| 45 | Daratumumab in transfusionâ€dependent patients with low or intermediateâ€<scp>1</scp> risk myelodysplastic syndromes. American Journal of Hematology, 2021, 96, E111-E114. | 2.0 | 0 |
| 46 | Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818. | | 14 |
| 47 | Acute myeloid leukemia: current progress and future directions. Blood Cancer Journal, 2021, 11, 41. | 2.8 | 313 |
| 48 | Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Modern Pathology, 2021, 34, 1143-1152. | 2.9 | 12 |
| 49 | Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leukemia Research, 2021, 101, 106511. | 0.4 | 4 |
| 50 | Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. Leukemia and Lymphoma, 2021, 62, 1774-1777. | 0.6 | 0 |
| 51 | Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer Journal, 2021, 11, 52. | 2.8 | 5 |
| 52 | Outcome of Tâ€cell acute lymphoblastic leukemia/lymphoma: Focus on <scp>nearâ€ETP</scp> phenotype and differential impact of nelarabine. American Journal of Hematology, 2021, 96, 589-598. | 2.0 | 42 |
| 53 | Associations between complete remission and 2- to 3-year survival following 7â€‰+â€‰3 induction for acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 1967-1972. | 0.6 | 1 |
| 54 | Longâ€term followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and miniâ€“hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2021, 127, 2025-2038. | 2.0 | 24 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<scp>MDS/MPNâ€RSâ€T</scp>) and myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>). American Journal of Hematology, 2021, 96, E246-E249. | 2.0 | 9 |
| 56 | Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Advances, 2021, 5, 2173-2183. | 2.5 | 35 |
| 57 | A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica, 2021, 106, 2121-2130. | 1.7 | 34 |
| 58 | Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer, 2021, 127, 3113-3124. | 2.0 | 5 |
| 59 | Prognostic factors for progression in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer, 2021, 127, 2648-2656. | 2.0 | 33 |
| 60 | Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes. Frontiers in Immunology, 2021, 12, 659625. | 2.2 | 6 |
| 61 | Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia treated with hyperâ€CVAD and dasatinib. Cancer, 2021, 127, 2641-2647. | 2.0 | 15 |
| 62 | Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Advances, 2021, 5, 1876-1883. | 2.5 | 56 |
| 63 | Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 1494-1499. | 3.3 | 16 |
| 64 | Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia, 2021, 35, 3282-3286. | 3.3 | 61 |
| 65 | Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer Journal, 2021, 11, 98. | 2.8 | 24 |
| 66 | Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1584-1594. | 0.8 | 278 |
| 67 | Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nature Communications, 2021, 12, 2607. | 5.8 | 61 |
| 68 | Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1426-1436. | 0.8 | 49 |
| 69 | A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival. Leukemia Research, 2021, 104, 106555. | 0.4 | 18 |
| 70 | Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 338-344. | 0.2 | 7 |
| 71 | Longâ€term results of lowâ€intensity chemotherapy with clofarabine or cladribine combined with lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2021, 96, 914-924. | 2.0 | 13 |
| 72 | Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.. Journal of Clinical Oncology, 2021, 39, 7001-7001. | 0.8 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Frontiers in Oncology, 2021, 11, 656218. | 1.3 | 63 |
| 74 | Targeting health-related quality of life in patients with myelodysplastic syndromes â€“ Current knowledge and lessons to be learned. Blood Reviews, 2021, 50, 100851. | 2.8 | 14 |
| 75 | What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?. Leukemia and Lymphoma, 2021, 62, 2762-2767. | 0.6 | 6 |
| 76 | A phase 1b/2 study of azacitidine with PDâ€Ł1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer, 2021, 127, 3761-3771. | 2.0 | 34 |
| 77 | Outcomes in patients with newly diagnosed TP53â€mutated acute myeloid leukemia with or without venetoclaxâ€based therapy. Cancer, 2021, 127, 3541-3551. | 2.0 | 40 |
| 78 | Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia, 2021, 35, 3542-3550. | 3.3 | 97 |
| 79 | Hyperâ€CVAD plus ofatumumab versus hyperâ€CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2021, 127, 3381-3389. | 2.0 | 10 |
| 80 | Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer, 2021, 127, 3552-3565. | 2.0 | 19 |
| 81 | Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Advances, 2021, 5, 3163-3173. | 2.5 | 17 |
| 82 | Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e552-e561. | 2.2 | 81 |
| 83 | Phase II study of single-agent nivolumab in patients with myelofibrosis. Annals of Hematology, 2021, 100, 2957-2960. | 0.8 | 11 |
| 84 | Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 3737-3746. | 0.8 | 90 |
| 85 | Phase II study of azacitidine with pembrolizumab in patients with intermediateâ€1 or higherâ€risk myelodysplastic syndrome. British Journal of Haematology, 2021, 195, 378-387. | 1.2 | 32 |
| 86 | Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S73-S76. | 0.2 | 0 |
| 87 | Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer Journal, 2021, 11, 162. | 2.8 | 32 |
| 88 | Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Advances, 2021, 5, 5415-5419. | 2.5 | 24 |
| 89 | MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-NaÃ¯ve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S343. | 0.2 | 4 |
| 90 | MDS-439: A Simplified Three-Marker Panel for Myelodysplastic Syndrome Prognostic Outperforms the Well-Established Revised International Prognostic Scoring Systems (IPSS-R). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S351. | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | MDS-404: Population Pharmacokinetics Modeling and Evaluation of Clinical Efficacy and Safety of Sabatolimab: Dose Selection and Dose-Response Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S349-S350. | 0.2 | 0 |
| 92 | Poster: MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-NaÃ¯ve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S227. | 0.2 | 0 |
| 93 | Poster: MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Highâ€“Risk Myelodysplastic Syndromes (MDS). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S230. | 0.2 | 0 |
| 94 | MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Highâ€“Risk Myelodysplastic Syndromes (MDS). Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S348-S349. | 0.2 | 1 |
| 95 | Poster: AML-204: Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S213. | 0.2 | 0 |
| 96 | AML-291: Treatment Response and Outcome in DNMT3A-mutated Acute Myeloblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S301-S302. | 0.2 | 0 |
| 97 | Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2768-2778. | 0.8 | 173 |
| 98 | Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to antiâ€“PD-1â€“based therapy. Blood Advances, 2021, 5, 4569-4574. | 2.5 | 15 |
| 99 | The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica, 2021, 106, 2853-2858. | 1.7 | 15 |
| 100 | Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nature Communications, 2021, 12, 6071. | 5.8 | 44 |
| 101 | Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leukemia and Lymphoma, 2021, 62, 1187-1194. | 0.6 | 6 |
| 102 | Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study. Blood, 2021, 138, 66-66. | 0.6 | 7 |
| 103 | Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome. Blood, 2021, 138, 537-537. | 0.6 | 13 |
| 104 | Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance. Blood, 2021, 138, 370-370. | 0.6 | 6 |
| 105 | Impact of Frontline Treatment Approach in Patients with Secondary AML and Prior Hypomethylating Agent Exposure: A Retrospective Analysis of 562 Patients with Treated Secondary AML. Blood, 2021, 138, 794-794. | 0.6 | 2 |
| 106 | Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML. Blood, 2021, 138, 4652-4652. | 0.6 | 1 |
| 107 | A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1239-1239. | 0.6 | 9 |
| 108 | High-Throughput Characterization of Cytogenomic Heterogeneity of MDS Using High-Resolution Optical Genome Mapping. Blood, 2021, 138, 105-105. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3363-3363. | 0.6 | 0 |
| 110 | Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2021, 138, 3421-3421. | 0.6 | 3 |
| 111 | Clinical Outcomes of Patients with Newly Diagnosed Myelodysplastic Syndrome with MLL Aberrations. Blood, 2021, 138, 4673-4673. | 0.6 | 0 |
| 112 | Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood, 2021, 138, 246-246. | 0.6 | 21 |
| 113 | Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial. Blood, 2021, 138, 538-538. | 0.6 | 2 |
| 114 | Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML). Blood, 2021, 138, 3409-3409. | 0.6 | 14 |
| 115 | A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 4398-4398. | 0.6 | 1 |
| 116 | Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood, 2021, 138, 2323-2323. | 0.6 | 2 |
| 117 | Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood, 2021, 138, 631-631. | 0.6 | 1 |
| 118 | Phase II Study of Lower-Intensity Frontline Therapy for Newly Diagnosed Patients with AML Who Are Unfit or Otherwise Not Eligible for Frontline Clinical Trials. Blood, 2021, 138, 4420-4420. | 0.6 | 0 |
| 119 | The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors. Blood, 2021, 138, 2554-2554. | 0.6 | 2 |
| 120 | Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect Â® Myeloid Disease Registry. Blood, 2021, 138, 3686-3686. | 0.6 | 2 |
| 121 | Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study. Blood, 2021, 138, 244-244. | 0.6 | 60 |
| 122 | Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , . | 2.9 | 9 |
| 123 | Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax. Blood, 2021, 138, 1304-1304. | 0.6 | 2 |
| 124 | Single-Cell RNA Sequencing Analysis Reveals Mechanisms of Initiation and Progression in Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 2588-2588. | 0.6 | 0 |
| 125 | A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. Blood, 2021, 138, 2326-2326. | 0.6 | 1 |
| 126 | Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. Blood, 2021, 138, 3677-3677. | 0.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Characteristics and Outcomes of Adult Patients with Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Single-Center, Prospective Analysis. Blood, 2021, 138, 1213-1213. | 0.6 | 0 |
| 128 | Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood, 2021, 138, 2349-2349. | 0.6 | 7 |
| 129 | Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3400-3400. | 0.6 | 8 |
| 130 | Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 3664-3664. | 0.6 | 0 |
| 131 | Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Blood, 2021, 138, 701-701. | 0.6 | 4 |
| 132 | NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). Blood, 2021, 138, 2287-2287. | 0.6 | 0 |
| 133 | Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. Blood, 2021, 138, 2319-2319. | 0.6 | 0 |
| 134 | Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1233-1233. | 0.6 | 3 |
| 135 | The Transcriptional and Epigenetic Reprogramming of Aged Hematopoietic Stem Cells Drives Myeloid Rewiring in Clonal Hematopoiesis-Associated Cytopenias. Blood, 2021, 138, 3273-3273. | 0.6 | 0 |
| 136 | Final Results of a Phase 2 Study of Sotatercept (ACE-011) for Anemia of MPN-Associated Myelofibrosis. Blood, 2021, 138, 144-144. | 0.6 | 9 |
| 137 | Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. Blood, 2021, 138, 2613-2613. | 0.6 | 1 |
| 138 | Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study. Blood, 2021, 138, 1524-1524. | 0.6 | 4 |
| 139 | A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-NaÃ¯ve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 535-535. | 0.6 | 7 |
| 140 | A Phase I Study of the Combination of Venetoclax and Azacitidine in Relapse/Refractory Higher Risk Myelodysplastic Syndrome (MDS). Blood, 2021, 138, 3704-3704. | 0.6 | 2 |
| 141 | Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML). Blood, 2021, 138, 2330-2330. | 0.6 | 3 |
| 142 | A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Blood, 2021, 138, 696-696. | 0.6 | 33 |
| 143 | Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study. Blood, 2021, 138, 1527-1527. | 0.6 | 0 |
| 144 | Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia. Blood, 2021, 138, 1224-1224. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Clinical Characteristics and Outcomes of Patients Diagnosed with Acute Myeloid Leukemia with Expression of CD71. Blood, 2021, 138, 4449-4449. | 0.6 | 0 |
| 146 | Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial. Blood, 2021, 138, 1517-1517. | 0.6 | 1 |
| 147 | Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood, 2021, 138, 1270-1270. | 0.6 | 1 |
| 148 | Updated Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents. Blood, 2021, 138, 3674-3674. | 0.6 | 2 |
| 149 | A Phase I/II Study of Venetoclax in Combination with ASTX727 (cedazuridine/decitabine) in Treatment-NaÃ¯ve High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2021, 138, 245-245. | 0.6 | 2 |
| 150 | Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study. Blood, 2021, 138, 3682-3682. | 0.6 | 1 |
| 151 | Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. Blood, 2021, 138, 798-798. | 0.6 | 5 |
| 152 | Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis. Blood, 2021, 138, 3687-3687. | 0.6 | 1 |
| 153 | Molecular Responses Are Observed across Mutational Spectrum in Treatment-NaÃ¯ve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine. Blood, 2021, 138, 241-241. | 0.6 | 20 |
| 154 | Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program. Blood, 2021, 138, 4669-4669. | 0.6 | 10 |
| 155 | Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2021, 138, 367-367. | 0.6 | 3 |
| 156 | Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood, 2021, 138, 694-694. | 0.6 | 0 |
| 157 | Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations. Blood, 2021, 138, 1536-1536. | 0.6 | 2 |
| 158 | A Phase I/II Study of Sapacitabine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2021, 138, 3419-3419. | 0.6 | 1 |
| 159 | Hematopoiesis under telomere attrition at the single-cell resolution. Nature Communications, 2021, 12, 6850. | 5.8 | 15 |
| 160 | Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood, 2021, 138, 371-371. | 0.6 | 41 |
| 161 | Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2021, 138, 2298-2298. | 0.6 | 19 |
| 162 | Investigating protein patterns in human leukemia cell line experiments: A Bayesian approach for extremely small sample sizes. Statistical Methods in Medical Research, 2020, 29, 1181-1196. | 0.7 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. British Journal of Haematology, 2020, 188, 404-412. | 1.2 | 9 |
| 164 | Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. American Journal of Hematology, 2020, 95, 227-229. | 2.0 | 29 |
| 165 | Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia, 2020, 34, 872-881. | 3.3 | 22 |
| 166 | The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphiaâ€negative Bâ€cell acute lymphoblastic leukemia is a strong predictor for survival. American Journal of Hematology, 2020, 95, 144-150. | 2.0 | 25 |
| 167 | Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151. | 13.9 | 335 |
| 168 | Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer, 2020, 126, 765-774. | 2.0 | 69 |
| 169 | Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nature Communications, 2020, 11, 5327. | 5.8 | 208 |
| 170 | Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. Journal of Hematology and Oncology, 2020, 13, 132. | 6.9 | 18 |
| 171 | 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology,the, 2020, 7, e724-e736. | 2.2 | 201 |
| 172 | Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. British Journal of Haematology, 2020, 191, e10-e13. | 1.2 | 2 |
| 173 | Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leukemia and Lymphoma, 2020, 61, 2811-2820. | 0.6 | 7 |
| 174 | Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1288-1295. | 2.0 | 28 |
| 175 | A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Advances, 2020, 4, 5580-5588. | 2.5 | 122 |
| 176 | Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1â€“Risk Myelodysplastic Syndromes. Annals of Internal Medicine, 2020, 172, 513. | 2.0 | 78 |
| 177 | Fidelity of peripheral blood for monitoring genomics and tumor immuneâ€microenvironment in myelodysplastic syndromes. EJHaem, 2020, 1, 552-557. | 0.4 | 3 |
| 178 | Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. American Journal of Hematology, 2020, 95, 1399-1420. | 2.0 | 119 |
| 179 | Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e523-e533. | 2.2 | 43 |
| 180 | Survivorship in AML â€“ a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leukemia and Lymphoma, 2020, 61, 3120-3127. | 0.6 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). American Journal of Hematology, 2020, 95, E326-E329. | 2.0 | 2 |
| 182 | Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the ConnectÂ®MDS/AML Disease Registry. EJHaem, 2020, 1, 58-68. | 0.4 | 5 |
| 183 | Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. American Journal of Hematology, 2020, 95, E313-E315. | 2.0 | 4 |
| 184 | ALL-216: Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S164-S165. | 0.2 | 0 |
| 185 | AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S188-S189. | 0.2 | 13 |
| 186 | AML-314: Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S201-S202. | 0.2 | 0 |
| 187 | AML-318: Predictors of Outcomes in AML with MLL Rearrangement. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S202-S203. | 0.2 | 0 |
| 188 | MDS-141: The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S315-S316. | 0.2 | 1 |
| 189 | MDS-179: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S318-S319. | 0.2 | 0 |
| 190 | Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Advances, 2020, 4, 5681-5689. | 2.5 | 105 |
| 191 | Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders. Haematologica, 2020, 105, 1567-1574. | 1.7 | 25 |
| 192 | Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leukemia Research, 2020, 94, 106369. | 0.4 | 15 |
| 193 | SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170. | 0.6 | 195 |
| 194 | Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia, 2020, 34, 2914-2924. | 3.3 | 7 |
| 195 | The clinical impact of time to response in de novo acceleratedâ€phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1127-1134. | 2.0 | 8 |
| 196 | Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Modern Pathology, 2020, 33, 1678-1689. | 2.9 | 16 |
| 197 | Phase 2 study of hyperâ€CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, 734-739. | 2.0 | 10 |
| 198 | A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 2020, 34, 2489-2492. | 3.3 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. American Journal of Hematology, 2020, 95, 612-622. | 2.0 | 51 |
| 200 | Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer, 2020, 126, 2193-2205. | 2.0 | 33 |
| 201 | LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leukemia and Lymphoma, 2020, 61, 1493-1499. | 0.6 | 14 |
| 202 | MDS/MPN-RS-T justified inclusion as a unique disease entity?. Best Practice and Research in Clinical Haematology, 2020, 33, 101147. | 0.7 | 1 |
| 203 | Longâ€term results of frontline dasatinib in chronic myeloid leukemia. Cancer, 2020, 126, 1502-1511. | 2.0 | 21 |
| 204 | Clinical value of event-free survival in acute myeloid leukemia. Blood Advances, 2020, 4, 1690-1699. | 2.5 | 4 |
| 205 | Results of a Phase 1/2a doseâ€“escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. Leukemia and Lymphoma, 2020, 61, 1943-1953. | 0.6 | 2 |
| 206 | Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Advances, 2020, 4, 1670-1677. | 2.5 | 24 |
| 207 | Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nature Immunology, 2020, 21, 535-545. | 7.0 | 92 |
| 208 | Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Advances, 2020, 4, 482-495. | 2.5 | 86 |
| 209 | Longâ€term results of a phase 2 trial of nilotinib 400Âmg twice daily in newly diagnosed patients with chronicâ€phase chronic myeloid leukemia. Cancer, 2020, 126, 1448-1459. | 2.0 | 14 |
| 210 | t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?. Annals of Hematology, 2020, 99, 487-500. | 0.8 | 6 |
| 211 | Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). Blood, 2020, 136, 37-38. | 0.6 | 16 |
| 212 | Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood, 2020, 136, 18-20. | 0.6 | 17 |
| 213 | Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the Medalist Study. Blood, 2020, 136, 10-12. | 0.6 | 6 |
| 214 | Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood, 2020, 136, 9-11. | 0.6 | 13 |
| 215 | Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy. Blood, 2020, 136, 23-24. | 0.6 | 7 |
| 216 | Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood, 2020, 136, 674-683. | 0.6 | 144 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2020, 38, 7539-7539. | 0.8 | 6 |
| 218 | MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 37-48. | 0.6 | 54 |
| 219 | Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Advances, 2019, 3, 508-518. | 2.5 | 62 |
| 220 | Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3â€internal tandem duplication mutationâ€“positive acute myeloid leukemia. Cancer, 2019, 125, 3755-3766. | 2.0 | 38 |
| 221 | Philadelphia chromosomeâ€positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. American Journal of Hematology, 2019, 94, 1388-1395. | 2.0 | 26 |
| 222 | Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Medicine, 2019, 8, 6559-6565. | 1.3 | 24 |
| 223 | Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematology,the, 2019, 6, e480-e488. | 2.2 | 103 |
| 224 | Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S181. | 0.2 | 0 |
| 225 | Evolution of the AML Genome and Epigenome during IDH Inhibitor Therapy and their Association with Clinical Response and Resistance. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S238-S239. | 0.2 | 0 |
| 226 | Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S180-S181. | 0.2 | 0 |
| 227 | Duplex Sequencing Identifies Low Level ABL1 Kinase Domain Mutations in Untreated Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S186. | 0.2 | 0 |
| 228 | Phase 1/2 study of DFPâ€10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer, 2019, 125, 1665-1673. | 2.0 | 5 |
| 229 | Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leukemia and Lymphoma, 2019, 60, 3172-3180. | 0.6 | 2 |
| 230 | Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification. Theranostics, 2019, 9, 3768-3779. | 4.6 | 24 |
| 231 | Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer, 2019, 125, 3219-3224. | 2.0 | 14 |
| 232 | Prognostic significance of baseline FLT3â€ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991. | 2.0 | 32 |
| 233 | Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematology,the, 2019, 6, e317-e327. | 2.2 | 71 |
| 234 | Inotuzumab ozogamicin in combination with lowâ€intensity chemotherapy (miniâ€HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2019, 125, 2579-2586. | 2.0 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. International Journal of Hematology, 2019, 109, 545-552. | 0.7 | 25 |
| 236 | Clonal hematopoiesis of indeterminate potentialâ€“associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer, 2019, 125, 2233-2241. | 2.0 | 19 |
| 237 | DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and highâ€risk disease. American Journal of Hematology, 2019, 94, 757-766. | 2.0 | 86 |
| 238 | Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts. American Journal of Hematology, 2019, 94, E188-E190. | 2.0 | 4 |
| 239 | An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematology,the, 2019, 6, e194-e203. | 2.2 | 97 |
| 240 | Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a PhaseÂIIIÂTrial. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 213-219.e4. | 0.2 | 3 |
| 241 | Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia. Cancer, 2019, 125, 1855-1866. | 2.0 | 21 |
| 242 | The role of TGFÎ² in hematopoiesis and myeloid disorders. Leukemia, 2019, 33, 1076-1089. | 3.3 | 39 |
| 243 | A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leukemia and Lymphoma, 2019, 60, 2207-2213. | 0.6 | 11 |
| 244 | Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Advances, 2019, 3, 851-861. | 2.5 | 88 |
| 245 | NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Advances, 2019, 3, 922-933. | 2.5 | 84 |
| 246 | Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide. Medicine (United States), 2019, 98, e14011. | 0.4 | 10 |
| 247 | Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematological Oncology, 2019, 37, 96-102. | 0.8 | 8 |
| 248 | Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37. | 2.2 | 84 |
| 249 | Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383. | 7.7 | 380 |
| 250 | Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology and Oncology, 2019, 12, 1. | 6.9 | 257 |
| 251 | Fatigue, symptom burden, and healthâ€related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Cancer Medicine, 2019, 8, 543-553. | 1.3 | 32 |
| 252 | TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758. | 3.3 | 195 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. Leukemia, 2019, 33, 554-558. | 3.3 | 8 |
| 254 | Relative survival following response to 7â€‰+â€‰3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia, 2019, 33, 371-378. | 3.3 | 9 |
| 255 | A phase II study of omacetaxine mepesuccinate for patients with higherâ€risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. American Journal of Hematology, 2019, 94, 74-79. | 2.0 | 10 |
| 256 | Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3â€internal tandem duplication genotypes. Cancer, 2019, 125, 1091-1100. | 2.0 | 50 |
| 257 | The distribution of Tâ€cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer, 2019, 125, 1470-1481. | 2.0 | 229 |
| 258 | A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML. Blood, 2019, 134, 176-176. | 0.6 | 16 |
| 259 | Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2019, 134, 2647-2647. | 0.6 | 11 |
| 260 | KDM6B Overexpression and TET2 Deficiency Cooperatively Drive Development of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia-like Phenotype in Mice. Blood, 2019, 134, 562-562. | 0.6 | 2 |
| 261 | Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) Receiving First Salvage Chemotherapy. Blood, 2019, 134, 735-735. | 0.6 | 2 |
| 262 | Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. Blood, 2019, 134, 846-846. | 0.6 | 55 |
| 263 | Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 4243-4243. | 0.6 | 11 |
| 264 | Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 841-841. | 0.6 | 7 |
| 265 | Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial. Blood, 2019, 134, 2999-2999. | 0.6 | 3 |
| 266 | Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 673-673. | 0.6 | 66 |
| 267 | A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-NaÃ¯ve Patients with Higher-Risk Myelodysplastic Syndrome. Blood, 2019, 134, 568-568. | 0.6 | 43 |
| 268 | Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO. Blood, 2019, 134, 3851-3851. | 0.6 | 3 |
| 269 | Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies. Blood, 2019, 134, 3907-3907. | 0.6 | 17 |
| 270 | A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome. Blood, 2019, 134, 565-565. | 0.6 | 46 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. Blood, 2019, 134, 4581-4581. | 0.6 | 3 |
| 272 | Sequencing of Circulating Cell-Free DNA in Patients with AML Detects Clinically Significant Mutations Not Detected in Bone Marrow: The Role for Complementary Peripheral Blood and Bone Marrow Genomic Analysis. Blood, 2019, 134, 2592-2592. | 0.6 | 1 |
| 273 | Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood, 2019, 134, 823-823. | 0.6 | 12 |
| 274 | Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2019, 134, 283-283. | 0.6 | 34 |
| 275 | A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC). Blood, 2019, 134, 2652-2652. | 0.6 | 3 |
| 276 | Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS). Blood, 2019, 134, 567-567. | 0.6 | 9 |
| 277 | Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS). Blood, 2019, 134, 1726-1726. | 0.6 | 4 |
| 278 | Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute Myeloid Leukemia Than FLAG and Idarubicin (FLAG-Ida). Blood, 2019, 134, 290-290. | 0.6 | 19 |
| 279 | The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results. Blood, 2019, 134, 569-569. | 0.6 | 161 |
| 280 | Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2019, 134, 1641-1641. | 0.6 | 11 |
| 281 | Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients. Blood, 2019, 134, 47-47. | 0.6 | 2 |
| 282 | Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm). Blood, 2019, 134, 1447-1447. | 0.6 | 1 |
| 283 | Comprehensive Analysis of Genotype and Prior Exposures in Therapy-Related Myeloid Neoplasms (t-MNs). Blood, 2019, 134, 458-458. | 0.6 | 4 |
| 284 | Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood, 2019, 134, 2637-2637. | 0.6 | 15 |
| 285 | Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2019, 134, 570-570. | 0.6 | 64 |
| 286 | Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood, 2019, 134, 645-645. | 0.6 | 9 |
| 287 | Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood, 2019, 134, 1296-1296. | 0.6 | 4 |
| 288 | Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse. Blood, 2019, 134, 3806-3806. | 0.6 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood, 2019, 134, 2642-2642. | 0.6 | 2 |
| 290 | Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. Blood, 2019, 134, 1715-1715. | 0.6 | 2 |
| 291 | Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Blood, 2019, 134, 4240-4240. | 0.6 | 9 |
| 292 | Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 3807-3807. | 0.6 | 21 |
| 293 | Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response. Blood, 2019, 134, 3846-3846. | 0.6 | 2 |
| 294 | Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration. Blood, 2019, 134, 2957-2957. | 0.6 | 3 |
| 295 | Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis. Blood, 2019, 134, 555-555. | 0.6 | 17 |
| 296 | The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2019, 134, 1642-1642. | 0.6 | 4 |
| 297 | Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD). Blood, 2019, 134, 1299-1299. | 0.6 | 4 |
| 298 | Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL). Blood, 2019, 134, 3810-3810. | 0.6 | 9 |
| 299 | Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). Blood, 2019, 134, 678-678. | 0.6 | 26 |
| 300 | Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood, 2019, 134, 1656-1656. | 0.6 | 5 |
| 301 | Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A (MLL) Rearrangement. Blood, 2019, 134, 2582-2582. | 0.6 | 2 |
| 302 | Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML). Blood, 2019, 134, 676-676. | 0.6 | 59 |
| 303 | The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Blood, 2019, 134, 1436-1436. | 0.6 | 4 |
| 304 | Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. Blood, 2019, 134, 830-830. | 0.6 | 38 |
| 305 | Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30). Blood, 2019, 134, 3015-3015. | 0.6 | 1 |
| 306 | Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood, 2019, 134, 566-566. | 0.6 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome. Blood, 2019, 134, 3016-3016. | 0.6 | 5 |
| 308 | Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy. Blood, 2019, 134, 1312-1312. | 0.6 | 6 |
| 309 | Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS). Blood, 2019, 134, 4268-4268. | 0.6 | 3 |
| 310 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. Blood, 2019, 134, 2723-2723. | 0.6 | 14 |
| 311 | A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy. Blood, 2019, 134, 2927-2927. | 0.6 | 3 |
| 312 | Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR). Blood, 2019, 134, 287-287. | 0.6 | 0 |
| 313 | Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib. Blood, 2019, 134, 2753-2753. | 0.6 | 0 |
| 314 | Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the ConnectÂ® MDS/AML Registry. Blood, 2019, 134, 4747-4747. | 0.6 | 0 |
| 315 | Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). Blood, 2019, 134, 2941-2941. | 0.6 | 1 |
| 316 | Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 2577-2577. | 0.6 | 3 |
| 317 | Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. Blood, 2019, 134, 291-291. | 0.6 | 3 |
| 318 | ILF2 Antisense Oligonucleotide Therapy and a CRISPR/Cas9-Based Screening for DNA Repair Effectors Identify Synthetic Lethal Approaches Enhancing Myeloma Cells Sensitivity to DNA Damage. Blood, 2019, 134, 685-685. | 0.6 | 0 |
| 319 | The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood, 2019, 134, 3815-3815. | 0.6 | 0 |
| 320 | Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome. Blood, 2019, 134, 1720-1720. | 0.6 | 0 |
| 321 | Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome. Blood, 2019, 134, 4252-4252. | 0.6 | 0 |
| 322 | High-Resolution Next-Generation Whole Genome Optical Mapping As a Novel Molecular Diagnostic Tool for Comprehensive Assessment of Structural Chromosomal Variations in Myelodysplastic Syndromes. Blood, 2019, 134, 5438-5438. | 0.6 | 0 |
| 323 | Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2019, 134, 1719-1719. | 0.6 | 0 |
| 324 | Comprehensive DNA 5-Hydroxymethylation Landscapes in Myelodysplastic Syndromes (MDS). Blood, 2019, 134, 2996-2996. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes. Blood, 2019, 134, 1711-1711. | 0.6 | 0 |
| 326 | Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype. Blood, 2019, 134, 3834-3834. | 0.6 | 0 |
| 327 | Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy. Blood, 2019, 134, 2641-2641. | 0.6 | 0 |
| 328 | Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy. Blood, 2019, 134, 647-647. | 0.6 | 0 |
| 329 | Single-Cell RNA Sequencing Reveals Distinct Hematopoietic Stem Cell Hierarchies in MDS. Blood, 2019, 134, 771-771. | 0.6 | 2 |
| 330 | Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 512-512. | 0.6 | 0 |
| 331 | Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood, 2019, 134, 17-17. | 0.6 | 0 |
| 332 | Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet. Blood, 2019, 134, 2930-2930. | 0.6 | 0 |
| 333 | The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults. Blood, 2019, 134, 4249-4249. | 0.6 | 1 |
| 334 | Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS). Blood, 2019, 134, 2578-2578. | 0.6 | 1 |
| 335 | A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood, 2019, 134, 4237-4237. | 0.6 | 0 |
| 336 | Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2311-E2319. | 3.3 | 9 |
| 337 | Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCRâ€“ABL kinase domain mutations. International Journal of Hematology, 2018, 107, 689-695. | 0.7 | 9 |
| 338 | Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia, 2018, 32, 1094-1105. | 3.3 | 164 |
| 339 | Improving the detection of patients with inherited predispositions to hematologic malignancies using nextâ€generation sequencingâ€based leukemia prognostication panels. Cancer, 2018, 124, 2704-2713. | 2.0 | 39 |
| 340 | Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer, 2018, 124, 2534-2540. | 2.0 | 23 |
| 341 | Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. American Journal of Surgical Pathology, 2018, 42, 799-806. | 2.1 | 29 |
| 342 | Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematology,the, 2018, 5, e63-e72. | 2.2 | 95 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome. Modern Pathology, 2018, 31, 1141-1154. | 2.9 | 23 |
| 344 | Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial. Leukemia and Lymphoma, 2018, 59, 2135-2143. | 0.6 | 5 |
| 345 | Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 240-248. | 5.1 | 192 |
| 346 | Outcomes with lower intensity therapy inTP53-mutated acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2238-2241. | 0.6 | 20 |
| 347 | Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 2018, 131, 1820-1832. | 0.6 | 40 |
| 348 | Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. Current Opinion in Hematology, 2018, 25, 146-153. | 1.2 | 22 |
| 349 | Prediction for sustained deep molecular response of BCRâ€ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer, 2018, 124, 1160-1168. | 2.0 | 23 |
| 350 | Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematology,the, 2018, 5, e136-e146. | 2.2 | 42 |
| 351 | Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Annals of Hematology, 2018, 97, 1183-1191. | 0.8 | 12 |
| 352 | The emerging role of immune checkpoint based approaches in AML and MDS. Leukemia and Lymphoma, 2018, 59, 790-802. | 0.6 | 90 |
| 353 | A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 813-820. | 0.6 | 16 |
| 354 | Hyperâ€CVAD plus nelarabine in newly diagnosed adult Tâ€cell acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma. American Journal of Hematology, 2018, 93, 91-99. | 2.0 | 74 |
| 355 | Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. American Journal of Hematology, 2018, 93, 84-90. | 2.0 | 40 |
| 356 | Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leukemia and Lymphoma, 2018, 59, 1312-1322. | 0.6 | 11 |
| 357 | Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Miniâ€“Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 230. | 3.4 | 124 |
| 358 | Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 1012-1015. | 0.6 | 3 |
| 359 | Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. American Journal of Hematology, 2018, 93, 371-374. | 2.0 | 68 |
| 360 | Myelodysplastic syndromes: 2018 update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2018, 93, 129-147. | 2.0 | 154 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Clinical experience with the <scp>BCL</scp>2â€inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. American Journal of Hematology, 2018, 93, 401-407. | 2.0 | 336 |
| 362 | A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. American Journal of Hematology, 2018, 93, 277-285. | 2.0 | 54 |
| 363 | Myeloid/lymphoid neoplasms withFGFR1rearrangement. Leukemia and Lymphoma, 2018, 59, 1672-1676. | 0.6 | 53 |
| 364 | Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1788-1797. | 0.8 | 156 |
| 365 | The Landscape of Genotype-Phenotype Correlation in AML. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S209-S210. | 0.2 | 0 |
| 366 | Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematology,the, 2018, 5, e618-e627. | 2.2 | 190 |
| 367 | Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions. Cancer, 2018, 124, 4601-4609. | 2.0 | 8 |
| 368 | Mutational landscape of myelodysplastic/myeloproliferative neoplasmâ€“unclassifiable. Blood, 2018, 132, 2100-2103. | 0.6 | 40 |
| 369 | Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer, 2018, 124, 4192-4201. | 2.0 | 27 |
| 370 | Chemoimmunotherapy with inotuzumab ozogamicin combined with miniâ€hyperâ€CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia in first salvage. Cancer, 2018, 124, 4044-4055. | 2.0 | 88 |
| 371 | Improving Prognostic Tools for Patients With Myelodysplastic Syndromes. Mayo Clinic Proceedings, 2018, 93, 1340-1342. | 1.4 | 1 |
| 372 | A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline secondâ€and thirdâ€generation tyrosine kinase inhibitors. Cancer Medicine, 2018, 7, 5457-5469. | 1.3 | 27 |
| 373 | PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell, 2018, 23, 700-713.e6. | 5.2 | 272 |
| 374 | Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57. | 0.4 | 20 |
| 375 | Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leukemia Research, 2018, 73, 78-85. | 0.4 | 9 |
| 376 | MEK Inhibitor Binimetinib (MEK162) in Relapse and Refractory Acute Myeloid Leukemia: Results of a Phase I/II Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S199. | 0.2 | 0 |
| 377 | Myelodysplastic Syndromes with EZH2 Mutations Frequently Show Multilineage Dysplasia, Chromosome 7 Alterations and Concomitant Mutations in ASXL1, RUNX1 and TET2. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S260. | 0.2 | 0 |
| 378 | Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Advances, 2018, 2, 1807-1816. | 2.5 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Advances, 2018, 2, 2491-2504. | 2.5 | 29 |
| 380 | A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 658-663.e2. | 0.2 | 30 |
| 381 | Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 528-532. | 0.2 | 14 |
| 382 | Secondary primary cancers before and after myeloid neoplasia: a two-way street. Lancet Haematology,the, 2018, 5, e328-e329. | 2.2 | 0 |
| 383 | Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. American Journal of Hematology, 2018, 93, E357-E360. | 2.0 | 2 |
| 384 | Prognosis of patients with intermediate risk IPSSâ€R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSSâ€R. American Journal of Hematology, 2018, 93, 1245-1253. | 2.0 | 34 |
| 385 | Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nature Communications, 2018, 9, 2670. | 5.8 | 79 |
| 386 | Sorafenib Combined with 5â€azacytidine in Older Patients with Untreated FLT3â€ITD Mutated Acute Myeloid Leukemia. American Journal of Hematology, 2018, 93, 1136-1141. | 2.0 | 95 |
| 387 | The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood, 2018, 131, 2661-2669. | 0.6 | 313 |
| 388 | Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia, 2018, 32, 2512-2518. | 3.3 | 26 |
| 389 | CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leukemia Research, 2018, 72, 79-85. | 0.4 | 20 |
| 390 | Blast-phase chronic myelomonocytic leukemia: more than just semantics. Leukemia, 2018, 32, 2093-2094. | 3.3 | 2 |
| 391 | Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematology,the, 2018, 5, e411-e421. | 2.2 | 66 |
| 392 | Response kinetics and factors predicting survival in core-binding factor leukemia. Leukemia, 2018, 32, 2698-2701. | 3.3 | 20 |
| 393 | Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 231-231. | 0.6 | 4 |
| 394 | The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 1-1. | 0.6 | 57 |
| 395 | Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study. Blood, 2018, 132, 234-234. | 0.6 | 26 |
| 396 | Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the ConnectÂ® MDS/AML Disease Registry. Blood, 2018, 132, 4731-4731. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Blood, 2018, 132, 971-971. | 0.6 | 29 |
| 398 | Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood, 2018, 132, 2674-2674. | 0.6 | 1 |
| 399 | Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 286-286. | 0.6 | 19 |
| 400 | A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes. Blood, 2018, 132, 793-793. | 0.6 | 20 |
| 401 | What Is the Optimal Time to Initiate Hypomethylating Agents (HMA) in Higher Risk Myelodysplastic Syndromes (MDS)?. Blood, 2018, 132, 3098-3098. | 0.6 | 3 |
| 402 | Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood, 2018, 132, 36-36. | 0.6 | 12 |
| 403 | Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. Blood, 2018, 132, 553-553. | 0.6 | 17 |
| 404 | Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood, 2018, 132, 34-34. | 0.6 | 4 |
| 405 | Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study. Blood, 2018, 132, 84-84. | 0.6 | 6 |
| 406 | Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2018, 132, 1548-1548. | 0.6 | 2 |
| 407 | Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome. Blood, 2018, 132, 464-464. | 0.6 | 4 |
| 408 | Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 905-905. | 0.6 | 21 |
| 409 | Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Blood, 2018, 132, 2667-2667. | 0.6 | 1 |
| 410 | Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 1438-1438. | 0.6 | 5 |
| 411 | Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data. Blood, 2018, 132, 1801-1801. | 0.6 | 4 |
| 412 | Pattern of Immune-Mediated Toxicities in Patients with Myelodysplastic Syndrome (MDS) Treated with Nivolumab and Ipilimumab. Blood, 2018, 132, 4367-4367. | 0.6 | 2 |
| 413 | Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 232-232. | 0.6 | 11 |
| 414 | Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. Blood, 2018, 132, 1798-1798. | 0.6 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience. Blood, 2018, 132, 5447-5447. | 0.6 | 2 |
| 416 | Characteristics and Role of Lenalidomide Therapy in Patients with Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis. Blood, 2018, 132, 5513-5513. | 0.6 | 5 |
| 417 | Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood, 2018, 132, 4057-4057. | 0.6 | 10 |
| 418 | Characteristics and Outcomes of Patients (pts) with Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adults: A Single-Center, Prospective Analysis of 36 Pts. Blood, 2018, 132, 3689-3689. | 0.6 | 1 |
| 419 | Safety and Efficacy of Blinatumomab in Patients with Central Nervous System (CNS) Disease: A Single Institution Experience. Blood, 2018, 132, 2702-2702. | 0.6 | 13 |
| 420 | Phase 2 Study of Lenalidomide Maintenance for Patients with High-Risk Acute Myeloid Leukemia in Remission. Blood, 2018, 132, 2714-2714. | 0.6 | 1 |
| 421 | A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2018, 132, 32-32. | 0.6 | 14 |
| 422 | Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 4017-4017. | 0.6 | 5 |
| 423 | Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203. Blood, 2018, 132, 1403-1403. | 0.6 | 2 |
| 424 | Predictors of Outcomes in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia at First Relapse in the Era of Tyrosine Kinase Inhibitors. Blood, 2018, 132, 2659-2659. | 0.6 | 1 |
| 425 | Phase I-II Study of Crenolanib Combined with Standard Salvage Chemotherapy and Crenolanib Combined with 5-Azacitidine in Acute Myeloid Leukemia Patients with FLT3 Activating Mutations. Blood, 2018, 132, 2715-2715. | 0.6 | 9 |
| 426 | Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood, 2018, 132, 3983-3983. | 0.6 | 2 |
| 427 | Outcomes with Subsequent FLT3-Inhibitor (FLT3i) Based Therapies in FLT3-Mutated (mu) Patients (pts) Refractory/Relapsed (R/R) to One or More Prior FLT3 Inhibitor Based Therapies: A Single Center Experience. Blood, 2018, 132, 663-663. | 0.6 | 7 |
| 428 | Weight Increase during Induction Therapy Predicts Intensive Care Unit (ICU) Transfer in Patients (Pts) with Acute Promyelocytic Leukemia (APL). Blood, 2018, 132, 4003-4003. | 0.6 | 1 |
| 429 | Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 1831-1831. | 0.6 | 13 |
| 430 | Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment NaÃ¯ve & Relapsed (Rel)/Refractory (Ref) Patients. Blood, 2018, 132, 230-230. | 0.6 | 10 |
| 431 | Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (â‰¤65 yrs) with Acute Myeloid Leukemia. Blood, 2018, 132, 4039-4039. | 0.6 | 1 |
| 432 | Induced PD-1 Expression on Bone Marrow CD34+ Cells from MDS Patients Treated with 5-Azacitadine in Combination with Nivolumab and/or Ipilimumab. Blood, 2018, 132, 1807-1807. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 465-465. | 0.6 | 48 |
| 434 | Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease. Blood, 2018, 132, 5212-5212. | 0.6 | 2 |
| 435 | Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients. Blood, 2018, 132, 3815-3815. | 0.6 | 2 |
| 436 | LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood, 2018, 132, 687-687. | 0.6 | 14 |
| 437 | A Clinical Study of Tomaralimab (OPN-305), a Toll-like Receptor 2 (TLR-2) Antibody, in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy. Blood, 2018, 132, 798-798. | 0.6 | 24 |
| 438 | Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2018, 132, 3091-3091. | 0.6 | 46 |
| 439 | Phase 2 Study of Nilotinib 400 Mg Twice Daily in Newly Diagnosed Patients with Accelerated Phase of Chronic Myeloid Leukemia, Results after 5.7 Years of Follow-up. Blood, 2018, 132, 3011-3011. | 0.6 | 1 |
| 440 | Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study. Blood, 2018, 132, 906-906. | 0.6 | 13 |
| 441 | Updated Results of Phase 2 Study of Ruxolitinib in Combination with 5-Azacitidine in Patients with Myelofibrosis. Blood, 2018, 132, 352-352. | 0.6 | 7 |
| 442 | Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Oncotarget, 2018, 9, 9714-9727. | 0.8 | 56 |
| 443 | Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood, 2018, 132, 1814-1814. | 0.6 | 0 |
| 444 | Telomere Damage Maintains Hematopoietic Stem Cells (HSCs) in an Activated Metabolic State, Which Compromises Their Self-Renewal Capability. Blood, 2018, 132, 174-174. | 0.6 | 0 |
| 445 | Post Allogeneic Stem Cell Transplant (SCT) Cyclophosphamide Improves Progression Free Survival (PFS) in Pts with AML/MDS Treated with CTLA-4 or PD-1 Blockade Prior to SCT. Blood, 2018, 132, 483-483. | 0.6 | 0 |
| 446 | Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 2018, 132, 3026-3026. | 0.6 | 0 |
| 447 | Survivorship in AML - Outcomes of Acute Myelogenous Leukemia (AML) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years (yrs). Blood, 2018, 132, 3976-3976. | 0.6 | 0 |
| 448 | Diverse Landscape of TET2 Variants in MDS and AML. Blood, 2018, 132, 1479-1479. | 0.6 | 0 |
| 449 | Does Trial Participation Improve Outcomes for Higher-Risk Myelodysplastic Syndromes (MDS) Patients Treated at Specialty Centers?. Blood, 2018, 132, 3096-3096. | 0.6 | 0 |
| 450 | Salvage Therapy Outcomes in a Historical Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 3985-3985. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 451 | Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. Blood, 2018, 132, 1514-1514. | 0.6 | 0 |
| 452 | Clinical Heterogeneity of AML Is Associated with Mutational Heterogeneity. Blood, 2018, 132, 5240-5240. | 0.6 | 2 |
| 453 | Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 2722-2722. | 0.6 | 2 |
| 454 | Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA. Blood, 2018, 132, 3095-3095. | 0.6 | 0 |
| 455 | The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 4359-4359. | 0.6 | 0 |
| 456 | Granulocyte Transfusions for Neutropenic Patients with Perirectal and Perineal Infections. Blood, 2018, 132, 2544-2544. | 0.6 | 0 |
| 457 | Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 88-88. | 0.6 | 1 |
| 458 | Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Surviving More Than 5 Years (yrs) after Initial Therapy with TKIs. Blood, 2018, 132, 5442-5442. | 0.6 | 0 |
| 459 | Distinct Gene Expression Patterns of Minimal Residual Disease (MRD) Cells in High-Risk AML Patients Identified By RNA-Sequencing. Blood, 2018, 132, 2757-2757. | 0.6 | 0 |
| 460 | Outcomes in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Longer-Term Follow-up Demonstrates Poor Outcomes in Patients with Skin-Only Presentation. Blood, 2018, 132, 3980-3980. | 0.6 | 0 |
| 461 | Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood, 2018, 132, 2664-2664. | 0.6 | 0 |
| 462 | Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. Blood, 2018, 132, 3103-3103. | 0.6 | 0 |
| 463 | Addition of Gemtuzumab Ozogamicin (GO) to Fludarabine, Cytarabine and G-CSF (FLAG) Based Induction Regimen Results in Better Early Molecular Response and Relapse Free Survival Compared to Idarubicin (FLAG-Ida) in Newly Diagnosed Core Binding Factor Leukemia. Blood, 2018, 132, 3993-3993. | 0.6 | 2 |
| 464 | Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. Blood, 2018, 132, 3013-3013. | 0.6 | 2 |
| 465 | Potential Predictors of Induction Failure and Complete Remission Duration in FLT3-ITD Mutated Acute Myeloid Leukemia. Blood, 2018, 132, 3996-3996. | 0.6 | 0 |
| 466 | RNA Expression Profile Using Targeted NGS As a Potential Predictor of Early Molecular Response and Relapse in Core-Binding Factor Acute Myeloid Leukemia. Blood, 2018, 132, 5113-5113. | 0.6 | 0 |
| 467 | Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood, 2018, 132, 2791-2791. | 0.6 | 0 |
| 468 | Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2695-2695. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 469 | Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Blood, 2018, 132, 1820-1820. | 0.6 | 0 |
| 470 | 2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. Blood, 2018, 132, 3978-3978. | 0.6 | 0 |
| 471 | c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Clinical Cancer Research, 2017, 23, 2542-2555. | 3.2 | 105 |
| 472 | Phase 2, randomized, doubleâ€blind study of pracinostat in combination with azacitidine in patients with untreated, higherâ€risk myelodysplastic syndromes. Cancer, 2017, 123, 994-1002. | 2.0 | 88 |
| 473 | Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. American Journal of Hematology, 2017, 92, 351-358. | 2.0 | 13 |
| 474 | Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. Leukemia Research, 2017, 56, 88-95. | 0.4 | 41 |
| 475 | Focal Adhesion Kinase as a Potential Target in AML and MDS. Molecular Cancer Therapeutics, 2017, 16, 1133-1144. | 1.9 | 30 |
| 476 | More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood, 2017, 129, 2584-2587. | 0.6 | 51 |
| 477 | Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 60-87. | 2.3 | 254 |
| 478 | An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. American Journal of Hematology, 2017, 92, 674-682. | 2.0 | 24 |
| 479 | Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 845-850. | 2.0 | 36 |
| 480 | Validation of the 2016 revisions to the <scp>WHO</scp> classification in lowerâ€risk myelodysplastic syndrome. American Journal of Hematology, 2017, 92, E168-E171. | 2.0 | 5 |
| 481 | Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncology, The, 2017, 18, 100-111. | 5.1 | 296 |
| 482 | Current management of patients with chronic myelomonocytic leukemia. Current Opinion in Oncology, 2017, 29, 79-87. | 1.1 | 9 |
| 483 | Factors associated with risk of central nervous system relapse in patients with nonâ€core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 924-928. | 2.0 | 17 |
| 484 | TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyperâ€CVADâ€based regimens. Cancer, 2017, 123, 3717-3724. | 2.0 | 18 |
| 485 | Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. American Journal of Hematology, 2017, 92, 599-606. | 2.0 | 38 |
| 486 | Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer, 2017, 123, 3050-3060. | 2.0 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 487 | Outcomes of adults with relapsed or refractory Burkitt and highâ€grade Bâ€cell leukemia/lymphoma. American Journal of Hematology, 2017, 92, E114-E117. | 2.0 | 32 |
| 488 | Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood, 2017, 129, 572-581. | 0.6 | 285 |
| 489 | Poor outcomes associated with +der(22)t(9;22) and â^'9/9p in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. American Journal of Hematology, 2017, 92, 238-243. | 2.0 | 41 |
| 490 | Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nature Immunology, 2017, 18, 236-245. | 7.0 | 85 |
| 491 | Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood, 2017, 129, 1275-1283. | 0.6 | 214 |
| 492 | <scp>S</scp>ignificance of recurrence of minimal residual disease detected by multiâ€parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. American Journal of Hematology, 2017, 92, 279-285. | 2.0 | 32 |
| 493 | Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S256-S257. | 0.2 | 2 |
| 494 | A Phase II Trial of Inotuzumab Ozogamicin Combined with Mini-HyperCVD as Salvage Therapy for Relapsed/Refractory ALL. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S264-S265. | 0.2 | 0 |
| 495 | Novel EZH2 Mutation in a Patient with Second Primary B-Cell Acute Lymphoblastic Leukemia after del5q Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S349. | 0.2 | 0 |
| 496 | Immune Checkpoint Based Approaches in AML. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S45-S46. | 0.2 | 0 |
| 497 | Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S9. | 0.2 | 4 |
| 498 | Th1/17 Hybrid CD4 + Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S10. | 0.2 | 1 |
| 499 | Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S255-S256. | 0.2 | 0 |
| 500 | Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncology, The, 2017, 18, 1317-1326. | 5.1 | 148 |
| 501 | Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer, 2017, 123, 4851-4859. | 2.0 | 45 |
| 502 | Clonal chromosomal abnormalities appearing in Philadelphia chromosomeâ€"negative metaphases during CML treatment. Blood, 2017, 130, 2084-2091. | 0.6 | 65 |
| 503 | Clinical outcomes in adult patients with aplastic anemia: A single institution experience. American Journal of Hematology, 2017, 92, 1295-1302. | 2.0 | 13 |
| 504 | Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 897-901. | 0.2 | 127 |

| # | Article | IF | Citations |
|---|---|---|---|
| 505 | Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S257-S258. | 0.2 | 1 |
| 506 | Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. Journal of Cutaneous Pathology, 2017, 44, 1075-1079. | 0.7 | 27 |
| 507 | Characterization of <scp>TP</scp>53 mutations in lowâ€grade myelodysplastic syndromes and myelodysplastic syndromes with a nonâ€complex karyotype. European Journal of Haematology, 2017, 99, 536-543. | 1.1 | 20 |
| 508 | Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica, 2017, 102, 1709-1717. | 1.7 | 13 |
| 509 | A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer, 2017, 123, 4430-4439. | 2.0 | 37 |
| 510 | Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and ImmuneÂCheckpoints. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S16-S25. | 0.2 | 6 |
| 511 | Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 2017, 123, 4391-4402. | 2.0 | 114 |
| 512 | Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood, 2017, 130, 1514-1522. | 0.6 | 151 |
| 513 | Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica, 2017, 102, 1661-1670. | 1.7 | 64 |
| 514 | Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer, 2017, 123, 609-616. | 2.0 | 4 |
| 515 | Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*. Leukemia and Lymphoma, 2017, 58, 1325-1331. | 0.6 | 23 |
| 516 | Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia and Lymphoma, 2017, 58, 866-871. | 0.6 | 4 |
| 517 | Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory <scp>B</scp>â€cell acute lymphoblastic leukemia. Cancer, 2017, 123, 294-302. | 2.0 | 70 |
| 518 | Phase 2 study of lowâ€dose clofarabine plus cytarabine for patients with higherâ€risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer, 2017, 123, 629-637. | 2.0 | 31 |
| 519 | Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. American Journal of Hematology, 2017, 92, 7-11. | 2.0 | 41 |
| 520 | Prognostic impact of pretreatment cytogenetics in adult <scp>P</scp>hiladelphia chromosomeâ€“negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer, 2017, 123, 459-467. | 2.0 | 49 |
| 521 | Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer, 2017, 123, 426-435. | 2.0 | 63 |
| 522 | Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer Journal, 2017, 7, 644. | 2.8 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 523 | Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Advances, 2017, 1, 1312-1323. | 2.5 | 83 |
| 524 | Copy number alterations detected as clonal hematopoiesis of indeterminate potential. Blood Advances, 2017, 1, 1031-1036. | 2.5 | 30 |
| 525 | Preclinical activity of FF-10501-01, a novel inosine-5â€²-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leukemia Research, 2017, 59, 85-92. | 0.4 | 8 |
| 526 | The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood, 2017, 130, 723-723. | 0.6 | 35 |
| 527 | Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2017, 130, 815-815. | 0.6 | 11 |
| 528 | Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.. Journal of Clinical Oncology, 2017, 35, 7034-7034. | 0.8 | 2 |
| 529 | Phase II Study of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality. Blood, 2017, 130, 892-892. | 0.6 | 0 |
| 530 | Malignancyâ€associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer, 2016, 122, 2857-2866. | 2.0 | 88 |
| 531 | Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future Oncology, 2016, 12, 293-302. | 1.1 | 36 |
| 532 | Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clinical Proteomics, 2016, 13, 14. | 1.1 | 11 |
| 533 | Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (<scp>AML</scp>) and myelodysplastic syndrome (<scp>MDS</scp>). American Journal of Hematology, 2016, 91, 227-232. | 2.0 | 46 |
| 534 | Final results of a single institution experience with a pediatricâ€based regimen, the augmented Berlinâ€“Frankfurtâ€“MÃ¼nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyperâ€CVAD regimen. American Journal of Hematology, 2016, 91, 819-823. | 2.0 | 102 |
| 535 | Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents. Journal of Clinical Pathology, 2016, 69, 1001-1008. | 1.0 | 8 |
| 536 | KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood, 2016, 128, 2819-2823. | 0.6 | 28 |
| 537 | Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genetics, 2016, 209, 205-214. | 0.2 | 6 |
| 538 | Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusionâ€dependent anemia and thrombocytopenia. BMC Hematology, 2016, 16, 12. | 2.6 | 31 |
| 539 | Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. Cancer Letters, 2016, 377, 149-157. | 3.2 | 33 |
| 540 | Time-dependent changes in mortality and transformation risk in MDS. Blood, 2016, 128, 902-910. | 0.6 | 140 |

| # | Article | IF | Citations |
|---|---|---|---|
| 541 | PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S67-S73. | 0.2 | 5 |
| 542 | A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S88-S89. | 0.2 | 0 |
| 543 | Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S10-S11. | 0.2 | 0 |
| 544 | Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S11-S12. | 0.2 | 0 |
| 545 | Outcomes after Blinatumomab Failure in Patients with Relapsed/ Refractory (R/R) B-cell ALL (ALL). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S12-S13. | 0.2 | 1 |
| 546 | Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer, 2016, 16, 652. | 1.1 | 12 |
| 547 | Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2016, 122, 3812-3820. | 2.0 | 17 |
| 548 | Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. American Journal of Hematology, 2016, 91, 1221-1226. | 2.0 | 12 |
| 549 | Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion. British Journal of Haematology, 2016, 173, 161-165. | 1.2 | 4 |
| 550 | Hyperâ€CVAD plus ponatinib versus hyperâ€CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia: A propensity score analysis. Cancer, 2016, 122, 3650-3656. | 2.0 | 156 |
| 551 | A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer, 2016, 122, 3336-3343. | 2.0 | 14 |
| 552 | Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica, 2016, 101, e324-e327. | 1.7 | 5 |
| 553 | Impact of complete molecular response on survival in patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Blood, 2016, 128, 504-507. | 0.6 | 194 |
| 554 | TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016, 122, 3484-3491. | 2.0 | 200 |
| 555 | Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis. Leukemia Research, 2016, 48, 1-5. | 0.4 | 17 |
| 556 | A Phase II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Patients with Relapsed/Refractory ALL. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S15-S16. | 0.2 | 0 |
| 557 | The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer, 2016, 122, 2186-2196. | 2.0 | 121 |
| 558 | The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica, 2016, 101, e224-e227. | 1.7 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 559 | Activity of the oral mitogenâ€activated protein kinase kinase inhibitor trametinib in <scp>RAS</scp>â€mutant relapsed or refractory myeloid malignancies. Cancer, 2016, 122, 1871-1879. | 2.0 | 113 |
| 560 | Minimal residual disease assessed by multiâ€parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 392-400. | 1.2 | 102 |
| 561 | Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Current Oncology Reports, 2016, 18, 4. | 1.8 | 17 |
| 562 | Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 163-168.e2. | 0.2 | 18 |
| 563 | Down-regulation of EZH2 expression in myelodysplastic syndromes. Leukemia Research, 2016, 44, 1-7. | 0.4 | 13 |
| 564 | Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2016, 17, 496-508. | 5.1 | 142 |
| 565 | CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count. Leukemia and Lymphoma, 2016, 57, 1965-1968. | 0.6 | 7 |
| 566 | Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leukemia Research, 2016, 41, 43-47. | 0.4 | 27 |
| 567 | Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leukemia and Lymphoma, 2016, 57, 812-819. | 0.6 | 7 |
| 568 | Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forÂPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 47-53. | 2.0 | 58 |
| 569 | A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. Blood, 2016, 128, 100-100. | 0.6 | 18 |
| 570 | High-Risk Subtype of Ph-like Acute Lymphoblastic Leukemia (ALL) in Adults: Dismal Outcomes of CRLF2+ ALL Patients Treated with Intensive Chemotherapy. Blood, 2016, 128, 1082-1082. | 0.6 | 2 |
| 571 | Long-Term Experience with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 111-111. | 0.6 | 1 |
| 572 | Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 112-112. | 0.6 | 2 |
| 573 | Ruxolitinib (RUX) in Combination with 5-Azacytidine (AZA) As Therapy for Patients (pts) with Myelofibrosis (MF). Blood, 2016, 128, 1127-1127. | 0.6 | 8 |
| 574 | Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study. Blood, 2016, 128, 114-114. | 0.6 | 11 |
| 575 | Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. Blood, 2016, 128, 1166-1166. | 0.6 | 5 |
| 576 | Phase II Study of the Salvage Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin (INO) for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 1606-1606. | 0.6 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 577 | Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3-ITDmutation. Blood, 2016, 128, 1611-1611. | 0.6 | 3 |
| 578 | Randomized Phase II Trial of Two Schedules of Decitabine As Frontline Therapy in Elderly Patients with Acute Myeloid Leukemia Ineligible for Standard Cytotoxic Induction Regimens. Blood, 2016, 128, 1612-1612. | 0.6 | 2 |
| 579 | Complete Remissions (CRs) with Azacitidine Regimens Compared to Crs with 7+3 Induction Chemotherapy and the Effect on Overall Survival. Blood, 2016, 128, 1613-1613. | 0.6 | 6 |
| 580 | Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (â‰65 yrs) with Acute Myeloid Leukemia. Blood, 2016, 128, 1639-1639. | 0.6 | 14 |
| 581 | Phase 1 Results of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. Blood, 2016, 128, 1640-1640. | 0.6 | 3 |
| 582 | Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood, 2016, 128, 1641-1641. | 0.6 | 4 |
| 583 | The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood, 2016, 128, 1642-1642. | 0.6 | 16 |
| 584 | Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma. Blood, 2016, 128, 177-177. | 0.6 | 2 |
| 585 | Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs). Blood, 2016, 128, 1919-1919. | 0.6 | 2 |
| 586 | CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US. Blood, 2016, 128, 1923-1923. | 0.6 | 2 |
| 587 | Survival Outcome of Patients with Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms. Blood, 2016, 128, 1940-1940. | 0.6 | 23 |
| 588 | A Phase II Clinical Trial of Azacitidine and Vorinostat for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) with Poor Performance Status, Comorbidities, Other Active Malignancies or Organ Dysfunction Not Eligible for Conventional Clinical Trials. Blood, 2016, 128, 1999-1999. | 0.6 | 2 |
| 589 | Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2011-2011. | 0.6 | 3 |
| 590 | A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2016, 128, 226-226. | 0.6 | 3 |
| 591 | A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy. Blood, 2016, 128, 227-227. | 0.6 | 22 |
| 592 | Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. Blood, 2016, 128, 2744-2744. | 0.6 | 17 |
| 593 | Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood, 2016, 128, 2783-2783. | 0.6 | 6 |
| 594 | Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation. Blood, 2016, 128, 2791-2791. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 595 | Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2817-2817. | 0.6 | 2 |
| 596 | Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study. Blood, 2016, 128, 2822-2822. | 0.6 | 5 |
| 597 | Pure Erythroid Leukemia Is Characterized By TP53mutations, a Complex Karyotype with Chromosome 17 Abnormalities, and Adverse Risk Independent of Therapy Type. Blood, 2016, 128, 2852-2852. | 0.6 | 2 |
| 598 | Defining the Immune Checkpoint Landscape in Patients (pts) with Acute Myeloid Leukemia (AML). Blood, 2016, 128, 2900-2900. | 0.6 | 35 |
| 599 | Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. Blood, 2016, 128, 2916-2916. | 0.6 | 1 |
| 600 | Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. Blood, 2016, 128, 2917-2917. | 0.6 | 1 |
| 601 | Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC). Blood, 2016, 128, 297-297. | 0.6 | 7 |
| 602 | Life after Ponatinib Failure: Outcomes of Chronic and Accelerated Phase CML Patients Who Discontinued Ponatinib in the Salvage Setting. Blood, 2016, 128, 3073-3073. | 0.6 | 7 |
| 603 | Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood, 2016, 128, 3105-3105. | 0.6 | 15 |
| 604 | Overexpression of KDM6B, an Epigenetic and Innate Immune Regulator, Results in Hematopoietic Alterations of Mice Including Changes in Hematopoietic Stem Cells. Blood, 2016, 128, 3149-3149. | 0.6 | 2 |
| 605 | Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. Blood, 2016, 128, 3166-3166. | 0.6 | 1 |
| 606 | Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study. Blood, 2016, 128, 3167-3167. | 0.6 | 4 |
| 607 | Myelodysplastic Syndromes with NPM1 Mutations May Constitute a Unique Entity Associated with Improved Outcomes When Treated with AML-like Chemotherapy. Blood, 2016, 128, 3171-3171. | 0.6 | 2 |
| 608 | STAG2 Mutations Are an Independent Prognostic Factor in Patients with Myelodysplastic Syndromes. Blood, 2016, 128, 3182-3182. | 0.6 | 2 |
| 609 | A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 344-344. | 0.6 | 60 |
| 610 | Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment. Blood, 2016, 128, 345-345. | 0.6 | 46 |
| 611 | Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2016, 128, 346-346. | 0.6 | 5 |
| 612 | Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECTÂ® Myelodysplastic Syndromes (MDS) and AML Disease Registry. Blood, 2016, 128, 3548-3548. | 0.6 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 613 | Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience. Blood, 2016, 128, 3975-3975. | 0.6 | 2 |
| 614 | CPX-351 for the Treatment of High-Risk Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 4047-4047. | 0.6 | 7 |
| 615 | Ruxolitinib (RUX) in Combination with Azacytidine (AZA) in Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood, 2016, 128, 4246-4246. | 0.6 | 1 |
| 616 | Phase I/II Study of Ruxolitinib (RUX) with Decitabine (DAC) in Patients with Post-Myeloproliferative Neoplasm Acute Myeloid Leukemia (post-MPN AML): Phase I Results. Blood, 2016, 128, 4262-4262. | 0.6 | 13 |
| 617 | Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes. Blood, 2016, 128, 4310-4310. | 0.6 | 1 |
| 618 | Phase I Study of Ruxolitinib for Patients (Pts) with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Who Failed at Least One Line of Therapy. Blood, 2016, 128, 4318-4318. | 0.6 | 1 |
| 619 | A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma. Blood, 2016, 128, 4320-4320. | 0.6 | 5 |
| 620 | Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2016, 128, 4322-4322. | 0.6 | 3 |
| 621 | Clinical Relevance of Driver Mutations and Number of Driver Mutations in Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Blood, 2016, 128, 54-54. | 0.6 | 1 |
| 622 | Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood, 2016, 128, 588-588. | 0.6 | 11 |
| 623 | Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Blood, 2016, 128, 757-757. | 0.6 | 2 |
| 624 | Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML). Blood, 2016, 128, 763-763. | 0.6 | 53 |
| 625 | SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 901-901. | 0.6 | 42 |
| 626 | CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies. Blood, 2016, 128, 905-905. | 0.6 | 8 |
| 627 | Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood, 2016, 128, 940-940. | 0.6 | 4 |
| 628 | The Role of Chip-Related DNA Damage Response Dysfunction in Therapy-Related Myeloid Neoplasms. Blood, 2016, 128, 958-958. | 0.6 | 2 |
| 629 | Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget, 2016, 7, 14172-14187. | 0.8 | 86 |
| 630 | Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget, 2016, 7, 14251-14258. | 0.8 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 631 | ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. Blood, 2016, 128, 359-359. | 0.6 | 0 |
| 632 | Homoharringtonine (HHT) with Imatinib in Chronic, Accelerated, and Blast Phase Chronic Myeloid Leukemia (CML). Blood, 2016, 128, 5449-5449. | 0.6 | 1 |
| 633 | Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Acute Myeloid Leukemia. Blood, 2016, 128, 2756-2756. | 0.6 | 0 |
| 634 | KIR Gene Haplotype: An Independent Predictor of Clinical Outcome in MDS Patients. Blood, 2016, 128, 4330-4330. | 0.6 | 0 |
| 635 | Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-Îºb Activation. Blood, 2016, 128, 3191-3191. | 0.6 | 0 |
| 636 | Characteristics and Outcomes of Older Patients with Secondary AML According to Treatment Approach. Blood, 2016, 128, 2788-2788. | 0.6 | 0 |
| 637 | Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2016, 128, 1067-1067. | 0.6 | 0 |
| 638 | Validation of the 2016 Revision to the World Health Organization (WHO) Classification of Myelodysplastic Syndromes with Diploid Karyotype. Blood, 2016, 128, 4319-4319. | 0.6 | 0 |
| 639 | An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML). Blood, 2016, 128, 5433-5433. | 0.6 | 0 |
| 640 | Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens. Blood, 2016, 128, 2779-2779. | 0.6 | 0 |
| 641 | Activity of Hypomethylating Agents in the Treatment of Therapy-Related Myelodysplastic Syndrome. Blood, 2016, 128, 3177-3177. | 0.6 | 0 |
| 642 | Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 4332-4332. | 0.6 | 1 |
| 643 | Eltrombopag for the Management of Thrombocytopenia Associated with Tyrosine Kinase Therapy in Patients with Chronic Myeloid Leukemia and Myelofibrosis. Blood, 2016, 128, 3062-3062. | 0.6 | 0 |
| 644 | Impact of Driver Mutations in Patients with Lower-Risk Myelodysplastic Syndromes Classified By the MD Anderson Lower-Risk Prognostic Scoring System. Blood, 2016, 128, 4317-4317. | 0.6 | 0 |
| 645 | Impact of the Next-Generation Sequencing Panel on Treatment Choice in Patients with Myelodysplastic Syndrome. Blood, 2016, 128, 4340-4340. | 0.6 | 0 |
| 646 | Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC). Blood, 2016, 128, 4321-4321. | 0.6 | 0 |
| 647 | Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. Blood, 2016, 128, 1737-1737. | 0.6 | 0 |
| 648 | Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response. Blood, 2016, 128, 4324-4324. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 649 | Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 3190-3190. | 0.6 | 0 |
| 650 | Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen. Blood, 2016, 128, 5194-5194. | 0.6 | 0 |
| 651 | Increased Number of Driver Mutations Is a Predictor of Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes. Blood, 2016, 128, 51-51. | 0.6 | 2 |
| 652 | Outcomes of Adult Patients with Relapsed/Refractory Burkitt or Burkitt-like Leukemia/Lymphoma. Blood, 2016, 128, 5150-5150. | 0.6 | 0 |
| 653 | Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors. Blood, 2016, 128, 3064-3064. | 0.6 | 0 |
| 654 | Patterns of Relapse in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Achieve Complete Molecular Response with Chemotherapy Plus a Tyrosine Kinase Inhibitor. Blood, 2016, 128, 3977-3977. | 0.6 | 0 |
| 655 | Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood, 2016, 128, 1224-1224. | 0.6 | 0 |
| 656 | Cryptic Philadelphia Chromosome in Newly Diagnosed Chronic Phase CML (CML-CP): Clinical Characteristics and Treatment Outcome after Treatment with 5 TKI Modalities. Blood, 2016, 128, 3082-3082. | 0.6 | 0 |
| 657 | A Phase II Trial of Omacetaxine Mepesuccinate for Patients with High-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agents. Blood, 2016, 128, 4328-4328. | 0.6 | 0 |
| 658 | Clonal Hematopoiesis Increases Risk of Therapy-Related Myeloid Neoplasms. Blood, 2016, 128, 38-38. | 0.6 | 0 |
| 659 | Archetypes of AML Defined Using Whole Exome Sequencing and Clinical Characteristics in a Diverse Group of Patients. Blood, 2016, 128, 597-597. | 0.6 | 0 |
| 660 | Clinical Characteristics of Philadelphia Positive T-Cell Lymphoid Leukemias - (de novo and blast phase) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 0.6 | 0 |
| 661 | Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. Blood, 2016, 128, 1220-1220. | 0.6 | 0 |
| 662 | Optimized Voronoi compartment determination using machine-learning to identify prognostic groups of patients based on cellular behavior in treated AML. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S22. | 0.2 | 1 |
| 663 | Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a <scp>CD</scp>22 monoclonal antibody. American Journal of Hematology, 2015, 90, 193-196. | 2.0 | 35 |
| 664 | Phase I/II trial of the combination of midostaurin (PKC412) and 5â€azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. American Journal of Hematology, 2015, 90, 276-281. | 2.0 | 139 |
| 665 | An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood, 2015, 125, 1857-1865. | 0.6 | 153 |
| 666 | Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission. American Journal of Hematology, 2015, 90, E134-5. | 2.0 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 667 | Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology, 2015, 90, 1065-1070. | 2.0 | 17 |
| 668 | Longâ€term followâ€up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with <scp>P</scp>hiladelphia chromosomeâ€“positive acute lymphoblastic leukemia. Cancer, 2015, 121, 4158-4164. | 2.0 | 181 |
| 669 | Myelodysplastic Syndromes, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 261-272. | 2.3 | 40 |
| 670 | Myelodysplastic syndromes: 2015 Update on diagnosis, riskâ€stratification and management. American Journal of Hematology, 2015, 90, 831-841. | 2.0 | 101 |
| 671 | Comparing the prognostic value of risk stratifying models for patients with lowerâ€risk myelodysplastic syndromes: Is one model better?. American Journal of Hematology, 2015, 90, 1036-1040. | 2.0 | 23 |
| 672 | Characteristics, clinical outcome, and prognostic significance of <scp>IDH</scp> mutations in <scp>AML</scp>. American Journal of Hematology, 2015, 90, 732-736. | 2.0 | 242 |
| 673 | Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. American Journal of Hematology, 2015, 90, 769-773. | 2.0 | 27 |
| 674 | TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. Journal of Hematology and Oncology, 2015, 8, 45. | 6.9 | 101 |
| 675 | Analysis of class I and II histone deacetylase gene expression in human leukemia. Leukemia and Lymphoma, 2015, 56, 3426-3433. | 0.6 | 20 |
| 676 | Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational New Drugs, 2015, 33, 870-880. | 1.2 | 17 |
| 677 | A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes. Clinical Cancer Research, 2015, 21, 985-994. | 3.2 | 47 |
| 678 | Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3â€² Splice Site Selection through Use of a Different Branch Point. Cell Reports, 2015, 13, 1033-1045. | 2.9 | 377 |
| 679 | Ruxolitinib (RUX) in combination with 5-Azacytidine (AZA) as therapy for patients with myelofibrosis (MF). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S59. | 0.2 | 2 |
| 680 | Results of phase 2 randomized study of lowâ€dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer, 2015, 121, 556-561. | 2.0 | 122 |
| 681 | Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematology,the, 2015, 2, e12-e20. | 2.2 | 24 |
| 682 | Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leukemia Research, 2015, 39, 348-354. | 0.4 | 115 |
| 683 | <scp>RUNX</scp>3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype. British Journal of Haematology, 2015, 169, 344-351. | 1.2 | 48 |
| 684 | Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. American Journal of Hematology, 2015, 90, 27-30. | 2.0 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 685 | Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 358-363. | 0.2 | 50 |
| 686 | Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 2015, 100, 653-661. | 1.7 | 191 |
| 687 | Outcome of patients with lowâ€risk and intermediateâ€1â€risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium. Cancer, 2015, 121, 876-882. | 2.0 | 93 |
| 688 | Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 556-562. | 0.2 | 8 |
| 689 | Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up. Leukemia Research, 2015, 39, 520-524. | 0.4 | 44 |
| 690 | Chronic myelomonocytic leukemia: Forefront of the field in 2015. Critical Reviews in Oncology/Hematology, 2015, 95, 222-242. | 2.0 | 22 |
| 691 | Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome. Cancer Cell, 2015, 27, 644-657. | 7.7 | 85 |
| 692 | Final results of a phase 2 trial of clofarabine and lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer, 2015, 121, 2375-2382. | 2.0 | 40 |
| 693 | Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. British Journal of Haematology, 2015, 168, 646-653. | 1.2 | 64 |
| 694 | Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Oncologist, 2015, 20, 1404-1412. | 1.9 | 32 |
| 695 | Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid plus chemotherapy or with all-transretinoic acid plus arsenic trioxide. Leukemia and Lymphoma, 2015, 56, 1342-1345. | 0.6 | 24 |
| 696 | Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. British Journal of Haematology, 2015, 169, 595-597. | 1.2 | 10 |
| 697 | Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. British Journal of Haematology, 2015, 170, 590-593. | 1.2 | 15 |
| 698 | <scp>TP</scp>53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. British Journal of Haematology, 2015, 171, 91-99. | 1.2 | 43 |
| 699 | An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 1117-1130. | 1.7 | 97 |
| 700 | Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncology, The, 2015, 16, 1547-1555. | 5.1 | 245 |
| 701 | Characteristics of therapy-related myeloid neoplasms in breast cancer patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S186-S187. | 0.2 | 0 |
| 702 | Acute Myeloid Leukemia with t(v;5q33-34) Does Not Always have Myelodysplastic Features but is Associated with Poor Outcome. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S187-S188. | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 703 | Inotuzumab ozogamicin in combination with mini-hyper-CVD as salvage therapy for patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S6. | 0.2 | 1 |
| 704 | Randomized Phase II Study of Clofarabine or Fludarabine Combined with Idarubicin and Cytarabine for the Treatment of Newly Diagnosed AML. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S18. | 0.2 | 1 |
| 705 | Expression Of Phosphodiesterase 4 (PDE4) In Myelodysplastic Syndromes (MDS) And Its Impact On Outcome: Result Of A Transcriptome Profiling Using RNA Sequencing From 43 Patients With MDS And Chronic Myelomonocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S45-S46. | 0.2 | 0 |
| 706 | MDS patients with TP53 mutation respond equally to hypomethylating agents (HMA) but has significantly shorter response duration compared to patients with wild type TP53. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S49. | 0.2 | 0 |
| 707 | Secondary Hemophagocytic Lymphohistiocytoisis (HLH) in Adults Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S76. | 0.2 | 0 |
| 708 | Does the concept of lower-risk myelodysplastic syndrome need to be revisited?. Leukemia Research, 2015, 39, 1003-1005. | 0.4 | 4 |
| 709 | Impact of Therapy-Related De Novo Acute Myeloid Leukemia on Response and Survival. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S181-S182. | 0.2 | 0 |
| 710 | Phase II Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph-positive ALL). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S5. | 0.2 | 0 |
| 711 | Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research, 2015, 39, 1367-1374. | 0.4 | 48 |
| 712 | Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. European Journal of Haematology, 2015, 95, 168-176. | 1.1 | 30 |
| 713 | Phase II study of methotrexate, vincristine, pegylatedâ€asparaginase, and dexamethasone (<scp>MO</scp>p<scp>AD</scp>) in patients with relapsed/refractory acute lymphoblastic leukemia. American Journal of Hematology, 2015, 90, 120-124. | 2.0 | 21 |
| 714 | Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 1392-1397. | 0.6 | 48 |
| 715 | Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Modern Pathology, 2015, 28, 373-382. | 2.9 | 28 |
| 716 | Deacetylase inhibitors for the treatment of myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 1205-1212. | 0.6 | 5 |
| 717 | The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 390-394. | 0.6 | 8 |
| 718 | Myeloid neoplasms after breast cancer: â€œtherapy-relatedâ€•not an independent poor prognostic factor. Leukemia and Lymphoma, 2015, 56, 1012-1019. | 0.6 | 16 |
| 719 | Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 1295-1295. | 0.6 | 8 |
| 720 | Outcome of Patients with Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) after Failure of Inotuzumab Ozogamicin. Blood, 2015, 126, 1298-1298. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 721 | Outcomes of Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphocytic Leukemia (ALL) Post Blinatumomab Failure. Blood, 2015, 126, 1335-1335. | 0.6 | 1 |
| 722 | Additional Chromosomal Abnormalities in Philadelphia Chromosome-Negative Metaphases Appearing during Therapy with Imatinib, Dasatinib, Nilotinib and Ponatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia. Blood, 2015, 126, 1577-1577. | 0.6 | 2 |
| 723 | Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI). Blood, 2015, 126, 1587-1587. | 0.6 | 4 |
| 724 | Long Non-Coding RNA Induces De Novo Myelodysplastic Syndrome through Epigenetic Regulation. Blood, 2015, 126, 1640-1640. | 0.6 | 1 |
| 725 | Presence of 4 or More Driver Mutations Predicts Poor Response to Hypomethylating Agent (HMA) Therapy and Poor Overall Survival in MDS. Blood, 2015, 126, 1663-1663. | 0.6 | 5 |
| 726 | TP53 Mutated MDS Patients Respond Equally to Hypomethylating Agents but Have Significantly Shorter Response Duration Compared to Patients with Wild Type TP53. Blood, 2015, 126, 1681-1681. | 0.6 | 2 |
| 727 | Results of First in Human (FIH) Phase 1 Pharmacokinetic (PK) Guided Dose-Escalation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 1683-1683. | 0.6 | 10 |
| 728 | Efficacy and Safety of Eltrombopag for Treatment of Patients with Myelodysplastic Syndromes after Hypomethylating-Agent Failure: A Phase 2 Clinical Trial. Blood, 2015, 126, 1691-1691. | 0.6 | 2 |
| 729 | Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs). Blood, 2015, 126, 1696-1696. | 0.6 | 4 |
| 730 | Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC). Blood, 2015, 126, 1697-1697. | 0.6 | 2 |
| 731 | A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 2094-2094. | 0.6 | 8 |
| 732 | Clinical Impact of First Complete Remission (CR1) Duration on Outcome of Patients with Relapsed Philadelphia Negative Pre-B Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 2504-2504. | 0.6 | 2 |
| 733 | Characterization of Fever, Infection, and Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab. Blood, 2015, 126, 2530-2530. | 0.6 | 2 |
| 734 | Phase II Study of Cladribine, Idarubicin, and Cytarabine (araC) in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2541-2541. | 0.6 | 7 |
| 735 | A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. Blood, 2015, 126, 2547-2547. | 0.6 | 42 |
| 736 | Fusion Transcript Reduction in Core Binding Factor Acute Myeloid Leukemia: Maintenance Strategy with Hypomethylating Agents. Blood, 2015, 126, 2604-2604. | 0.6 | 1 |
| 737 | Seven Year Follow up of Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib 400 Mg Twice Daily - a Single Center Study at MDACC. Blood, 2015, 126, 2796-2796. | 0.6 | 1 |
| 738 | Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. Blood, 2015, 126, 2861-2861. | 0.6 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 739 | Impact of Cytogenetic Abnormalities and Cytogenetic Response to Hypomethylating Agents (HMAs) in Patients (pts) with Lower Risk Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 2877-2877. | 0.6 | 1 |
| 740 | Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. Blood, 2015, 126, 2879-2879. | 0.6 | 1 |
| 741 | Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood, 2015, 126, 3718-3718. | 0.6 | 1 |
| 742 | Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 3721-3721. | 0.6 | 13 |
| 743 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes. Blood, 2015, 126, 3746-3746. | 0.6 | 11 |
| 744 | Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia. Blood, 2015, 126, 3756-3756. | 0.6 | 1 |
| 745 | Anti-Leukemia Effect of FF-10501-01, a Novel Inosine 5'-Monophosphate Dehydrogenase Inhibitor, in Advanced Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Hypomethylating Agent (HMA) Failures. Blood, 2015, 126, 3800-3800. | 0.6 | 2 |
| 746 | Safety, Pharmacokinetics, and Efficacy of BP-100-1.01 (Liposomal Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 3801-3801. | 0.6 | 6 |
| 747 | Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia. Blood, 2015, 126, 3804-3804. | 0.6 | 1 |
| 748 | Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Survival for Patients with Chronic Myelomonocytic Leukemia. Blood, 2015, 126, 4347-4347. | 0.6 | 1 |
| 749 | CC-486 (Oral Azacitidine) Monotherapy in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 452-452. | 0.6 | 7 |
| 750 | Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 453-453. | 0.6 | 20 |
| 751 | Comparison of Efficacy and Safety Results in 103 Treatment-NaÃ¯ve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA). Blood, 2015, 126, 458-458. | 0.6 | 7 |
| 752 | Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 461-461. | 0.6 | 9 |
| 753 | Single-Center Experience of Immunosuppressive Therapy with or without Eltrombopag in Patients with Aplastic Anemia. Blood, 2015, 126, 4779-4779. | 0.6 | 4 |
| 754 | Clinical and Molecular Characterization of p53-Mutated Acute Myeloid Leukemia. Blood, 2015, 126, 564-564. | 0.6 | 2 |
| 755 | An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 609-609. | 0.6 | 5 |
| 756 | 5-Azacytidine (AZA) in Combination with Ruxolitinib (RUX) As Therapy for Patients (pts) with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPNs). Blood, 2015, 126, 823-823. | 0.6 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 757 | Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 83-83. | 0.6 | 19 |
| 758 | Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907. | 0.6 | 85 |
| 759 | Validation of International Working Group (IWG) Response Criteria in Higher-Risk Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC). Blood, 2015, 126, 909-909. | 0.6 | 7 |
| 760 | A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 910-910. | 0.6 | 5 |
| 761 | A Randomized, Placebo-Controlled, Phase II Study of Pracinostat in Combination with Azacitidine (AZA) in Patients with Previously Untreated Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 911-911. | 0.6 | 10 |
| 762 | Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2015, 126, 94-94. | 0.6 | 9 |
| 763 | Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. PLoS ONE, 2015, 10, e0135520. | 1.1 | 54 |
| 764 | p38 MAPK in MDS. Aging, 2015, 7, 346-347. | 1.4 | 4 |
| 765 | Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities. Blood, 2015, 126, 1705-1705. | 0.6 | 0 |
| 766 | Frontline Hyper-CVAD with Ponatinib for Patients (pts) with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study. Blood, 2015, 126, 2496-2496. | 0.6 | 0 |
| 767 | Age Distribution and Pattern of Myeloid Marrow Mutations in Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) after Failure of Hypomethylating Agents (HMAs). Blood, 2015, 126, 5257-5257. | 0.6 | 0 |
| 768 | Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. Blood, 2015, 126, 2508-2508. | 0.6 | 0 |
| 769 | Telomere Dysfunction-Induced DNA Damage Drives Hematopoietic Stem Cell Fate. Blood, 2015, 126, 1156-1156. | 0.6 | 1 |
| 770 | Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD. Blood, 2015, 126, 4874-4874. | 0.6 | 0 |
| 771 | Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure. Blood, 2015, 126, 4873-4873. | 0.6 | 0 |
| 772 | The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 3771-3771. | 0.6 | 0 |
| 773 | Pharmacological Inhibition of Histone Demethylase JMJD3 Reduces Leukemia Cell Survival and Represses Production of the Cytokine CCL2 in MDS/AML. Blood, 2015, 126, 5219-5219. | 0.6 | 0 |
| 774 | PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes. Blood, 2015, 126, 5227-5227. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 775 | Does the Achievement of MR4.5 Improve the Outcome of Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Front Line Tyrosine Kinase Inhibitors (TKI)?. Blood, 2015, 126, 5158-5158. | 0.6 | 0 |
| 776 | Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Mouse Models: Unveiling the Mechanisms of Remission and Relapse. Blood, 2015, 126, 2852-2852. | 0.6 | 5 |
| 777 | IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL). Blood, 2015, 126, 4136-4136. | 0.6 | 0 |
| 778 | Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival. Blood, 2015, 126, 3722-3722. | 0.6 | 0 |
| 779 | Prognostic Significance of Somatic Mutations in Treatment of AML in Salvage Setting: A Retrospective Analysis. Blood, 2015, 126, 1313-1313. | 0.6 | 0 |
| 780 | Long Term Outcome of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid, Arsenic Trioxide with or without Gemtuzumab Ozogamicin. Blood, 2015, 126, 3776-3776. | 0.6 | 0 |
| 781 | North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood, 2015, 126, 1138-1138. | 0.6 | 4 |
| 782 | Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial. Blood, 2015, 126, 3720-3720. | 0.6 | 0 |
| 783 | Fatigue, Quality of Life and Related Symptoms: Patient Reported Outcomes in Myelodysplastic Syndrome, Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2015, 126, 4456-4456. | 0.6 | 0 |
| 784 | A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. Blood, 2015, 126, 2888-2888. | 0.6 | 0 |
| 785 | The Impact of 20q Deletion on Clinical Presentation, Treatment Response and Survival in Patients with Acute Myeloid Leukemia (AML): The University of Texas MD Anderson Cancer Center Experience. Blood, 2015, 126, 1369-1369. | 0.6 | 0 |
| 786 | Outcome of Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ALL) and Isolated Central Nervous System (CNS) Relapse. Blood, 2015, 126, 2503-2503. | 0.6 | 0 |
| 787 | Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry Is a Strong Predictor of Outcome in Younger Patients with Acute Myeloid Leukemia. Blood, 2015, 126, 2579-2579. | 0.6 | 0 |
| 788 | Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia. Blood, 2015, 126, 143-143. | 0.6 | 0 |
| 789 | MutatedNPM1in patients with acute myeloid leukemia in remission and relapse. Leukemia and Lymphoma, 2014, 55, 1337-1344. | 0.6 | 28 |
| 790 | Lack of association ofIDH1, IDH2andDNMT3Amutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leukemia and Lymphoma, 2014, 55, 1925-1929. | 0.6 | 60 |
| 791 | Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 1425-1427. | 0.6 | 2 |
| 792 | Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. American Journal of Hematology, 2014, 89, 282-287. | 2.0 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 793 | Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. American Journal of Hematology, 2014, 89, 813-818. | 2.0 | 66 |
| 794 | BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wildâ€type RAS. American Journal of Hematology, 2014, 89, 499-504. | 2.0 | 30 |
| 795 | Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to highâ€dose cytarabineâ€based induction chemotherapy. American Journal of Hematology, 2014, 89, 395-398. | 2.0 | 49 |
| 796 | Impact of comorbidities by ACEâ€27 in the revisedâ€IPSS for patients with myelodysplastic syndromes. American Journal of Hematology, 2014, 89, 509-516. | 2.0 | 30 |
| 797 | A Phase II Expansion Study of Vorinostat in Combination With Idarubicin and Cytarabine for Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S123. | 0.2 | 1 |
| 798 | Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leukemia and Lymphoma, 2014, 55, 2879-2886. | 0.6 | 35 |
| 799 | Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure. Therapeutic Advances in Hematology, 2014, 5, 29-34. | 1.1 | 4 |
| 800 | Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leukemia Research, 2014, 38, 149-154. | 0.4 | 41 |
| 801 | Third-party umbilical cord bloodâ€“derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy, 2014, 16, 90-100. | 0.3 | 53 |
| 802 | Evaluation of epidemiological factors in survival of patients with de novo myelodysplastic syndromes. Cancer Causes and Control, 2014, 25, 425-435. | 0.8 | 3 |
| 803 | Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2014, 73, 495-501. | 1.1 | 46 |
| 804 | Myelodysplastic syndromes: 2014 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2014, 89, 97-108. | 2.0 | 118 |
| 805 | Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAGâ€GO) as frontâ€line regimen in patients with core binding factor acute myelogenous leukemia. American Journal of Hematology, 2014, 89, 964-968. | 2.0 | 62 |
| 806 | Treatment with FLT3 inhibitor in patients with FLT3â€mutated acute myeloid leukemia is associated with development of secondary FLT3â€“tyrosine kinase domain mutations. Cancer, 2014, 120, 2142-2149. | 2.0 | 107 |
| 807 | Safety and clinical activity of 5â€azaâ€2â€²â€deoxycytidine (decitabine) with or without Hyperâ€<scp>CVAD</scp> in relapsed/refractory acute lymphocytic leukaemia. British Journal of Haematology, 2014, 167, 356-365. | 1.2 | 37 |
| 808 | Augmented Berlinâ€Frankfurtâ€MÃ¼nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer, 2014, 120, 3660-3668. | 2.0 | 91 |
| 809 | Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to haveIDH1orIDH2mutations. Leukemia and Lymphoma, 2014, 55, 1431-1434. | 0.6 | 4 |
| 810 | A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 401-410. | 0.2 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 811 | Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer, 2014, 120, 1670-1676. | 2.0 | 33 |
| 812 | A phase 2, randomized, doubleâ€blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System lowâ€or intermediateâ€1â€“risk myelodysplastic syndrome. American Journal of Hematology, 2014, 89, E156-62. | 2.0 | 20 |
| 813 | Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. British Journal of Haematology, 2014, 166, 646-659. | 1.2 | 26 |
| 814 | TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood, 2014, 124, 2705-2712. | 0.6 | 486 |
| 815 | Persistence of Minimal Residual Disease Assessed By Multi-Parameter Flow Cytometry (MFC) at 30 and 90 Days after Achieving Complete Remission Predicts Outcome in Patients with Acute Myeloid Leukemia. Blood, 2014, 124, 1015-1015. | 0.6 | 1 |
| 816 | Relationship Between Chelation and Clinical Outcomes in Lower-Risk Patients with Myelodysplastic Syndrome (MDS): Registry Analysis at 5 Years. Blood, 2014, 124, 1350-1350. | 0.6 | 4 |
| 817 | Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs). Blood, 2014, 124, 163-163. | 0.6 | 12 |
| 818 | Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression. Blood, 2014, 124, 2642-2642. | 0.6 | 2 |
| 819 | Comparison of Symptom Burden in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2014, 124, 2652-2652. | 0.6 | 2 |
| 820 | An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. Blood, 2014, 124, 3251-3251. | 0.6 | 23 |
| 821 | A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Blood, 2014, 124, 3252-3252. | 0.6 | 4 |
| 822 | A Phase 1b/2a Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are NaÃ¯ve, Refractory to or Have Relapsed on 5-Azacitadine: a Preliminary Analysis. Blood, 2014, 124, 3263-3263. | 0.6 | 4 |
| 823 | Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA). Blood, 2014, 124, 3273-3273. | 0.6 | 3 |
| 824 | A Bayesian Phase II Randomized Trial of Azacitidine Versus Azacitidine + Vorinostat in Patients with Newly Diagnosed AML or High-Risk MDS with Poor Performance Status, Organ Dysfunction, or Other Comorbidities. Blood, 2014, 124, 3277-3277. | 0.6 | 2 |
| 825 | Phase II Study of Cladribine and Low-Dose Cytarabine (AraC) Alternating with Decitabine in Older Patients with Acute Myeloid Leukemia (AML). Blood, 2014, 124, 3671-3671. | 0.6 | 3 |
| 826 | Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS). Blood, 2014, 124, 385-385. | 0.6 | 12 |
| 827 | The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia. Blood, 2014, 124, 387-387. | 0.6 | 36 |
| 828 | The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial. Blood, 2014, 124, 388-388. | 0.6 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 829 | Phase II Clinical Trial Results of Dasatinib for Frontline Therapy in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). Blood, 2014, 124, 4565-4565. | 0.6 | 4 |
| 830 | Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS). Blood, 2014, 124, 4640-4640. | 0.6 | 2 |
| 831 | Comparison of Continuation of HMA Vs Allogeneic Stem Cell Transplant and Its Timing in Myelodysplastic Syndromes: Can It Wait? Results of a Retrospective Study. Blood, 2014, 124, 4666-4666. | 0.6 | 1 |
| 832 | First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2014, 124, 529-529. | 0.6 | 4 |
| 833 | An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies. Blood, 2014, 124, 530-530. | 0.6 | 4 |
| 834 | TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. Blood, 2014, 124, 532-532. | 0.6 | 6 |
| 835 | Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Who Have Relapsed or Are Refractory to Hypomethylating Agent (HMA) Therapy. Blood, 2014, 124, 534-534. | 0.6 | 1 |
| 836 | Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia (MLL) Gene Rearrangements. Blood, 2014, 124, 5342-5342. | 0.6 | 2 |
| 837 | Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients (â‰¥60 years) with Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 794-794. | 0.6 | 5 |
| 838 | Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML). Blood, 2014, 124, 947-947. | 0.6 | 2 |
| 839 | Survivorship in APL- Outcomes of Acute Promyelocytic Leukemia (APL) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years. Blood, 2014, 124, 954-954. | 0.6 | 4 |
| 840 | Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Salvage Therapy for Adult Patients with Refractory/Relapse (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 964-964. | 0.6 | 2 |
| 841 | Overexpression of miR-125a in Myelodysplastic Syndrome CD34+ Cells Modulates NF-ÎºB Activation and Enhances Erythroid Differentiation Arrest. PLoS ONE, 2014, 9, e93404. | 1.1 | 42 |
| 842 | Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience. Blood, 2014, 124, 2273-2273. | 0.6 | 0 |
| 843 | Association Between Down-Regulation of EZH2 and Abnormal Karyotype, Response to Hypomethylation Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood, 2014, 124, 3241-3241. | 0.6 | 15 |
| 844 | Comparison of Risk Models for Patients with Lower Risk Myelodysplastic Syndromes. Blood, 2014, 124, 1919-1919. | 0.6 | 0 |
| 845 | Multigene Mutational Clinical Profiling Using Next Generation Sequencing in a Cohort of 451 Patients with MDS: Impact on Clinical Outcomes. Blood, 2014, 124, 4658-4658. | 0.6 | 0 |
| 846 | Therapy-Related Myeloid Neoplasms in Breast Cancer Patients: A Single-Institution Report of 150 Cases. Blood, 2014, 124, 962-962. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 847 | A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2014, 124, 164-164. | 0.6 | 0 |
| 848 | Knowledge That the Myelodysplastic Syndromes (MDS) Are a Type of Cancer Does Not Influence Patient Perception of Treatment Discontinuation. Blood, 2014, 124, 6015-6015. | 0.6 | 0 |
| 849 | Long-Term Outcome of Patients with Myelodysplastic Syndromes (MDS) Treated with Hypomethylating Agents (HMA): A Report on Behalf of the MDS Clinical Research Consortium. Blood, 2014, 124, 4641-4641. | 0.6 | 0 |
| 850 | Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade. Blood, 2014, 124, 949-949. | 0.6 | 1 |
| 851 | Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs). Blood, 2014, 124, 3259-3259. | 0.6 | 0 |
| 852 | Azacytidine and Vorinostat in Patients with Chronic Lymphocytic Leukemia (CLL) Diagnosed with Therapy-Related Myelodysplastic Syndromes/Acute Myeloid Leukemia (t-MDS/AML). Blood, 2014, 124, 5627-5627. | 0.6 | 0 |
| 853 | Discontinuation of HMA Therapy after Achieving Complete or Partial Response: Retrospective Analysis of Survival after Long-Term Follow up. Blood, 2014, 124, 4664-4664. | 0.6 | 0 |
| 854 | A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome. Blood, 2014, 124, 523-523. | 0.6 | 0 |
| 855 | The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure. Blood, 2014, 124, 3275-3275. | 0.6 | 0 |
| 856 | Incidence of Central Nervous System (CNS) Relapse in De Novo Adult Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 940-940. | 0.6 | 3 |
| 857 | Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype. Blood, 2014, 124, 3548-3548. | 0.6 | 0 |
| 858 | Minimal Residual Disease (MRD) Assessed By Multi-Parameter Flow Cytometry (MFC) Is Highly Predictive of Outcome in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 1079-1079. | 0.6 | 0 |
| 859 | Prognostic Factors for Outcome in Patients (pts) with Refractory and Relapsed Acute Lymphocytic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (IO), a CD22 Monoclonal Antibody. Blood, 2014, 124, 2288-2288. | 0.6 | 0 |
| 860 | Frequency and Impact of Molecular Responseâ€™s with Nilotinib (Tasigna) in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood, 2014, 124, 3156-3156. | 0.6 | 0 |
| 861 | Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy. Blood, 2014, 124, 3258-3258. | 0.6 | 0 |
| 862 | Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-ÎºB Activation. Blood, 2014, 124, 1930-1930. | 0.6 | 0 |
| 863 | Association Between Downregulation of POT1 Expression and Chromosome 7 Deletion, Response to Hypomethylation Agent Treatment, and Patient Survival in Myelodysplastic Syndromes. Blood, 2014, 124, 4663-4663. | 0.6 | 0 |
| 864 | MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes. Blood, 2014, 124, 5334-5334. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 865 | The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA). Blood, 2014, 124, 1935-1935. | 0.6 | 0 |
| 866 | Retrospective Analysis of Survival in Patients with Acute Erythroid Leukemia (AML-6) Treated with Conventional Chemotherapy Versus Hypomethylating Agents. Blood, 2014, 124, 2278-2278. | 0.6 | 0 |
| 867 | A Phase II Feasibility Study of Prophylactic White Cell Transfusions for the Prevention of Infection in AML Patients Undergoing Induction Therapy. Blood, 2014, 124, 1564-1564. | 0.6 | 0 |
| 868 | Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications. Blood, 2014, 124, 4631-4631. | 0.6 | 0 |
| 869 | Phase I-II Study of Sequential Therapy with Decitabine Followed By Clofarabine, Idarubicin, and Cytarabine (DAC-CIA regimen) in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2014, 124, 5283-5283. | 0.6 | 0 |
| 870 | Long-Term Outcome of Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Single-Institution Experience. Blood, 2014, 124, 1924-1924. | 0.6 | 0 |
| 871 | Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA) Failure: Primary Resistance (PriRes) Vs. Secondary Resistance (SecRes). Blood, 2014, 124, 1922-1922. | 0.6 | 0 |
| 872 | Retrospective Analysis to Correlate Impact of Symptom Burden and Quality of Life to Treatment Outcome with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Chronic Phase. Blood, 2014, 124, 4548-4548. | 0.6 | 0 |
| 873 | The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Annals of Hematology, 2013, 92, 1335-1343. | 0.8 | 22 |
| 874 | Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biology of Blood and Marrow Transplantation, 2013, 19, 214-220. | 2.0 | 23 |
| 875 | Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leukemia Research, 2013, 37, 1461-1467. | 0.4 | 32 |
| 876 | CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Research, 2013, 23, 1446-1461. | 2.4 | 526 |
| 877 | Myelodysplastic syndromes should been renamed as myelodysplastic neoplasms. Leukemia Research, 2013, 37, 463-464. | 0.4 | 1 |
| 878 | Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. American Journal of Hematology, 2013, 88, 1024-1029. | 2.0 | 61 |
| 879 | Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients â‰¥60 years with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2013, 88, 961-966. | 2.0 | 46 |
| 880 | Acquisition of cytogenetic abnormalities in patients with IPSS defined lowerâ€risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. American Journal of Hematology, 2013, 88, 831-837. | 2.0 | 43 |
| 881 | FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. American Journal of Hematology, 2013, 88, 56-59. | 2.0 | 82 |
| 882 | Comparison of Outcome in Erythroleukemia Patients Treated with Standard Chemotherapy Regimens or Hypomethylating Agents. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S380-S381. | 0.2 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 883 | Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndrome (MDS) and Failure ofÂTherapy with Hypomethylating Agents (HMA): An Emerging Entity With a Poor Prognosis. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S379. | 0.2 | 1 |
| 884 | Is acute myeloid leukemia a liquid tumor?. International Journal of Cancer, 2013, 133, 534-543. | 2.3 | 47 |
| 885 | Oncogenic functions of the transcription factor Nrf2. Free Radical Biology and Medicine, 2013, 65, 750-764. | 1.3 | 176 |
| 886 | Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica, 2013, 98, 217-221. | 1.7 | 65 |
| 887 | A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leukemia and Lymphoma, 2013, 54, 321-328. | 0.6 | 76 |
| 888 | Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. Journal of Clinical Oncology, 2013, 31, 2662-2670. | 0.8 | 265 |
| 889 | Salvage therapy using <scp>FLT</scp>3 inhibitors may improve longâ€term outcome of relapsed or refractory <scp>AML</scp> in patients with <scp>FLT</scp>3â€<scp>ITD</scp>. British Journal of Haematology, 2013, 161, 659-666. | 1.2 | 20 |
| 890 | Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study. American Journal of Hematology, 2013, 88, 198-200. | 2.0 | 13 |
| 891 | Dietary Intake of Vegetables, Fruits, and Meats/Beans as Potential Risk Factors of Acute Myeloid Leukemia: A Texas Case-Control Study. Nutrition and Cancer, 2013, 65, 1132-1140. | 0.9 | 10 |
| 892 | Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. American Journal of Hematology, 2013, 88, 365-369. | 2.0 | 30 |
| 893 | Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2013, 31, 2548-2553. | 0.8 | 96 |
| 894 | Low frequency of H3.3 mutations and upregulated DAXX expression in MDS. Blood, 2013, 121, 4009-4011. | 0.6 | 15 |
| 895 | Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood, 2013, 121, 4655-4662. | 0.6 | 355 |
| 896 | Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood, 2013, 122, 2807-2811. | 0.6 | 50 |
| 897 | Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 838-874. | 2.3 | 181 |
| 898 | Epigenetic Inactivation of Notch-Hes Pathway in Human B-Cell Acute Lymphoblastic Leukemia. PLoS ONE, 2013, 8, e61807. | 1.1 | 44 |
| 899 | Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes. PLoS ONE, 2013, 8, e71120. | 1.1 | 61 |
| 900 | Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium. Blood, 2013, 122, 1505-1505. | 0.6 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 901 | Clofarabine Plus Low-Dose Cytarabine For The Treatment Of Patients Withhigher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, Or Are Refractory To, Hypomethylator Agent Therapy. Blood, 2013, 122, 1525-1525. | 0.6 | 1 |
| 902 | DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. Blood, 2013, 122, 1548-1548. | 0.6 | 1 |
| 903 | Outcome Of Patients (pts) With Myelofibrosis (MF) After Ruxolutinib (Rux) Therapy. Blood, 2013, 122, 1584-1584. | 0.6 | 4 |
| 904 | Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy. Blood, 2013, 122, 2654-2654. | 0.6 | 3 |
| 905 | Phase II Study Of The Hyper-CVAD Regimen In Combination With Ofatumumab As Frontline Therapy For Adults With CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 2664-2664. | 0.6 | 14 |
| 906 | A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS. Blood, 2013, 122, 2698-2698. | 0.6 | 5 |
| 907 | A Randomized Phase II Study Of Sapacitabine In MDS Refractory To Hypomethylating Agents. Blood, 2013, 122, 2752-2752. | 0.6 | 3 |
| 908 | Expression Of Immune Checkpoints PD-L1, PD-L2, PD-1 and CTLA4 Predict For Prognosis and Resistance To Hypomethylating Agents (HMAs) In Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 2767-2767. | 0.6 | 2 |
| 909 | 48-Month Update On Survival and AML Transformation In a 600-Patient Registry Of Lower-Risk MDS Patients. Blood, 2013, 122, 2775-2775. | 0.6 | 5 |
| 910 | Prior Hypomethylating Agents Or Chemotherapy Does Not Improve The Outcome Of Allogeneic Hematopoietic Transplantation For High Risk MDS. Blood, 2013, 122, 305-305. | 0.6 | 1 |
| 911 | Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes. Blood, 2013, 122, 387-387. | 0.6 | 7 |
| 912 | Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure. Blood, 2013, 122, 388-388. | 0.6 | 5 |
| 913 | Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience. Blood, 2013, 122, 3917-3917. | 0.6 | 1 |
| 914 | Early Results Of a Phase I/II Trial Of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) For Patients (Pts) With Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2013, 122, 3949-3949. | 0.6 | 1 |
| 915 | Replacing Gemtuzumab Ozogamicin With Idarubicin In Frontline Fludarabine, Cytarabine and G-CSF Based Regimen Does Not Compromise Outcome In Core Binding Factor Acute Myelogenous Leukemia. Blood, 2013, 122, 3971-3971. | 0.6 | 2 |
| 916 | Prognostic Factors For Outcome In Patients (pts) With Myelofibrosis (MF) Treated With Ruxolitinib (Rux). Blood, 2013, 122, 4050-4050. | 0.6 | 1 |
| 917 | First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). Blood, 2013, 122, 497-497. | 0.6 | 23 |
| 918 | Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML). Blood, 2013, 122, 5011-5011. | 0.6 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 919 | HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b. PLoS ONE, 2013, 8, e83018. | 1.1 | 40 |
| 920 | Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 126-33. | 0.7 | 17 |
| 921 | MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. ELife, 2013, 2, e00825. | 2.8 | 32 |
| 922 | Prognostic Models for Patients with Myelodysplastic Syndromes. , 2013, , 153-167. | | 0 |
| 923 | Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 2663-2663. | 0.6 | 1 |
| 924 | MD Anderson Scoring System (MDACC) Predicts Outcomes After Hematopoietic Stem Cell Transplantation (HSCT) Better Than Other Prognostic Classifications In MDS. Blood, 2013, 122, 3340-3340. | 0.6 | 4 |
| 925 | Effect Of Comorbidities In Myelodysplastic Syndrome By Revised-IPSS and Age. Blood, 2013, 122, 1530-1530. | 0.6 | 0 |
| 926 | Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA). Blood, 2013, 122, 2801-2801. | 0.6 | 0 |
| 927 | Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). Blood, 2013, 122, 1424-1424. | 0.6 | 0 |
| 928 | A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. Blood, 2013, 122, 2684-2684. | 0.6 | 2 |
| 929 | Incidence Of and Risk Factors For Acute Myeloid Leukemia Involvement Of The Central Nervous System. Blood, 2013, 122, 3883-3883. | 0.6 | 0 |
| 930 | Fludarabine and Cytarabine Based Induction Therapy Is Associated With High Response Rate and Durable Remission With Low Treatment Related Mortality In Elderly Patients With Core-Binding Factor AML (CBF-AML). Blood, 2013, 122, 3945-3945. | 0.6 | 0 |
| 931 | Overexpression Of Mir-125a In Bone Marrow CD34+ cells Of Patients With Myelodysplastic Syndrome Is Correlated To a Poor Prognosis and May Contribute To The Pathogenesis Of The Disease Through The Modulation Of NF-Kb Activation and Enhancement Of Differentiation Arrest. Blood, 2013, 122, 5206-5206. | 0.6 | 0 |
| 932 | Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR+) Populations In Patients With Myelodysplastic Syndrome (MDS). Blood, 2013, 122, 5231-5231. | 0.6 | 0 |
| 933 | Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years. Blood, 2013, 122, 3886-3886. | 0.6 | 0 |
| 934 | Clofarabine Plus Low-Dose Cytarabine Induction Followed By Clofarabine Plus Low-Dose Cytarabine Alternating With Decitabine Consolidation In Acute Myeloid Leukemia Frontline Therapy For Older Patients. Blood, 2013, 122, 3948-3948. | 0.6 | 0 |
| 935 | Outcome Of Patients With Myelodysplastic Syndrome (MDS) With Bone Marrow Blasts Between 10-30% Treated With Hypomethylating Agents Versus Intensive Chemotherapy. Blood, 2013, 122, 2788-2788. | 0.6 | 2 |
| 936 | Longer Follow-Up Of The Combination Of Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy For Patients Younger Than 61 Years With Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2013, 122, 1451-1451. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 937 | A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 2751-2751. | 0.6 | 3 |
| 938 | Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural History and Clinical Outcome By Therapeutic Approach. Blood, 2013, 122, 2825-2825. | 0.6 | 0 |
| 939 | FOXP3 Is a Direct Target Of miR15a/16 in Umbilical Cord Blood Regulatory T Cells. Blood, 2013, 122, 3261-3261. | 0.6 | 0 |
| 940 | Clinical Characteristics and Outcomes In Patients With Acute Promyelocytic Leukemia (APL) and Hyperleukocytosis. Blood, 2013, 122, 1343-1343. | 0.6 | 0 |
| 941 | Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 2805-2805. | 0.6 | 0 |
| 942 | EphB1 Downregulation In Acute Myeloid Leukemia: Suppressing p53-Dependent DNA Damage Control System. Blood, 2013, 122, 2484-2484. | 0.6 | 0 |
| 943 | Recurrent Patterns Of Histone Methylation and Acetylation Regulating Protein Expression In Acute Myelogenous Leukemia (AML). Blood, 2013, 122, 3733-3733. | 0.6 | 0 |
| 944 | Down-Regulated Expression Of Protection Of Telomeres 1 (POT1) Gene In Bone Marrow Hematopoietic Progenitor Cell Compartment Has Prognostic Value In Myelodysplastic Syndromes (MDS). Blood, 2013, 122, 1511-1511. | 0.6 | 0 |
| 945 | Final Report Of Phase II Study Of Sorafenib and 5-Azacytidine In Patients With Relapsed Or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. Blood, 2013, 122, 3934-3934. | 0.6 | 1 |
| 946 | Differential Prognostic Impact Of Peripheral Blood Blast Clearance In AML Based On Type Of Therapy and FLT3 Mutation Status. Blood, 2013, 122, 2584-2584. | 0.6 | 0 |
| 947 | K-rasG12V transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysis. Cell Research, 2012, 22, 399-412. | 5.7 | 257 |
| 948 | EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro-Oncology, 2012, 14, 1125-1135. | 0.6 | 47 |
| 949 | Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution. Leukemia and Lymphoma, 2012, 53, 1013-1014. | 0.6 | 0 |
| 950 | Acute Myeloid Leukemia and Myelodysplastic Syndromes After Radiation Therapy Are Similar to De Novo Disease and Differ From Other Therapy-Related Myeloid Neoplasms. Journal of Clinical Oncology, 2012, 30, 2340-2347. | 0.8 | 89 |
| 951 | Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Journal of Clinical Oncology, 2012, 30, 2204-2210. | 0.8 | 158 |
| 952 | Rare Case of Septic Arthritis Caused by Candida krusei: Case Report and Literature Review: Table 1.. Journal of Rheumatology, 2012, 39, 1308-1309. | 1.0 | 14 |
| 953 | Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood, 2012, 119, 1981-1987. | 0.6 | 298 |
| 954 | EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood, 2012, 119, 4524-4526. | 0.6 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 955 | Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood, 2012, 120, 4840-4845. | 0.6 | 193 |
| 956 | Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2012, 30, 3376-3382. | 0.8 | 419 |
| 957 | SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood, 2012, 119, 569-572. | 0.6 | 203 |
| 958 | Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 153-166. | 7.7 | 621 |
| 959 | New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. Journal of Clinical Oncology, 2012, 30, 820-829. | 0.8 | 584 |
| 960 | Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood, 2012, 120, 2454-2465. | 0.6 | 2,458 |
| 961 | Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation. Science, 2012, 337, 1541-1546. | 6.0 | 355 |
| 962 | Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544. | 4.3 | 3,122 |
| 963 | Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncology, The, 2012, 13, 1096-1104. | 5.1 | 58 |
| 964 | Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Best Practice and Research in Clinical Haematology, 2012, 25, 427-435. | 0.7 | 12 |
| 965 | Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 244-251. | 0.2 | 34 |
| 966 | Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. Leukemia Research, 2012, 36, 1376-1379. | 0.4 | 13 |
| 967 | Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatric Blood and Cancer, 2012, 58, 682-689. | 0.8 | 40 |
| 968 | Myelodysplastic syndromes: 2012 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2012, 87, 692-701. | 2.0 | 72 |
| 969 | Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wildâ€typeTP53. Cancer, 2012, 118, 2879-2888. | 2.0 | 68 |
| 970 | Very longâ€term followâ€up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer, 2012, 118, 3116-3122. | 2.0 | 32 |
| 971 | Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with highâ€dose cytarabine and idarubicin. Cancer, 2012, 118, 2665-2673. | 2.0 | 47 |
| 972 | A phase 1 doseâ€escalation study of ARRYâ€520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer, 2012, 118, 3556-3564. | 2.0 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 973 | Predicting survival of patients with hypocellular myelodysplastic syndrome. Cancer, 2012, 118, 4462-4470. | 2.0 | 38 |
| 974 | Clofarabine plus lowâ€dose cytarabine followed by clofarabine plus lowâ€dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer, 2012, 118, 4471-4477. | 2.0 | 60 |
| 975 | De novo acute myeloid leukemia risk factors. Cancer, 2012, 118, 4589-4596. | 2.0 | 38 |
| 976 | Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer, 2012, 118, 5550-5559. | 2.0 | 36 |
| 977 | Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leukemia Research, 2012, 36, 974-981. | 0.4 | 30 |
| 978 | Final results of the phase <scp>II</scp> study of rabbit antiâ€thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colonyâ€stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. British Journal of Haematology, 2012, 157, 312-320. | 1.2 | 36 |
| 979 | A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higherâ€risk myelodysplastic syndrome. Cancer, 2012, 118, 722-728. | 2.0 | 26 |
| 980 | Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome. American Journal of Hematology, 2012, 87, 127-129. | 2.0 | 25 |
| 981 | Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia. American Journal of Hematology, 2012, 87, 317-318. | 2.0 | 13 |
| 982 | Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule. Blood, 2012, 120, 1337-1337. | 0.6 | 6 |
| 983 | Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation. Blood, 2012, 120, 1519-1519. | 0.6 | 1 |
| 984 | Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia. Blood, 2012, 120, 164-164. | 0.6 | 5 |
| 985 | Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.. Blood, 2012, 120, 2617-2617. | 0.6 | 1 |
| 986 | Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.. Blood, 2012, 120, 2627-2627. | 0.6 | 1 |
| 987 | Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. Blood, 2012, 120, 311-311. | 0.6 | 3 |
| 988 | Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies. Blood, 2012, 120, 3557-3557. | 0.6 | 5 |
| 989 | Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. Blood, 2012, 120, 3572-3572. | 0.6 | 2 |
| 990 | A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2012, 120, 3587-3587. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 991 | Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update. Blood, 2012, 120, 3588-3588. | 0.6 | 2 |
| 992 | Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) in Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms. Blood, 2012, 120, 3606-3606. | 0.6 | 2 |
| 993 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2012, 120, 3619-3619. | 0.6 | 1 |
| 994 | SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. Blood, 2012, 120, 3625-3625. | 0.6 | 10 |
| 995 | Relationship Between Chelation and Clinical Outcomes in 600 Lower-Risk MDS Patients: Registry Analysis At 36 Months. Blood, 2012, 120, 3800-3800. | 0.6 | 2 |
| 996 | Induction of PD-1 and PD-1 Ligand Expression by Hypomethylating Agents (HMA) in Myelodysplastic Syndromes and Acute Myelogenous Leukemia Suggest a Role for T Cell Function in Clinical Resistance to Hmas. Blood, 2012, 120, 3810-3810. | 0.6 | 1 |
| 997 | Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome. Blood, 2012, 120, 3821-3821. | 0.6 | 11 |
| 998 | Results From the Dose Escalation Phase of a Randomized Phase 1â€“2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. Blood, 2012, 120, 414-414. | 0.6 | 11 |
| 999 | Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes. Blood, 2012, 120, 424-424. | 0.6 | 14 |
| 1000 | Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease. Blood, 2012, 120, 677-677. | 0.6 | 16 |
| 1001 | The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP). Blood, 2012, 120, 72-72. | 0.6 | 3 |
| 1002 | Low Dose Azacitidine (AZA) Reduces the Incidence of Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Blood, 2012, 120, 742-742. | 0.6 | 1 |
| 1003 | Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center. Blood, 2012, 120, 918-918. | 0.6 | 1 |
| 1004 | Cytogenetic and Molecular Characterization of Sweet's Syndrome in Patients with Acute Myeloid Leukemia.. Blood, 2012, 120, 2587-2587. | 0.6 | 0 |
| 1005 | Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia. Blood, 2012, 120, 1516-1516. | 0.6 | 9 |
| 1006 | Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). Blood, 2012, 120, 3610-3610. | 0.6 | 1 |
| 1007 | Infectious Complications in Patients with Relapsed Acute Myeloid Leukemia (AML) Receiving Clofarabine Versus Fludarabine-Containing Salvage Chemotherapy Regimens. Blood, 2012, 120, 4322-4322. | 0.6 | 0 |
| 1008 | The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution. Blood, 2012, 120, 1693-1693. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1009 | Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). Blood, 2012, 120, 3797-3797. | 0.6 | 0 |
| 1010 | Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities. Blood, 2012, 120, 2029-2029. | 0.6 | 0 |
| 1011 | Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia. Blood, 2012, 120, 3617-3617. | 0.6 | 0 |
| 1012 | A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC. Blood, 2012, 120, 131-131. | 0.6 | 0 |
| 1013 | Disparity in Perceptions of Disease, Treatment Effectiveness and Treatment Adherence Between Physicians and Patients with Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 4949-4949. | 0.6 | 0 |
| 1014 | Low Frequency of Molecular Alterations of H3.3-Atrx-Daxx Chromatin Remodeling Component Genes in Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 3844-3844. | 0.6 | 0 |
| 1015 | Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen. Blood, 2012, 120, 3609-3609. | 0.6 | 0 |
| 1016 | Upregulation of Focal Adhesion Kinase, a Potential Therapeutic Target, in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).. Blood, 2012, 120, 2827-2827. | 0.6 | 0 |
| 1017 | Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).. Blood, 2012, 120, 2623-2623. | 0.6 | 0 |
| 1018 | A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily Ã— 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood, 2012, 120, 3851-3851. | 0.6 | 0 |
| 1019 | Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21. Blood, 2012, 120, 1488-1488. | 0.6 | 0 |
| 1020 | Serum Amyloid Protein A 1 (hSAA1) Is Overexpressed in Myelodysplastic Syndromes and Potentially Mediates Toll-Like Receptor 2 Innate Immunity Signaling in CD34+ Hematopoietic Stem Cells. Blood, 2012, 120, 1703-1703. | 0.6 | 2 |
| 1021 | Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (Â± Histone Deacetylase Inhibitors).. Blood, 2012, 120, 2483-2483. | 0.6 | 0 |
| 1022 | Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.. Blood, 2012, 120, 2562-2562. | 0.6 | 4 |
| 1023 | Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients <= 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2012, 120, 43-43. | 0.6 | 1 |
| 1024 | Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis. Blood, 2012, 120, 3802-3802. | 0.6 | 0 |
| 1025 | Analysis of Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm. Blood, 2012, 120, 3554-3554. | 0.6 | 0 |
| 1026 | Cytogenetic and Molecular Characterization of Extramedullary Disease (EMD) in Patients (pts) with Acute Myeloid Leukemia (AML).. Blood, 2012, 120, 2592-2592. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1027 | Incidence and Outcomes of a Rare Translocation t(3,5) in Patients (pts) with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2012, 120, 1456-1456. | 0.6 | 1 |
| 1028 | Toll-Like Receptor (TLR) Signaling Adaptor Protein MYD88 in Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 556-556. | 0.6 | 0 |
| 1029 | Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy. Blood, 2012, 120, 1417-1417. | 0.6 | 0 |
| 1030 | Expression Profiles of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinases (TIMPs) in Myelodysplastic Syndromes (MDS): Level of MMP-9 Is Associated with Improved Prognosis in MDS Patients. Blood, 2012, 120, 3845-3845. | 0.6 | 0 |
| 1031 | Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience. Blood, 2012, 120, 3783-3783. | 0.6 | 8 |
| 1032 | Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 1700-1700. | 0.6 | 0 |
| 1033 | Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP). Blood, 2012, 120, 4939-4939. | 0.6 | 0 |
| 1034 | Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2011, 29, 516-523. | 0.8 | 148 |
| 1035 | Introduction: Advances in Myelodysplastic Syndromes. Seminars in Oncology, 2011, 38, 612. | 0.8 | 1 |
| 1036 | Significance of Thrombocytopenia in Myelodysplastic Syndromes: Associations and Prognostic Implications. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 237-241. | 0.2 | 22 |
| 1037 | Standard Therapy for Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 303-313. | 0.2 | 3 |
| 1038 | Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 661-672. | 1.5 | 21 |
| 1039 | Nontransplantation Options for Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2011, 17, S9-S10. | 2.0 | 1 |
| 1040 | Clinical Effect of Point Mutations in Myelodysplastic Syndromes. New England Journal of Medicine, 2011, 364, 2496-2506. | 13.9 | 1,444 |
| 1041 | Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 30-56. | 2.3 | 177 |
| 1042 | Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood, 2011, 117, 1822-1827. | 0.6 | 64 |
| 1043 | Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood, 2011, 118, 4690-4693. | 0.6 | 88 |
| 1044 | The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood, 2011, 118, 4541-4546. | 0.6 | 133 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1045 | Integrating Care for Patients With Lower Risk Myelodysplastic Syndrome. Seminars in Oncology, 2011, 38, 658-666. | 0.8 | 4 |
| 1046 | Treatment of Higher-Risk Myelodysplastic Syndrome. Seminars in Oncology, 2011, 38, 673-681. | 0.8 | 12 |
| 1047 | Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?. Journal of Clinical Oncology, 2011, 29, 4260-4265. | 0.8 | 71 |
| 1048 | The Search for Better Prognostic Models in Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2011, 6, 13-21. | 1.2 | 11 |
| 1049 | Levels of miRâ€29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5â€azacytidine, valproic acid, and ATRA. American Journal of Hematology, 2011, 86, 237-238. | 2.0 | 19 |
| 1050 | Prediction model for mortality after intracranial hemorrhage in patients with leukemia. American Journal of Hematology, 2011, 86, 546-549. | 2.0 | 30 |
| 1051 | Myelodysplastic syndromes: 2011 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2011, 86, 490-498. | 2.0 | 46 |
| 1052 | Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome. American Journal of Hematology, 2011, 86, 950-952. | 2.0 | 6 |
| 1053 | Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia. Cancer, 2011, 117, 572-580. | 2.0 | 46 |
| 1054 | A phase 1â€2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and highâ€risk myelodysplastic syndrome. Cancer, 2011, 117, 1236-1244. | 2.0 | 36 |
| 1055 | Outcome of therapyâ€related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer, 2011, 117, 110-115. | 2.0 | 32 |
| 1056 | Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib. Cancer, 2011, 117, 5085-5093. | 2.0 | 16 |
| 1057 | Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features. Leukemia Research, 2011, 35, 351-357. | 0.4 | 15 |
| 1058 | Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leukemia Research, 2011, 35, 834-836. | 0.4 | 11 |
| 1059 | Histone methylation in myelodysplastic syndromes. Epigenomics, 2011, 3, 193-205. | 1.0 | 12 |
| 1060 | Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opinion on Investigational Drugs, 2011, 20, 823-829. | 1.9 | 98 |
| 1061 | Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 2521-2527. | 0.8 | 232 |
| 1062 | Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System. Journal of Clinical Oncology, 2011, 29, 1963-1970. | 0.8 | 139 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1063 | Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 3173-3178. | 0.8 | 49 |
| 1064 | Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. Journal of Clinical Oncology, 2011, 29, 2507-2513. | 0.8 | 62 |
| 1065 | Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model. Journal of Clinical Oncology, 2011, 29, 2240-2246. | 0.8 | 131 |
| 1066 | A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. Blood, 2011, 118, 115-115. | 0.6 | 16 |
| 1067 | Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes. Blood, 2011, 118, 118-118. | 0.6 | 14 |
| 1068 | FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations. Blood, 2011, 118, 1493-1493. | 0.6 | 6 |
| 1069 | Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML). Blood, 2011, 118, 1546-1546. | 0.6 | 3 |
| 1070 | Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes. Blood, 2011, 118, 1720-1720. | 0.6 | 3 |
| 1071 | High Expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukemiaâ€“Time to Target Autophagy to Improve Therapy Outcomes?. Blood, 2011, 118, 2513-2513. | 0.6 | 1 |
| 1072 | Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood, 2011, 118, 2613-2613. | 0.6 | 5 |
| 1073 | Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. Blood, 2011, 118, 2698-2698. | 0.6 | 2 |
| 1074 | 24-Month Analysis of the Impact of Chelation on Clinical Outcomes in a 600 Patient Registry of Lower-Risk MDS Patients. Blood, 2011, 118, 2800-2800. | 0.6 | 6 |
| 1075 | FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations,. Blood, 2011, 118, 3623-3623. | 0.6 | 2 |
| 1076 | Phase 1/ 2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML,. Blood, 2011, 118, 3630-3630. | 0.6 | 4 |
| 1077 | A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),. Blood, 2011, 118, 3801-3801. | 0.6 | 12 |
| 1078 | Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP). Blood, 2011, 118, 454-454. | 0.6 | 14 |
| 1079 | Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Blood, 2011, 118, 459-459. | 0.6 | 4 |
| 1080 | Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities. Blood, 2011, 118, 608-608. | 0.6 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1081 | Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples. Blood, 2011, 118, 969-969. | 0.6 | 5 |
| 1082 | Therapeutic Modalities and New Molecular Targets in MDS. , 2011, , 219-238. | | 0 |
| 1083 | Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL,. Blood, 2011, 118, 3902-3902. | 0.6 | 0 |
| 1084 | Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (TelintraÂ®, TLK199) in Combination with Lenalidomide (RevlimidÂ®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Blood, 2011, 118, 2778-2778. | 0.6 | 0 |
| 1085 | Clofarabine Does Not Impact Negatively the Outcomes of Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Stem Cell Transplantation and Is Not Associated with Higher Liver Toxicity Rates Compared with Standard Chemotherapy. Blood, 2011, 118, 1489-1489. | 0.6 | 0 |
| 1086 | Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2011, 118, 1550-1550. | 0.6 | 0 |
| 1087 | Impact of Epigenetic Therapy Versus Conventional Chemotherapy on Survival of Elderly Patients with Acute Myeloid Leukemia. Blood, 2011, 118, 1494-1494. | 0.6 | 0 |
| 1088 | AR-67, a DNA Topo-Isomerase I Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase II Trial of Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML),. Blood, 2011, 118, 3820-3820. | 0.6 | 0 |
| 1089 | Very Long-Term Follow-up Results of Imatinib Mesylate Therapy in Chronic Phase Chronic Myeloid Leukemia After Failure of Interferon Alpha Therapy. Blood, 2011, 118, 2749-2749. | 0.6 | 0 |
| 1090 | Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS). Blood, 2011, 118, 763-763. | 0.6 | 1 |
| 1091 | Activating Mutations of the FMS-Like Tyrosine Kinase-3 (FLT3) At Complete Response and Relapse in Patients with Acute Myeloid Leukemia,. Blood, 2011, 118, 3557-3557. | 0.6 | 0 |
| 1092 | Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia,. Blood, 2011, 118, 3629-3629. | 0.6 | 0 |
| 1093 | Phase II Study of the Histone Deacetylase Inhibitor Panabinostat (LBH589) in Patients with Low or Intermediate-1 Risk Myelodysplastic syndrome. Blood, 2011, 118, 1731-1731. | 0.6 | 0 |
| 1094 | Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder. Blood, 2011, 118, 2522-2522. | 0.6 | 0 |
| 1095 | Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience. Blood, 2011, 118, 2750-2750. | 0.6 | 0 |
| 1096 | Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes,. Blood, 2011, 118, 3812-3812. | 0.6 | 0 |
| 1097 | EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),. Blood, 2011, 118, 3769-3769. | 0.6 | 0 |
| 1098 | Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS),. Blood, 2011, 118, 3639-3639. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1099 | Patients' Comorbidities and Overall Survival in Primary Myelofibrosis (PMF). Blood, 2011, 118, 5164-5164. | 0.6 | 0 |
| 1100 | Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis. Blood, 2011, 118, 2598-2598. | 0.6 | 1 |
| 1101 | Final Report of a Randomized Study of Decitabine Versus Conventional Care (CC) for Maintenance Therapy in Patients with Intermediate and High Risk Acute Myeloid Leukemia (AML) in First or Subsequent Complete Remission (CR). Blood, 2011, 118, 1530-1530. | 0.6 | 0 |
| 1102 | Impact of Combining Targeted Agents with High-Dose Cytarabine-Based Induction Chemotherapy on Acute Myeloid Leukemia Outcomes: The M.D. Anderson Cancer Center Experience. Blood, 2011, 118, 1539-1539. | 0.6 | 0 |
| 1103 | Long Term Results of Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome: Analysis of Prognostic Factors. Blood, 2011, 118, 4531-4531. | 0.6 | 0 |
| 1104 | Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center. Blood, 2011, 118, 2606-2606. | 0.6 | 0 |
| 1105 | Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),. Blood, 2011, 118, 3779-3779. | 0.6 | 1 |
| 1106 | Clofarabine-Containing Chemotherapy Does Not Increase the Risk of Infectious Complications in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2011, 118, 4256-4256. | 0.6 | 0 |
| 1107 | Early Clearance of Peripheral Blood Blasts but Not White Blood Cells Is a Powerful Prognostic marker for complete Response and Overall Survival in Patients with Acute Myeloid Leukemia (AML) receiving Induction Chemotherapy. Blood, 2011, 118, 1553-1553. | 0.6 | 1 |
| 1108 | ROS Activation Independent From Iron Overload in MDS. Blood, 2011, 118, 2798-2798. | 0.6 | 0 |
| 1109 | Clinical or Sub-Clinical Pancreatitis (PA) Associated with Nilotinib (Nb) As Frontline for Chronic Myelogenous Leukemia (CML). Blood, 2011, 118, 4443-4443. | 0.6 | 0 |
| 1110 | Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),. Blood, 2011, 118, 3802-3802. | 0.6 | 0 |
| 1111 | Allogeneic Hematopoeitic Stem Cell Transplantation (AHSCT) Versus Hypomethylating Agents (HMA) in Patients (pts) with Myelodysplastic Syndrome (MDS): A Case-Control Study. Blood, 2011, 118, 1707-1707. | 0.6 | 0 |
| 1112 | Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen. Blood, 2011, 118, 1524-1524. | 0.6 | 0 |
| 1113 | Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia,. Blood, 2011, 118, 3594-3594. | 0.6 | 1 |
| 1114 | Predictors of Outcome In Adult Patients with Acute Myeloid Leukemia In First Relapse,. Blood, 2011, 118, 3569-3569. | 0.6 | 0 |
| 1115 | Safety and Efficacy of Frontline Nilotinib (Nb) for Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Diabetic Patients (pts). Blood, 2011, 118, 2764-2764. | 0.6 | 1 |
| 1116 | Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC). Blood, 2011, 118, 981-981. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1117 | EphrinB1 Activation As a Potential New Treatment Option in AML. Blood, 2011, 118, 5235-5235. | 0.6 | 4 |
| 1118 | Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy. Blood, 2011, 118, 1518-1518. | 0.6 | 0 |
| 1119 | A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Blood, 2011, 118, 967-967. | 0.6 | 2 |
| 1120 | Inhibition of IGFâ€IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinibâ€resistant chronic myeloid leukaemia cells. Journal of Cellular and Molecular Medicine, 2010, 14, 1777-1792. | 1.6 | 19 |
| 1121 | Modeling interactions between leukemiaâ€specific chromosomal changes, somatic mutations, and gene expression patterns during progression of coreâ€binding factor leukemias. Genes Chromosomes and Cancer, 2010, 49, 182-191. | 1.5 | 25 |
| 1122 | Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound Î²-phenylethyl isothiocyanate. Blood, 2010, 116, 2732-2741. | 0.6 | 96 |
| 1123 | First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosomeâ€“positive (Ph+) acute lymphoblastic leukemia. Blood, 2010, 116, 2070-2077. | 0.6 | 319 |
| 1124 | Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood, 2010, 116, 4422-4429. | 0.6 | 336 |
| 1125 | Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood, 2010, 116, 5818-5823. | 0.6 | 93 |
| 1126 | Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood, 2010, 115, 1131-1136. | 0.6 | 210 |
| 1127 | Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood, 2010, 116, 3163-3170. | 0.6 | 143 |
| 1128 | Characteristics of pericardial effusions in patients with leukemia. Cancer, 2010, 116, 2366-2371. | 2.0 | 29 |
| 1129 | Cause of death in patients with lowerâ€risk myelodysplastic syndrome. Cancer, 2010, 116, 2174-2179. | 2.0 | 142 |
| 1130 | Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer, 2010, 116, 3830-3834. | 2.0 | 241 |
| 1131 | Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer, 2010, 116, 5568-5574. | 2.0 | 104 |
| 1132 | Maintenance therapy with lowâ€dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 2010, 116, 5420-5431. | 2.0 | 393 |
| 1133 | Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia. Cancer, 2010, 116, 5272-5278. | 2.0 | 8 |
| 1134 | Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor. Leukemia Research, 2010, 34, 221-228. | 0.4 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1135 | Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leukemia Research, 2010, 34, 752-756. | 0.4 | 102 |
| 1136 | Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). British Journal of Haematology, 2010, 148, 386-393. | 1.2 | 13 |
| 1137 | A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. British Journal of Haematology, 2010, 150, 72-82. | 1.2 | 40 |
| 1138 | Clinical impact of dose reductions and interruptions of secondâ€generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. British Journal of Haematology, 2010, 150, 303-312. | 1.2 | 37 |
| 1139 | Safety and efficacy of azacitidine in myelodysplastic syndromes. Drug Design, Development and Therapy, 2010, 4, 221. | 2.0 | 29 |
| 1140 | Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosomeâ€“Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3880-3889. | 0.8 | 361 |
| 1141 | The Combination of a Histone Deacetylase Inhibitor with the Bcl-2 Homology Domain-3 Mimetic GX15-070 Has Synergistic Antileukemia Activity by Activating Both Apoptosis and Autophagy. Clinical Cancer Research, 2010, 16, 3923-3932. | 3.2 | 60 |
| 1142 | Acute Myeloid Leukemia With t(9;11)(p21â€“22;q23). American Journal of Clinical Pathology, 2010, 133, 686-693. | 0.4 | 36 |
| 1143 | Therapy with azanucleosides for myelodysplastic syndromes. Nature Reviews Clinical Oncology, 2010, 7, 433-444. | 12.5 | 76 |
| 1144 | Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood, 2010, 115, 2412-2419. | 0.6 | 77 |
| 1145 | Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome. Journal of Clinical Oncology, 2010, 28, 285-291. | 0.8 | 70 |
| 1146 | Decitabine in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy, 2010, 10, 9-22. | 1.1 | 58 |
| 1147 | Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome. Journal of Clinical Oncology, 2010, 28, 2755-2760. | 0.8 | 52 |
| 1148 | Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 1856-1862. | 0.8 | 347 |
| 1149 | Prognosis of Myelodysplastic Syndromes. Hematology American Society of Hematology Education Program, 2010, 2010, 330-337. | 0.9 | 25 |
| 1150 | Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics, 2010, 5, 499-508. | 1.3 | 100 |
| 1151 | Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leukemia and Lymphoma, 2010, 51, 475-480. | 0.6 | 16 |
| 1152 | The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Autophagy, 2010, 6, 976-978. | 4.3 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1153 | Current and Future Management Options for Myelodysplastic Syndromes. Drugs, 2010, 70, 1381-1394. | 4.9 | 10 |
| 1154 | Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leukemia and Lymphoma, 2010, 51, 1478-1484. | 0.6 | 4 |
| 1155 | Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients. Leukemia and Lymphoma, 2010, 51, 598-605. | 0.6 | 43 |
| 1156 | Phase II Study of All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), with or without Gemtuzumab OzogamIcin (GO) for the Frontline Therapy of Patients with Acute Promyelocytic Leukemia (APL).. Blood, 2010, 116, 1080-1080. | 0.6 | 5 |
| 1157 | Chromosomal Abnormalities In Philadelphia Chromosome (Ph)-Negative Metaphases Appearing During Second Generation Tyrosine Kinase Inhibitors (2nd TKI) Therapy In Patients (pts) with Chronic Myeloid Leukemia (CML).. Blood, 2010, 116, 1232-1232. | 0.6 | 2 |
| 1158 | A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents. Blood, 2010, 116, 1857-1857. | 0.6 | 3 |
| 1159 | Discrepancy In Diagnosis of Myelodysplastic Syndrome (MDS) Between Referral and Tertiary Care Centers: Experience at MD Anderson Cancer Center (MDACC). Blood, 2010, 116, 1870-1870. | 0.6 | 2 |
| 1160 | Intracranial Hemorrhage (ICH) In Patients (Pts) Presenting with Myeloid Leukemia to a Tertiary Care Center. Blood, 2010, 116, 2170-2170. | 0.6 | 1 |
| 1161 | The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2nd) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS). Blood, 2010, 116, 2289-2289. | 0.6 | 1 |
| 1162 | Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants.. Blood, 2010, 116, 2831-2831. | 0.6 | 1 |
| 1163 | Updated Results of Combination Cytokine Immunotherapy In the Treatment of Aplastic Anemia and Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2920-2920. | 0.6 | 5 |
| 1164 | Impact of RAS Mutations In Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2926-2926. | 0.6 | 1 |
| 1165 | Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies. Blood, 2010, 116, 3292-3292. | 0.6 | 8 |
| 1166 | Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. Blood, 2010, 116, 3298-3298. | 0.6 | 3 |
| 1167 | Frontline Therapy for Older Patients (pts) with Acute Myeloid Leukemia (AML): Clofarabine Plus Low-Dose Cytarabine Induction Followed by Prolonged Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine. Blood, 2010, 116, 336-336. | 0.6 | 8 |
| 1168 | The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs).. Blood, 2010, 116, 3429-3429. | 0.6 | 3 |
| 1169 | Phase Ib Study of Oral Panobinostat In Combination with 5-Azacitidine (5-aza) In Patients with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Blood, 2010, 116, 4957-4957. | 0.6 | 1 |
| 1170 | Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study. Blood, 2010, 116, 603-603. | 0.6 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1171 | Phase II Study of 5-Azacitidine and Vorinostat In Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance or Presence of Other comorbidities. Blood, 2010, 116, 604-604. | 0.6 | 4 |
| 1172 | Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index. Blood, 2010, 116, 605-605. | 0.6 | 1 |
| 1173 | Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML). Blood, 2010, 116, 656-656. | 0.6 | 10 |
| 1174 | Final Report of a Phase I Trial of Decitabine with or without hyperCVAD In Relapsed Acute Lymphocytic Leukemia (ALL). Blood, 2010, 116, 867-867. | 0.6 | 10 |
| 1175 | BARD1: a New Target In Leukemia. Blood, 2010, 116, 4642-4642. | 0.6 | 0 |
| 1176 | Point Mutations In Myelodysplastic Syndromes Are Associated with Clinical Features and Are Independent Predictors of Overall Survival. Blood, 2010, 116, 300-300. | 0.6 | 0 |
| 1177 | Analysis of Regulatory miRNAs of Histone Demethylase JMJD3 In MDS CD34+ Hematoprogenitor Cells. Blood, 2010, 116, 609-609. | 0.6 | 0 |
| 1178 | A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2188-2188. | 0.6 | 1 |
| 1179 | Decitabine Is Effective and Safe In Patients with Chronic Myelomonocytic Leukemia. Blood, 2010, 116, 4032-4032. | 0.6 | 0 |
| 1180 | Prognostic Factors Associated with Progression of Myelodysplastic Syndromes (MDS) to Acute Myeloid Leukemia (AML) In Patients (pts) Treated with Decitabine. Blood, 2010, 116, 4956-4956. | 0.6 | 0 |
| 1181 | Clinical Characterization, Prognostic Implications, and Response to Therapy In Patients with Myelodysplastic Syndrome (MDS) and Chromsome 17 Abnormality: A Single Institutional Experience. Blood, 2010, 116, 2930-2930. | 0.6 | 0 |
| 1182 | Final Report of a Phase II Trial of Vorinostat, Idarubicin and Cytarabine In Previously Untreated Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2189-2189. | 0.6 | 3 |
| 1183 | Levels of Nrf2 and Keap1 Are Associated with Poor Prognostic Features In Myelodysplastic Syndromes (MDS). Blood, 2010, 116, 1874-1874. | 0.6 | 1 |
| 1184 | Seven-Year Follow-up Data on Sequential Prospective Trials of Imatinib 400mg Vs 800mg Daily Schedule for Front-Line Treatment of Chronic Myeloid Leukemia (CML).. Blood, 2010, 116, 3438-3438. | 0.6 | 0 |
| 1185 | Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy. Blood, 2010, 116, 2936-2936. | 0.6 | 0 |
| 1186 | Third Party Umbilical Cord Blood Regulatory T Cells Prevents Graft Versus Host Disease In a Xenogenic Murine Model.. Blood, 2010, 116, 3737-3737. | 0.6 | 0 |
| 1187 | Phase I Study Results of Gimatecan In the Treatment of Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 1883-1883. | 0.6 | 0 |
| 1188 | Death In Complete Remission Among Patients with Acute Myeloid Leukemia: A Preventable Problem?. Blood, 2010, 116, 2710-2710. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1189 | Proteomic Profiling In CD34+CD38- Stem Cells and CD34+ Cells From 185 Myelodysplasia Patients Using Reverse Phase Proteins Arrays (RPPA) Reveals Recurrent Proteins Expression Signatures with Prognostic Implications. Blood, 2010, 116, 2126-2126. | 0.6 | 0 |
| 1190 | Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab. Blood, 2010, 116, 1781-1781. | 0.6 | 1 |
| 1191 | MYBL2 Is a Candidate Tumor Suppressor Gene In MDS. Blood, 2010, 116, 1865-1865. | 0.6 | 0 |
| 1192 | Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).. Blood, 2010, 116, 1085-1085. | 0.6 | 0 |
| 1193 | Cytogenetic Evolution (CE) In Patients (pts) with Low and Intermediate Risk Myelodysplastic Syndromes (MDS) Is Associated with Poor Prognosis. Blood, 2010, 116, 2941-2941. | 0.6 | 0 |
| 1194 | Outcome After Failure to Second Generation Thyrosine Kinase Inhibitors(TKI) Treatment as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase(CP).. Blood, 2010, 116, 3442-3442. | 0.6 | 1 |
| 1195 | Prognostic Significance of Mutations In Isocitrate Dehydrogenase (IDH) Enzyme Isoforms 1 and 2 and Single Nucleotide Polymorphisms (SNP) In IDH1, In Patients with Acute Myeloid Leukemia Treated with High Dose Cytarabine and Idarubicin Induction. Blood, 2010, 116, 2706-2706. | 0.6 | 4 |
| 1196 | Levels of Mir-29b or Mir-101 Do Not Predict Response In Patients (pts) with Acute Myelogenous Leukemia (AML) Treated with the Combination of 5-Azacytidine, Valproic Acid and ATRA. Blood, 2010, 116, 1701-1701. | 0.6 | 0 |
| 1197 | Different Definitions of Progression-Free Survival (PFS) and Event-Free Survival (EFS) May Result In Perceived but Not Real Differences In Long-Term Outcome When Comparing Trials In Chronic Myeloid Leukemia (CML). Blood, 2010, 116, 672-672. | 0.6 | 1 |
| 1198 | Update on treatments for patients with myelodysplastic syndrome. Clinical Advances in Hematology and Oncology, 2010, 8, 407-9. | 0.3 | 0 |
| 1199 | Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4760-4766. | 0.8 | 152 |
| 1200 | Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology, 2009, 27, 504-510. | 0.8 | 355 |
| 1201 | Managing Iron Overload in Patients with Myelodysplastic Syndromes with Oral Deferasirox Therapy. Oncologist, 2009, 14, 489-496. | 1.9 | 17 |
| 1202 | Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. Journal of Clinical Oncology, 2009, 27, 1637-1643. | 0.8 | 71 |
| 1203 | Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial. Journal of Clinical Oncology, 2009, 27, 3842-3848. | 0.8 | 321 |
| 1204 | Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. International Journal of Cancer, 2009, 125, 723-729. | 2.3 | 134 |
| 1205 | Therapyâ€related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer, 2009, 115, 101-106. | 2.0 | 15 |
| 1206 | Lowâ€dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer, 2009, 115, 1899-1905. | 2.0 | 191 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1207 | Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer, 2009, 115, 4737-4744. | 2.0 | 45 |
| 1208 | The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities. Cancer, 2009, 115, 5202-5209. | 2.0 | 40 |
| 1209 | Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer, 2009, 115, 5490-5498. | 2.0 | 57 |
| 1210 | Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. Journal of Hematopathology, 2009, 2, 2-8. | 0.2 | 43 |
| 1211 | In reply to â€˜Improving the prognostic evaluation of patients with lower-risk myelodysplastic syndromesâ€™ by Kuendgen et al.. Leukemia, 2009, 23, 185-185. | 3.3 | 0 |
| 1212 | A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms. Nature Genetics, 2009, 41, 455-459. | 9.4 | 322 |
| 1213 | Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRÎ± mutation status. Leukemia Research, 2009, 33, 837-839. | 0.4 | 27 |
| 1214 | Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leukemia Research, 2009, 33, 1361-1366. | 0.4 | 16 |
| 1215 | Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood, 2009, 113, 6330-6337. | 0.6 | 175 |
| 1216 | Epigenetic therapy of leukemia: An update. International Journal of Biochemistry and Cell Biology, 2009, 41, 72-80. | 1.2 | 45 |
| 1217 | Progress in Myelodysplastic Syndromes. Clinical Lymphoma and Myeloma, 2009, 9, S286-S292. | 1.4 | 3 |
| 1218 | Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood, 2009, 114, 144-147. | 0.6 | 661 |
| 1219 | Residual DNA methylation at remission is prognostic in adult Philadelphia chromosomeâ€“negative acute lymphocytic leukemia. Blood, 2009, 113, 1892-1898. | 0.6 | 24 |
| 1220 | Epigenetics of Acute Lymphocytic Leukemia. Seminars in Hematology, 2009, 46, 24-32. | 1.8 | 80 |
| 1221 | Improving survival in myelodysplastic syndromes. Lancet Oncology, The, 2009, 10, 200-201. | 5.1 | 7 |
| 1222 | Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood, 2009, 113, 2154-2160. | 0.6 | 151 |
| 1223 | Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood, 2009, 113, 5058-5063. | 0.6 | 24 |
| 1224 | FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status.. Blood, 2009, 114, 1026-1026. | 0.6 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1225 | Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome- Outcome in Previously Untreated Patients.. Blood, 2009, 114, 1053-1053. | 0.6 | 7 |
| 1226 | Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS).. Blood, 2009, 114, 1055-1055. | 0.6 | 7 |
| 1227 | A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).. Blood, 2009, 114, 117-117. | 0.6 | 5 |
| 1228 | Oral Clofarabine in the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome.. Blood, 2009, 114, 118-118. | 0.6 | 2 |
| 1229 | A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS).. Blood, 2009, 114, 119-119. | 0.6 | 6 |
| 1230 | Baseline Serum Ferritin Predicts Rate of Infection in Patients with Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.. Blood, 2009, 114, 1611-1611. | 0.6 | 2 |
| 1231 | A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Older Patients with Myelodysplastic Syndrome (MDS) Refractory to Hypomethylating Agents.. Blood, 2009, 114, 1758-1758. | 0.6 | 3 |
| 1232 | Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysplastic Syndrome (MDS) Receiving Decitabine.. Blood, 2009, 114, 1769-1769. | 0.6 | 6 |
| 1233 | Augmented Hyper-CVAD in Adult ALL Salvage Therapy: The MDACC Experience of Hyper-CVAD Using Dose-Intense Vincristine, Dexamethasone, and Pegaspargase.. Blood, 2009, 114, 2031-2031. | 0.6 | 3 |
| 1234 | Count Recovery in AML Patients Achieving a Complete Response.. Blood, 2009, 114, 2062-2062. | 0.6 | 3 |
| 1235 | Hypomethylating Therapy for the Treatment of Acute Erythroleukemia Patients.. Blood, 2009, 114, 2069-2069. | 0.6 | 4 |
| 1236 | Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid.. Blood, 2009, 114, 2074-2074. | 0.6 | 4 |
| 1237 | Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 2079-2079. | 0.6 | 4 |
| 1238 | Myelodysplastic Syndrome with Fibrosis: Experience of a Single-Institution with 139 Patients.. Blood, 2009, 114, 2775-2775. | 0.6 | 2 |
| 1239 | Comorbidities and Myelodysplatic Syndromes.. Blood, 2009, 114, 2789-2789. | 0.6 | 3 |
| 1240 | Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).. Blood, 2009, 114, 3431-3431. | 0.6 | 14 |
| 1241 | A Prognostic Model of Therapy-Related Myelodysplastic syndrome .. Blood, 2009, 114, 3796-3796. | 0.6 | 4 |
| 1242 | Prognositc Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score.. Blood, 2009, 114, 3819-3819. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1243 | Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy.. Blood, 2009, 114, 4756-4756. | 0.6 | 7 |
| 1244 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Deferasirox (ExjadeÂ®) in Patients with Low/Intermediate-1 Risk MDS and Transfusional Iron Overload.. Blood, 2009, 114, 4854-4854. | 0.6 | 3 |
| 1245 | Lack of IKZF1 Aberrant DNA Methylation in Acute Lymphocytic Leukemia.. Blood, 2009, 114, 982-982. | 0.6 | 2 |
| 1246 | Clinical Parameters in 391 Iron-Overloaded Patients with Lower-Risk MDS Enrolled in a Prospective, Non-Interventional Multicenter Registry.. Blood, 2009, 114, 4834-4834. | 0.6 | 0 |
| 1247 | Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes.. Blood, 2009, 114, 1248-1248. | 0.6 | 0 |
| 1248 | Genome-Wide Chip-Seq Analysis of Histone Methylation Reveals Modulators of NF-Î¹B Signaling and the Histone Demethylase JMJD3 as Implicated in Disease Progression in Myelodysplastic Syndrome (MDS).. Blood, 2009, 114, 291-291. | 0.6 | 1 |
| 1249 | A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.. Blood, 2009, 114, 1772-1772. | 0.6 | 0 |
| 1250 | Characteristics and Outcome of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy.. Blood, 2009, 114, 1038-1038. | 0.6 | 11 |
| 1251 | Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts.. Blood, 2009, 114, 3102-3102. | 0.6 | 1 |
| 1252 | The Combination of PEITC (Phenehyl Isothiocyanate) with a Histone Deacetylase Inhibitor (HDACi) Has Synergistic Antileukemia Activity by Overcoming a Redox-Mediated Resistance Pathway.. Blood, 2009, 114, 1739-1739. | 0.6 | 0 |
| 1253 | A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.. Blood, 2009, 114, 2047-2047. | 0.6 | 1 |
| 1254 | The Outcome of Patients (pts) with Acute Promyelocytic Leukemia (APL) Who Fail Both Allâ€“Trans-retinoic Acid (ATRA) and Arsenic Trioxide (ATO).. Blood, 2009, 114, 4143-4143. | 0.6 | 0 |
| 1255 | Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) â‰¥ 60 Years (yrs).. Blood, 2009, 114, 2058-2058. | 0.6 | 1 |
| 1256 | Favorable Outcome for Lymphoblastic Lymphoma (LL) After Frontline Therapy with the Hyper-CVAD Regimens: An Update.. Blood, 2009, 114, 4099-4099. | 0.6 | 133 |
| 1257 | Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia.. Blood, 2009, 114, 330-330. | 0.6 | 0 |
| 1258 | A Phase 1 Study of Dose-Dense 5-Aza-2â€²-Deoxycitidine (decitabine) in Relapse Refractory Acute Lymphocytic Leukemia (ALL).. Blood, 2009, 114, 2030-2030. | 0.6 | 1 |
| 1259 | Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.. Blood, 2009, 114, 509-509. | 0.6 | 4 |
| 1260 | Outcome of Therapy-Related Acute Promyelocytic Leukemia (t-APL) with or without Arsenic Trioxide (ATO) as a Component of Frontline Therapy.. Blood, 2009, 114, 1050-1050. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1261 | DNA Methylation and Gene Expression Analysis in a Phase II Randomized Study of Decitabine Vs. Decitabine Plus Valproic Acid in MDS and AML.. Blood, 2009, 114, 3808-3808. | 0.6 | 0 |
| 1262 | Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 836-836. | 0.6 | 1 |
| 1263 | A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse.. Blood, 2009, 114, 1061-1061. | 0.6 | 4 |
| 1264 | Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer, 2008, 112, 837-845. | 2.0 | 106 |
| 1265 | Evolution of decitabine development. Cancer, 2008, 112, 2341-2351. | 2.0 | 187 |
| 1266 | Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer, 2008, 113, 1933-1952. | 2.0 | 84 |
| 1267 | Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer, 2008, 113, 1351-1361. | 2.0 | 458 |
| 1268 | Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer, 2008, 113, 3186-3191. | 2.0 | 129 |
| 1269 | Treatment of coreâ€bindingâ€factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colonyâ€stimulating factor results in improved eventâ€free survival. Cancer, 2008, 113, 3181-3185. | 2.0 | 68 |
| 1270 | Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia. Leukemia Research, 2008, 32, 1505-1509. | 0.4 | 25 |
| 1271 | Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) Tj ETQq1 1 0.784314 rgBT /Overlock 10 | 0.6 | 440 |
| 1272 | A pilot pharmacokinetic study of oral azacitidine. Leukemia, 2008, 22, 1680-1684. | 3.3 | 74 |
| 1273 | A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia, 2008, 22, 538-543. | 3.3 | 296 |
| 1274 | Role of epigenetic therapy in myelodysplastic syndrome. Expert Review of Hematology, 2008, 1, 161-174. | 1.0 | 0 |
| 1275 | Spontaneous Remission of Acute Myeloid Leukemia: Report of Three Cases and Review of the Literature. Clinical Leukemia, 2008, 2, 64-67. | 0.2 | 6 |
| 1276 | Treatment Strategies in Myelodysplastic Syndromes. Cancer Investigation, 2008, 26, 208-216. | 0.6 | 13 |
| 1277 | Phase II Study of Dasatinib in Philadelphia Chromosomeâ€“Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis. Clinical Cancer Research, 2008, 14, 3906-3915. | 3.2 | 151 |
| 1278 | Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2008, 26, 196-203. | 0.8 | 145 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1279 | Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers. Clinical Cancer Research, 2008, 14, 6296-6301. | 3.2 | 153 |
| 1280 | Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia. Journal of Clinical Oncology, 2008, 26, 5684-5688. | 0.8 | 123 |
| 1281 | A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2008, 112, 1638-1645. | 0.6 | 199 |
| 1282 | Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood, 2008, 112, 981-989. | 0.6 | 229 |
| 1283 | Demethylating agents in myeloid malignancies. Current Opinion in Oncology, 2008, 20, 705-710. | 1.1 | 96 |
| 1284 | Relapse and death during first remission in acute myeloid leukemia. Haematologica, 2008, 93, 633-634. | 1.7 | 26 |
| 1285 | Maintenance Therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Relapsed or Refractory AML or MDS: A Dose and Schedule Finding Study.. Blood, 2008, 112, 1134-1134. | 0.6 | 2 |
| 1286 | Outcome of Patients (pts) with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Decitabine Failure.. Blood, 2008, 112, 1659-1659. | 0.6 | 6 |
| 1287 | Association of Pleural Effusion and Bleeding in Patients with Chronic Myelogenous Leukemia Receiving Dasatinib.. Blood, 2008, 112, 2112-2112. | 0.6 | 2 |
| 1288 | Imatinib Frontline Therapy Is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction.. Blood, 2008, 112, 2126-2126. | 0.6 | 1 |
| 1289 | Oral (po) and Intravenous (iv) Clofarabine for Patients (pts) with Myelodysplastic Syndrome (MDS). Blood, 2008, 112, 222-222. | 0.6 | 6 |
| 1290 | Effect of Romiplostim in Patients (pts) with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Azacytidine. Blood, 2008, 112, 224-224. | 0.6 | 13 |
| 1291 | Identification of Multiple Promoter Associated CpG Islands Commonly Methylated in Both Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukemia(CLL) Using Novel Genome-Wide Microarray Technique: Implications for Common Primordial Molecular Pathways in Lymphoid Leukemias.. Blood, 2008, 112, 2263-2263. | 0.6 | 2 |
| 1292 | Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML. Blood, 2008, 112, 228-228. | 0.6 | 15 |
| 1293 | Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy. Blood, 2008, 112, 2955-2955. | 0.6 | 1 |
| 1294 | Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome. Blood, 2008, 112, 2985-2985. | 0.6 | 7 |
| 1295 | Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy. Blood, 2008, 112, 2987-2987. | 0.6 | 3 |
| 1296 | Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations. Blood, 2008, 112, 3302-3302. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1297 | Epigenetic Silencing of the RUNX3 Gene by Promoter Hypermethylation in Patients with Acute Myeloid Leukemia.. Blood, 2008, 112, 3341-3341. | 0.6 | 1 |
| 1298 | Efficacy of Nilotinib (formerly AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood, 2008, 112, 446-446. | 0.6 | 9 |
| 1299 | A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results. Blood, 2008, 112, 5084-5084. | 0.6 | 8 |
| 1300 | Pegylated Interferon-ALFA-2A (PEG-IFN-Î±-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV). Blood, 2008, 112, 658-658. | 0.6 | 5 |
| 1301 | Combined Therapy with Lenalidomide and Prednisone Renders Durable Clinical, Histopathological, and Molecular Responses in Patients with Myelofibrosis. Blood, 2008, 112, 662-662. | 0.6 | 1 |
| 1302 | Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years. Blood, 2008, 112, 768-768. | 0.6 | 3 |
| 1303 | Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.. Blood, 2008, 112, 925-925. | 0.6 | 5 |
| 1304 | Disease-Related Mortality in Patients with Lower-Risk Myelodysplastic Syndrome (MDS). Blood, 2008, 112, 5073-5073. | 0.6 | 1 |
| 1305 | Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): The MD Anderson Cancer Center (MDACC) Experience. Blood, 2008, 112, 3982-3982. | 0.6 | 8 |
| 1306 | Epigenetic Inactivation of Notch Signaling Target Genes HES in B Cell Acute Lymphoblastic Leukemia.. Blood, 2008, 112, 3372-3372. | 0.6 | 0 |
| 1307 | Outcome of First Salvage Therapy in Core Binding Factor Associated Acute Myelogenous Leukemia Is Less Than Optimal. Blood, 2008, 112, 2952-2952. | 0.6 | 0 |
| 1308 | Development and Validation of a New Prognostic Model for Myelodysplastic Syndrome (MDS) That Accounts for Events Not Considered by the International Prognostic Scoring System (IPSS). Blood, 2008, 112, 635-635. | 0.6 | 20 |
| 1309 | The Heterogeneous Prognosis of Patients with Myelodysplastic Syndrome (MDS) and Chromosome 5 Abnormalities: How Does It Relate to the Original Lenalidomide Experience in MDS?.. Blood, 2008, 112, 1644-1644. | 0.6 | 0 |
| 1310 | The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways.. Blood, 2008, 112, 1633-1633. | 0.6 | 1 |
| 1311 | Experience with the Combination of a Hypomethylating Agent and Valproic Acid in Pediatric Acute Myelogenous Leukemia. Blood, 2008, 112, 4036-4036. | 0.6 | 0 |
| 1312 | Increase in the Incidence of Secondary Acute Myeloid Leukemia (2-AML): A Single Institution Experience Over 20 Years.. Blood, 2008, 112, 1498-1498. | 0.6 | 0 |
| 1313 | Phase II Study of Thymoglobulin, Cyclosporine and G-CSF for Initial Treatment of Aplastic Anemia and Low Risk Myelodysplastic Syndrome. Blood, 2008, 112, 5080-5080. | 0.6 | 0 |
| 1314 | Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment.. Blood, 2008, 112, 2078-2078. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1315 | Antileukemia Activity of JNJ-26481585, a Potent Second-Generation Histone Deacetylase Inhibitor. Blood, 2008, 112, 2631-2631. | 0.6 | 0 |
| 1316 | Clinical Significance of Dose Reductions of Second-Generation Tyrosine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML). Blood, 2008, 112, 3217-3217. | 0.6 | 5 |
| 1317 | Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy.. Blood, 2008, 112, 2111-2111. | 0.6 | 1 |
| 1318 | Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy.. Blood, 2008, 112, 2094-2094. | 0.6 | 0 |
| 1319 | Malignancies Occurring during Therapy with Tyrosine Kinase Inhibitors (TKI) for Chronic Myeloid Leukemia (CML) and Other Hematologic Malignancies.. Blood, 2008, 112, 2125-2125. | 0.6 | 0 |
| 1320 | Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clinical Advances in Hematology and Oncology, 2008, 6, 1-15. | 0.3 | 12 |
| 1321 | Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood, 2007, 109, 4679-4685. | 0.6 | 303 |
| 1322 | Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines. Clinical Cancer Research, 2007, 13, 4225-4232. | 3.2 | 119 |
| 1323 | Modifying the Epigenome as a Therapeutic Strategy in Myelodysplasia. Hematology American Society of Hematology Education Program, 2007, 2007, 405-411. | 0.9 | 21 |
| 1324 | A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leukemia and Lymphoma, 2007, 48, 283-289. | 0.6 | 45 |
| 1325 | RIL, a LIM Gene on 5q31, Is Silenced by Methylation in Cancer and Sensitizes Cancer Cells to Apoptosis. Cancer Research, 2007, 67, 1997-2005. | 0.4 | 72 |
| 1326 | Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2007, 109, 52-57. | 0.6 | 675 |
| 1327 | Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood, 2007, 109, 3214-3218. | 0.6 | 174 |
| 1328 | The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opinion on Pharmacotherapy, 2007, 8, 65-73. | 0.9 | 30 |
| 1329 | Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood, 2007, 110, 2302-2308. | 0.6 | 391 |
| 1330 | Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer, 2007, 109, 265-273. | 2.0 | 113 |
| 1331 | Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer, 2007, 109, 248-255. | 2.0 | 121 |
| 1332 | Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Cancer, 2007, 109, 1133-1137. | 2.0 | 182 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1333 | Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer, 2007, 110, 2000-2006. | 2.0 | 40 |
| 1334 | PEG-IFN-Î±-2b therapy in BCR-ABLâ€“negative myeloproliferative disorders. Cancer, 2007, 110, 2012-2018. | 2.0 | 107 |
| 1335 | Potential cure of acute myeloid leukemia. Cancer, 2007, 110, 2756-2760. | 2.0 | 30 |
| 1336 | HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Modern Pathology, 2007, 20, 54-62. | 2.9 | 37 |
| 1337 | Biphenotypic acute leukaemia: a case series. British Journal of Haematology, 2007, 138, 213-216. | 1.2 | 54 |
| 1338 | Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome. British Journal of Haematology, 2007, 138, 555-557. | 1.2 | 5 |
| 1339 | Survival and Efficacy of Decitabine in Myelodysplastic Syndromes (MDS), Analysis of the 5-Day IV Dosing Regimen.. Blood, 2007, 110, 115-115. | 0.6 | 2 |
| 1340 | Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine.. Blood, 2007, 110, 1449-1449. | 0.6 | 4 |
| 1341 | Results of an Exploratory Study of Oral (po) and Intravenous (iv) Clofarabine in Patients with Myelodysplastic Syndrome.. Blood, 2007, 110, 1455-1455. | 0.6 | 2 |
| 1342 | Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myelogenous Leukemia Associated with Chromosome 5 Abnormalities.. Blood, 2007, 110, 1459-1459. | 0.6 | 2 |
| 1343 | Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2â€²-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.. Blood, 2007, 110, 1468-1468. | 0.6 | 8 |
| 1344 | A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia.. Blood, 2007, 110, 1842-1842. | 0.6 | 2 |
| 1345 | Intensively Timed Induction (ITI) Chemotherapy in Adults with Acute Myelogenous Leukemia (AML).. Blood, 2007, 110, 1851-1851. | 0.6 | 4 |
| 1346 | Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML).. Blood, 2007, 110, 1932-1932. | 0.6 | 4 |
| 1347 | Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2.. Blood, 2007, 110, 1939-1939. | 0.6 | 13 |
| 1348 | Eph Receptor Tyrosine Kinases and Ephrin Ligands Are Epigenetically Inactivated in Acute Lymphoblastic Leukemia and Are Potential New Tumor Suppressor Genes in Human Leukemia.. Blood, 2007, 110, 2128-2128. | 0.6 | 10 |
| 1349 | Analysis of Class I and II Histone Deacetylase Fails To Identify a Human Leukemia Specific Expression Profile.. Blood, 2007, 110, 2130-2130. | 0.6 | 1 |
| 1350 | Multivariate Evaluation of the Prognostic and Therapeutic Relevance of Cytogenetics in a Merged European-American Cohort of 3860 Patients with MDS.. Blood, 2007, 110, 247-247. | 0.6 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1351 | Multivariate Analysis Suggests That the Prognostic Impact of Poor Cytogenetics Is Potentially Underestimated in the IPSS.. Blood, 2007, 110, 248-248. | 0.6 | 5 |
| 1352 | Phase I Study of 5-aza-2â€²-Deoxycitidine, Alone or in Combination with Hyper-CVAD, in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).. Blood, 2007, 110, 2826-2826. | 0.6 | 3 |
| 1353 | Benefit of Anti-Infectious Prophylaxis in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Receiving Frontline â€œTargeted Therapyâ€•. Blood, 2007, 110, 2858-2858. | 0.6 | 5 |
| 1354 | Randomized Study of Decitabine Versus Observation or Continued Cytotoxic Chemotherapy in Patients with Intermediate and Poor Risk Acute Myeloid Leukemia in First or Subsequent Complete Remission.. Blood, 2007, 110, 2859-2859. | 0.6 | 1 |
| 1355 | Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).. Blood, 2007, 110, 29-29. | 0.6 | 25 |
| 1356 | Survival Outcomes for Patients (Pts) with Chronic Myeloid Leukemia (CML) with Clonal Evolution (CE) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure.. Blood, 2007, 110, 2949-2949. | 0.6 | 1 |
| 1357 | A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.. Blood, 2007, 110, 298-298. | 0.6 | 5 |
| 1358 | Pegylated Interferon-alfa-2a (PEG-IFN-Î±-2A; PEGASYSâ„¢) for Essential Thrombocythemia (ET) and Polycythemia Vera (PV): An Update of an Ongoing Phase II Study.. Blood, 2007, 110, 3542-3542. | 0.6 | 2 |
| 1359 | Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.. Blood, 2007, 110, 3543-3543. | 0.6 | 10 |
| 1360 | Phase II Study of Dasatinib (SPRYCELâ„¢) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.. Blood, 2007, 110, 3551-3551. | 0.6 | 4 |
| 1361 | Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented) Tj ETQq1 1 0.784314 rgBT /Overlo (ALL).. Blood, 2007, 110, 4324-4324. | 0.6 | 2 |
| 1362 | Final Update of Phase I-II Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome.. Blood, 2007, 110, 441-441. | 0.6 | 4 |
| 1363 | Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).. Blood, 2007, 110, 444-444. | 0.6 | 15 |
| 1364 | Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA) and Decitabine in Patients with Relapsed, Refractory or Poor Prognosis Leukemia.. Blood, 2007, 110, 897-897. | 0.6 | 15 |
| 1365 | Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. Blood, 2007, 110, 9-9. | 0.6 | 9 |
| 1366 | Treatment of Myelodysplastic Syndrome (MDS) with Cytokine Immunotherapy for Low-Risk MDS.. Blood, 2007, 110, 1463-1463. | 0.6 | 0 |
| 1367 | Phase II Study of Lenalidomide and Prednisone for Patients with Myelofibrosis.. Blood, 2007, 110, 3545-3545. | 0.6 | 0 |
| 1368 | Genome-Wide DNA Methylation Profile of CLL with 17p del Allowed Identification of Multiple Epigenetically Inactivated Molecular Pathways with Prognostic Value in Human Leukemia.. Blood, 2007, 110, 492-492. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1369 | Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.. Blood, 2007, 110, 2832-2832. | 0.6 | 0 |
| 1370 | Efficacy of Azacytidine (5-AC) Given as Maintenance or Salvage Therapy for Patients (pts) with Acute Leukemia Post Allogeneic Stem Cell Transplantation (HSCT).. Blood, 2007, 110, 3013-3013. | 0.6 | 0 |
| 1371 | All-Trans Retinoic Acid (ATRA) and Arsenic Trioxide (As2O3) Combination Therapy Induces High Rates of Durable Molecular Remission in Newly Diagnosed Acute Promyelocytic Leukemia (APL).. Blood, 2007, 110, 1834-1834. | 0.6 | 2 |
| 1372 | Use of Post-Treatment Clinical Data To Predict Response to Decitabine.. Blood, 2007, 110, 1448-1448. | 0.6 | 10 |
| 1373 | Clinical Characteristics and Outcome of Patients (pts) with F317L BCR-ABL Kinase Domain (KD) Mutation after Therapy with Tyrosine Kinase Inhibitors (TKIs).. Blood, 2007, 110, 1949-1949. | 0.6 | 0 |
| 1374 | Phase I Study of Sapacitabine, an Oral Nucleoside Analogue, in Patients with Advanced Leukemias or Myelodysplastic Syndromes (MDS).. Blood, 2007, 110, 884-884. | 0.6 | 1 |
| 1375 | Salvage Therapy with Standard Dose Cytarabine Is Appropriate for Patients with Acute Myelogenous Leukemia Refractory to Front-Line Therapy with Hypomethylating Agents.. Blood, 2007, 110, 4382-4382. | 0.6 | 0 |
| 1376 | Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival.. Blood, 2007, 110, 1852-1852. | 0.6 | 0 |
| 1377 | Long-Term Significance of Achieving a Major Cytogenetic Response (MCyR) without a Complete Hematologic Response (CHR) among Patients (pts) with Chronic Myeloid Leukemia (CML) in Advanced Phase Treated with Second Generation Tyrosine Kinase Inhibitors (TKI).. Blood, 2007, 110, 1944-1944. | 0.6 | 0 |
| 1378 | Genome-Wide Identification of Aberrant Promoter Associated CpG Island Methylation in Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 2127-2127. | 0.6 | 0 |
| 1379 | Use of hypomethylating agents in myelodysplastic syndromes. Clinical Advances in Hematology and Oncology, 2007, 5, 544-52. | 0.3 | 6 |
| 1380 | Evaluating new treatment options for MDS. Clinical Advances in Hematology and Oncology, 2007, 5, 1-9; quiz 10-2. | 0.3 | 2 |
| 1381 | Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood, 2006, 107, 880-884. | 0.6 | 83 |
| 1382 | Decitabine in Myelodysplastic Syndromes. Drugs, 2006, 66, 959-960. | 4.9 | 2 |
| 1383 | Phase 1/2 study of the combination of 5-aza-2â€²-deoxycytidine with valproic acid in patients with leukemia. Blood, 2006, 108, 3271-3279. | 0.6 | 492 |
| 1384 | DNA Methylation Changes after 5-Aza-2â€²-Deoxycytidine Therapy in Patients with Leukemia. Cancer Research, 2006, 66, 5495-5503. | 0.4 | 253 |
| 1385 | Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood, 2006, 107, 3469-3473. | 0.6 | 371 |
| 1386 | Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood, 2006, 107, 480-482. | 0.6 | 65 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1387 | Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood, 2006, 108, 1174-1182. | 0.6 | 83 |
| 1388 | Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. British Journal of Haematology, 2006, 134, 58-60. | 1.2 | 24 |
| 1389 | Point-of-care biosensor systems for cancer diagnostics/prognostics. Biosensors and Bioelectronics, 2006, 21, 1932-1942. | 5.3 | 307 |
| 1390 | Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leukemia Research, 2006, 30, 813-822. | 0.4 | 49 |
| 1391 | Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer, 2006, 106, 120-127. | 2.0 | 85 |
| 1392 | Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome:. Cancer, 2006, 106, 1090-1098. | 2.0 | 550 |
| 1393 | Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer, 2006, 106, 1569-1580. | 2.0 | 503 |
| 1394 | A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies. Clinical Cancer Research, 2006, 12, 4628-4635. | 3.2 | 320 |
| 1395 | Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).. Blood, 2006, 108, 1954-1954. | 0.6 | 9 |
| 1396 | MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.. Blood, 2006, 108, 1967-1967. | 0.6 | 8 |
| 1397 | High-Dose (HD) Imatinib Provides Better Responses in Patients with Untreated Early Chronic Phase (CP) CML.. Blood, 2006, 108, 2143-2143. | 0.6 | 6 |
| 1398 | Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCELÂ®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy.. Blood, 2006, 108, 2163-2163. | 0.6 | 3 |
| 1399 | Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure.. Blood, 2006, 108, 2164-2164. | 0.6 | 6 |
| 1400 | Immune Modulation of Minimal Residual Disease (MRD) in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CP): A Randomized Trial of Frontline High-Dose (HS) Imatinib Mesylate (IM) with or without Pegylated-Interferon (PEG-IFN) and GM-CSF.. Blood, 2006, 108, 2207-2207. | 0.6 | 8 |
| 1401 | Detection of Residual p73 DNA Methylation Predicts for Shorter Disease Free and Overall Survival in Patients (pts) with Philadelphia (Ph) Chromosome Negative Acute Lymphocytic Leukemia (ALL) in Remission.. Blood, 2006, 108, 2333-2333. | 0.6 | 2 |
| 1402 | A Phase II Study of Azacitidine (Vidazaâ„¢) for Patients with Myelofibrosis (MF).. Blood, 2006, 108, 2706-2706. | 0.6 | 1 |
| 1403 | Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. Blood, 2006, 108, 284-284. | 0.6 | 13 |
| 1404 | Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.. Blood, 2006, 108, 3668-3668. | 0.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1405 | Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM).. Blood, 2006, 108, 432-432. | 0.6 | 14 |
| 1406 | Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Targeted Therapy May Benefit from Prophylactic Measures Against Infections.. Blood, 2006, 108, 4483-4483. | 0.6 | 1 |
| 1407 | MK-0457 Is a Novel Aurora Kinase and Janus Kinase 2 (JAK2) Inhibitor with Activity in Transformed JAK2-Positive Myeloproliferative Disease (MPD).. Blood, 2006, 108, 4893-4893. | 0.6 | 4 |
| 1408 | Decitabine Induces Responses in Patients with Myelodysplastic Syndrome (MDS) after Failure of Azacitidine Therapy.. Blood, 2006, 108, 518-518. | 0.6 | 15 |
| 1409 | Dynamics of BCR-ABL Kinase Domain Mutations in Patients with Chronic Myeloid Leukemia (CML) after Treatment with One, Two or Three Tyrosine Kinase Inhibitors (TKI).. Blood, 2006, 108, 750-750. | 0.6 | 10 |
| 1410 | Prognostic Significance of Î²-2 Microglobulin Levels in Acute Myeloid Leukemia: Analysis of 1293 Patients.. Blood, 2006, 108, 802-802. | 0.6 | 1 |
| 1411 | Characteristics and Outcomes of 38 Patients with Acute Myeloid Leukemia Evolving from Previous Well Characterized Myeloproliferative Disorder.. Blood, 2006, 108, 2705-2705. | 0.6 | 0 |
| 1412 | Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).. Blood, 2006, 108, 1861-1861. | 0.6 | 0 |
| 1413 | Clinical Significance of Loss of Chromosome Y (âˆ’Y) in Patients with Chronic Myeloid Leukemia (CML): Is It Clonal Evolution?.. Blood, 2006, 108, 2117-2117. | 0.6 | 0 |
| 1414 | Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2006, 108, 1999-1999. | 0.6 | 7 |
| 1415 | Effect of Failure To Respond to Targeted Therapy on Response to Cytotoxic Therapy in Pts Age â‰¥ 60 with Newly-Diagnosed AML.. Blood, 2006, 108, 1965-1965. | 0.6 | 3 |
| 1416 | Phase I Trial of Sphingosomal Vincristine (SV, MarqiboÂ®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).. Blood, 2006, 108, 4539-4539. | 0.6 | 0 |
| 1417 | Incidence of Venothromboembolism (VTE) in Patients (pts) with Acute Lymphocytic Leukemia (ALL), Burkittâ€™s Leukemia/Lymphoma (BL) or Lymphoblastic Leukemia (LL).. Blood, 2006, 108, 4534-4534. | 0.6 | 0 |
| 1418 | Methylation Profiling of Three Homogenous Cancers: Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia (APL) and Gastrointestinal Stromal Tumors (GIST).. Blood, 2006, 108, 736-736. | 0.6 | 0 |
| 1419 | Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).. Blood, 2006, 108, 2652-2652. | 0.6 | 1 |
| 1420 | RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines.. Blood, 2006, 108, 2134-2134. | 0.6 | 1 |
| 1421 | Significant Clinical Activity of the Combination of 5-Azacytidine, Valproic Acid and All-Trans Retinoic (ATRA) Acid in Leukemia: Results of a Phase I/II Study.. Blood, 2006, 108, 160-160. | 0.6 | 7 |
| 1422 | PEG-Intron Therapy in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders (MPD): Final Result of a Phase II Study.. Blood, 2006, 108, 3636-3636. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1423 | Frequency of NUP214-ABL1 Oncogene in Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Analysis of the Activity of Imatinib and Nilotinib in NUP214-ABL1-Expressing T-ALL Cell Lines.. Blood, 2006, 108, 710-710. | 0.6 | 0 |
| 1424 | Phase I Study of XL-119, a Rebeccamycin Analog, in Patients with Refractory Hematological Malignancies.. Blood, 2006, 108, 1969-1969. | 0.6 | 0 |
| 1425 | Decitabine Induces High Response Rates in Patients with Chronic Myelomonocytic Leukemia (CMML).. Blood, 2006, 108, 2655-2655. | 0.6 | 23 |
| 1426 | Changes in DNA Methylation of Repetitive Elements during the Progression of Chronic Myelogenous Leukemia.. Blood, 2006, 108, 4302-4302. | 0.6 | 0 |
| 1427 | Clinical Responses to Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Are Associated with Specific Gene Expression Signatures in Patients with Advanced Leukemias: Results of a Phase I Trial.. Blood, 2006, 108, 2320-2320. | 0.6 | 1 |
| 1428 | Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RARS-T) Is a Favorable Prognostic Subgroup.. Blood, 2006, 108, 2612-2612. | 0.6 | 0 |
| 1429 | Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood, 2005, 105, 940-947. | 0.6 | 213 |
| 1430 | Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood, 2005, 105, 2281-2286. | 0.6 | 102 |
| 1431 | Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leukemia Research, 2005, 29, 649-652. | 0.4 | 17 |
| 1432 | Antileukemia activity of the combination of 5-aza-2â€²-deoxycytidine with valproic acid. Leukemia Research, 2005, 29, 739-748. | 0.4 | 167 |
| 1433 | Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leukemia Research, 2005, 29, 881-885. | 0.4 | 18 |
| 1434 | Interferon Î± therapy for patients with essential thrombocythemia. Cancer, 2005, 103, 2551-2557. | 2.0 | 21 |
| 1435 | Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer, 2005, 104, 547-554. | 2.0 | 61 |
| 1436 | Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies. Clinical Cancer Research, 2005, 11, 6615-6624. | 3.2 | 81 |
| 1437 | Phase I Study of BMS-214662, a Farnesyl Transferase Inhibitor in Patients With Acute Leukemias and High-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2005, 23, 2805-2812. | 0.8 | 52 |
| 1438 | Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate. Journal of Clinical Oncology, 2005, 23, 3948-3956. | 0.8 | 290 |
| 1439 | Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate. Clinical Cancer Research, 2005, 11, 3425-3432. | 3.2 | 256 |
| 1440 | Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia. Clinical Cancer Research, 2005, 11, 7817-7824. | 3.2 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1441 | Protein Expression of a Triad of Frequently Methylated Genes, p73, p57Kip2, and p15, Has Prognostic Value in Adult Acute Lymphocytic Leukemia Independently of Its Methylation Status. Journal of Clinical Oncology, 2005, 23, 3932-3939. | 0.8 | 45 |
| 1442 | Future Directions for the Use of Hypomethylating Agents. Seminars in Hematology, 2005, 42, S50-S59. | 1.8 | 21 |
| 1443 | Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic Agents. Cancer Investigation, 2005, 23, 635-642. | 0.6 | 94 |
| 1444 | A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP).. Blood, 2005, 106, 1084-1084. | 0.6 | 8 |
| 1445 | Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Imatinib Mesylate (IM) Therapy in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase.. Blood, 2005, 106, 1090-1090. | 0.6 | 1 |
| 1446 | Outcome of Salvage Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) Who Failed Imatinib after Developing BCR-ABL Kinase Mutation.. Blood, 2005, 106, 1092-1092. | 0.6 | 17 |
| 1447 | Phase II Study of Decitabine in Combination with Imatinib Mesylate in Patients with Accelerated (AP) or Blastic Phase (BP) of Chronic Myeloid Leukemia (CML).. Blood, 2005, 106, 1099-1099. | 0.6 | 3 |
| 1448 | Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP).. Blood, 2005, 106, 1103-1103. | 0.6 | 3 |
| 1449 | Chemo-Immunotherapy with Hyper-CVAD Plus Ritixumab for Adult Burkittâ€™s and Burkittâ€™s Type Lymphoma (BL) or Acute Lymphoblastic Leukemia (B-ALL).. Blood, 2005, 106, 149-149. | 0.6 | 3 |
| 1450 | Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).. Blood, 2005, 106, 1830-1830. | 0.6 | 3 |
| 1451 | Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.. Blood, 2005, 106, 1840-1840. | 0.6 | 1 |
| 1452 | Decitabine Low-Dose Schedule (100 mg/m2/Course) in Myelodysplastic Syndrome (MDS). Comparison of 3 Different Dose Schedules.. Blood, 2005, 106, 2522-2522. | 0.6 | 4 |
| 1453 | Final Results of a Phase I Study of the Histone Deacetylase Inhibitor Vorinostat (Suberoyanilide) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2801-2801. | 0.6 | 14 |
| 1454 | Clofarabine and Clofarabine Plus Low-Dose Cytarabine (ara-C) as Induction Therapy for Patients (pts) â‰¥ 60 Years with Newly Diagnosed Acute Myeloid Leukemia (AML).. Blood, 2005, 106, 2804-2804. | 0.6 | 2 |
| 1455 | Continuous Infusion/Subcutaneous Alemtuzumab (Campath-1H) Plus Rituximab Is Active for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 2963-2963. | 0.6 | 4 |
| 1456 | Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2â€²-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia.. Blood, 2005, 106, 408-408. | 0.6 | 22 |
| 1457 | A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).. Blood, 2005, 106, 4639-4639. | 0.6 | 7 |
| 1458 | A Pilot Trial of Imatinib, Low-Dose Cytarabine (ara-C) and Idarubicin (Ida) in Patients (pts) with Chronic Myeloid Leukemia (CML) in Myeloid Blastic Phase (BP).. Blood, 2005, 106, 4840-4840. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1459 | Secondary Leukemia after Imatinib Mesylate (IM) Therapy for Chronic Myelogenous Leukemia (CML).. Blood, 2005, 106, 4862-4862. | 0.6 | 1 |
| 1460 | Clinical Relevance of CRp in Untreated AML.. Blood, 2005, 106, 541-541. | 0.6 | 13 |
| 1461 | Blockade of Adaptive Defensive Changes in Cholesterol Uptake and Synthesis in AML by the Addition of Pravastatin to Idarubicin + High Dose Ara-C: A Phase I Study.. Blood, 2005, 106, 405-405. | 0.6 | 1 |
| 1462 | Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome - Predictive Prognostic Models for Outcome.. Blood, 2005, 106, 1846-1846. | 0.6 | 12 |
| 1463 | Phase I Study of TriapineÂ® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 4925-4925. | 0.6 | 0 |
| 1464 | Study of Intra-Venous Homoharringtonine (HHT) in the Treatment of Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 4903-4903. | 0.6 | 1 |
| 1465 | Clofarabine Combinations in Acute Myeloid Leukemia (AML) Salvage: A Dose-Finding Phase I Study of Clofarabine Plus Idarubicin and Clofarabine/Idarubicin Plus Cytarabine (ara-C).. Blood, 2005, 106, 2803-2803. | 0.6 | 0 |
| 1466 | Farnesyl Transferase Inhibitor (Tipifarnib, Zarnestra; Z) in Combination with Standard Chemotherapy with Idarubicin (Ida) and Cytarabine (ara-C) for Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS).. Blood, 2005, 106, 2796-2796. | 0.6 | 1 |
| 1467 | The Cyclin-Dependent Kinase Inhibitor p57KIP2 Functions as a Tumor Suppressor Gene in Human Leukemia.. Blood, 2005, 106, 1604-1604. | 0.6 | 54 |
| 1468 | Aberrant DNA Methylation of a Cell Cycle Regulatory Pathway Composed of p73, p15 and P57kip2 Is Associated with Poor Prognosis in Adult Patients with Philadelphia Chromosome Negative Acute Lymphocytic Leukemia (ALL).. Blood, 2005, 106, 481-481. | 0.6 | 0 |
| 1469 | Leukemia and lymphoma: what is the role for intrathecal prophylactic treatment in adults?. Expert Review of Neurotherapeutics, 2004, 4, S25-S31. | 1.4 | 2 |
| 1470 | Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma. Clinical Cancer Research, 2004, 10, 88-95. | 3.2 | 110 |
| 1471 | Hypermethylation and Silencing of the Putative Tumor Suppressor Tazarotene-Induced Gene 1 in Human Cancers. Cancer Research, 2004, 64, 2411-2417. | 0.4 | 80 |
| 1472 | Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-Î± Failure and in Late CML-CP, Comparison with Historical Controls. Clinical Cancer Research, 2004, 10, 68-75. | 3.2 | 56 |
| 1473 | A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia. Clinical Cancer Research, 2004, 10, 2908-2917. | 3.2 | 47 |
| 1474 | Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias. Clinical Cancer Research, 2004, 10, 3371-3376. | 3.2 | 195 |
| 1475 | Phase II Study of R115777, a Farnesyl Transferase Inhibitor, in Myelodysplastic Syndrome. Journal of Clinical Oncology, 2004, 22, 1287-1292. | 0.8 | 141 |
| 1476 | Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. British Journal of Haematology, 2004, 125, 187-195. | 1.2 | 88 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1477 | Cytoprotection in Acute Myelogenous Leukemia (AML) therapy. Seminars in Oncology, 2004, 31, 67-73. | 0.8 | 14 |
| 1478 | Management of patients with systemic mastocytosis: Review of M. D. Anderson Cancer Center experience. American Journal of Hematology, 2004, 77, 209-214. | 2.0 | 47 |
| 1479 | Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer, 2004, 100, 581-589. | 2.0 | 41 |
| 1480 | Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer, 2004, 100, 2592-2597. | 2.0 | 59 |
| 1481 | C-kit receptor expression in acute leukemiasâ€"association with patient and disease characteristics and with outcome. Leukemia Research, 2004, 28, 373-378. | 0.4 | 21 |
| 1482 | Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leukemia Research, 2004, 28, 657-660. | 0.4 | 10 |
| 1483 | Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leukemia Research, 2004, 28, 991-994. | 0.4 | 32 |
| 1484 | Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2â€²-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004, 103, 1635-1640. | 0.6 | 783 |
| 1485 | High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosomeâ€“positive chronic phase chronic myeloid leukemia. Blood, 2004, 103, 2873-2878. | 0.6 | 369 |
| 1486 | Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood, 2004, 103, 4396-4407. | 0.6 | 522 |
| 1487 | Long-Term Incidence and Outcome of BCR-ABL Mutations in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Mesylate - P-Loop Mutations Are Not Associated with Worse Outcome.. Blood, 2004, 104, 1007-1007. | 0.6 | 4 |
| 1488 | A Phase I Study of Tipifarnib in Combination with Imatinib Mesylate (IM) for Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Who Failed IM Therapy.. Blood, 2004, 104, 1011-1011. | 0.6 | 8 |
| 1489 | PEG-Intron for Myeloproliferative Diseases: An Update of Ongoing Phase II Study.. Blood, 2004, 104, 1517-1517. | 0.6 | 7 |
| 1490 | A Phase I/II Study of Intravenous LBH589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Patients (pts) with Advanced Hematologic Malignancies.. Blood, 2004, 104, 1802-1802. | 0.6 | 2 |
| 1491 | Results of a Phase I/II Study of the Combination of 5-aza-2â€²-Deoxycytidine (DAC) and Valproic Acid (VPA) in Patients (pts) with Leukemia.. Blood, 2004, 104, 263-263. | 0.6 | 15 |
| 1492 | Clinical Significance of Molecular Monitoring in Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Imatinib Therapy.. Blood, 2004, 104, 272-272. | 0.6 | 2 |
| 1493 | Hypomethylation Dynamics Following Decitabine Therapy in Chronic Myelogenous Leukemia.. Blood, 2004, 104, 2956-2956. | 0.6 | 4 |
| 1494 | Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.. Blood, 2004, 104, 3297-3297. | 0.6 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1495 | Use of All-Transretinoic Acid (ATRA) + Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL).. Blood, 2004, 104, 393-393. | 0.6 | 5 |
| 1496 | A Phase II Study of Temsirolimus (CCI-779) in Patients with Advanced Leukemias.. Blood, 2004, 104, 4523-4523. | 0.6 | 2 |
| 1497 | Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) â‰¥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).. Blood, 2004, 104, 875-875. | 0.6 | 6 |
| 1498 | Plausibility of Delaying Induction Therapy in Untreated AML.. Blood, 2004, 104, 879-879. | 0.6 | 4 |
| 1499 | Characteristics and Prognosis of Patients (pts) with Acute Megakaryocytic Leukemia (AMegL) Treated at M.D. Anderson Cancer Center Since 1987.. Blood, 2004, 104, 3003-3003. | 0.6 | 1 |
| 1500 | 2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES).. Blood, 2004, 104, 4764-4764. | 0.6 | 0 |
| 1501 | Prolonged Administration of Arsenic Trioxide (TrisenoxÂ®) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study.. Blood, 2004, 104, 4731-4731. | 0.6 | 1 |
| 1502 | Aberrant DNA Methylation of the Src Tyrosine Kinase Hck Is a Frequent Event in Human Leukemia and May Predict for Poor Prognosis in Adult Acute Lymphocytic Leukemia (ALL).. Blood, 2004, 104, 1542-1542. | 0.6 | 1 |
| 1503 | ARTS, a Pro-Apoptotic Mitochondrial Septin-Like Protein That Binds to XIAP, Is Silenced in Acute Lymphoblastic and Primitive Acute Myeloblastic Leukemia Cells.. Blood, 2004, 104, 3378-3378. | 0.6 | 9 |
| 1504 | Detection of Aberrant DNA Methylation in Acute Lymphocytic Leukemia (ALL) Using a Real-Time Polymerase Chain Reaction (PCR) Assay.. Blood, 2004, 104, 998-998. | 0.6 | 0 |
| 1505 | Is the Proposed World Health Organization (WHO) Classification for Chronic Myeloid Leukemia (CML) of Clinical Value in the Imatinib Era?.. Blood, 2004, 104, 1014-1014. | 0.6 | 1 |
| 1506 | Survival Advantage for Patients (pts) with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) Treated with Imatinib.. Blood, 2004, 104, 1006-1006. | 0.6 | 0 |
| 1507 | Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome.. Blood, 2004, 104, 4530-4530. | 0.6 | 0 |
| 1508 | Phase I Study of Clofarabine Plus Idarubicin and Clofarabine Plus Idarubicin Plus Cytarabine (ARA-C) in Patients (PTS) with Relapsed and Primary Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloid Blast Phase of Chronic Myeloid Leukemia (CML).. Blood, 2004, 104, 1809-1809. | 0.6 | 0 |
| 1509 | Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2003, 51, 87-90. | 1.1 | 71 |
| 1510 | Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology, 2003, 52, 449-452. | 1.1 | 31 |
| 1511 | Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer, 2003, 97, 695-702. | 2.0 | 66 |
| 1512 | Phase II study of SU5416â€"a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitorâ€"in patients with refractory myeloproliferative diseases. Cancer, 2003, 97, 1920-1928. | 2.0 | 95 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1513 | Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer, 2003, 97, 2760-2766. | 2.0 | 107 |
| 1514 | Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer, 2003, 97, 3010-3016. | 2.0 | 10 |
| 1515 | Chronic myelogenous leukemia: A review and update of therapeutic strategies. Cancer, 2003, 98, 437-457. | 2.0 | 84 |
| 1516 | Results of decitabine (5-aza-2?deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer, 2003, 98, 522-528. | 2.0 | 230 |
| 1517 | Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-? regimens for early chronic phase. Cancer, 2003, 98, 1430-1437. | 2.0 | 19 |
| 1518 | Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer, 2003, 98, 1905-1911. | 2.0 | 124 |
| 1519 | Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase. Cancer, 2003, 98, 2636-2642. | 2.0 | 89 |
| 1520 | Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leukemia Research, 2003, 27, 301-304. | 0.4 | 11 |
| 1521 | Empirical examination of the neutrophil criterion (>1500 Î¼lâ^'1) currently needed to declare CR in AML. Leukemia Research, 2003, 27, 475-479. | 0.4 | 6 |
| 1522 | Prognostic implications of epigenetic silencing of p15INK4B in acute promyelocytic leukemia. Leukemia, 2003, 17, 839-840. | 3.3 | 5 |
| 1523 | Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research, 2003, 27, 893-897. | 0.4 | 74 |
| 1524 | Phase I and pharmacodynamic study of TriapineÂ®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leukemia Research, 2003, 27, 1077-1083. | 0.4 | 89 |
| 1525 | DNA methylation in haematological malignancies: the role of decitabine. Expert Opinion on Investigational Drugs, 2003, 12, 1985-1993. | 1.9 | 28 |
| 1526 | Randomized Phase I/II Study of Troxacitabine Combined With Cytarabine, Idarubicin, or Topotecan in Patients With Refractory Myeloid Leukemias. Journal of Clinical Oncology, 2003, 21, 1050-1056. | 0.8 | 38 |
| 1527 | Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 2003, 102, 2379-2386. | 0.6 | 313 |
| 1528 | Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid Leukemia. Journal of Clinical Oncology, 2003, 21, 1722-1727. | 0.8 | 86 |
| 1529 | Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 2003, 101, 473-475. | 0.6 | 304 |
| 1530 | Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood, 2003, 101, 3413-3415. | 0.6 | 247 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1531 | Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 2003, 101, 1692-1697. | 0.6 | 210 |
| 1532 | Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood, 2003, 101, 4131-4136. | 0.6 | 127 |
| 1533 | Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood, 2003, 101, 3794-3800. | 0.6 | 215 |
| 1534 | Result of high-dose imatinib mesylate in patients with Philadelphia chromosomeâ€"positive chronic myeloid leukemia after failure of interferon-Î±. Blood, 2003, 102, 83-86. | 0.6 | 174 |
| 1535 | Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosomeâ€"positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood, 2003, 101, 97-100. | 0.6 | 147 |
| 1536 | Fatal Hepatic Veno-Occlusive Disease in a Phase I Study of Mylotarg and Troxatyl in Patients with Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Acta Haematologica, 2002, 108, 164-167. | 0.7 | 16 |
| 1537 | Current Therapy of Chronic Myelogenous Leukemia.. Internal Medicine, 2002, 41, 254-264. | 0.3 | 16 |
| 1538 | Imatinib mesylate (STI571) therapy for Philadelphia chromosomeâ€"positive chronic myelogenous leukemia in blast phase. Blood, 2002, 99, 3547-3553. | 0.6 | 282 |
| 1539 | Lack of p21CIP1 DNA methylation in acute lymphocytic leukemia. Blood, 2002, 100, 3432-3433. | 0.6 | 23 |
| 1540 | Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia. Journal of Clinical Oncology, 2002, 20, 656-664. | 0.8 | 73 |
| 1541 | Simultaneous homoharringtonine and interferon-Î± in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer, 2002, 94, 2024-2032. | 2.0 | 65 |
| 1542 | DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clinical Cancer Research, 2002, 8, 1897-903. | 3.2 | 60 |
| 1543 | Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia. Clinical Cancer Research, 2002, 8, 2134-41. | 3.2 | 23 |
| 1544 | Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clinical Cancer Research, 2002, 8, 2167-76. | 3.2 | 84 |
| 1545 | Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clinical Cancer Research, 2002, 8, 2177-87. | 3.2 | 97 |
| 1546 | DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clinical Cancer Research, 2002, 8, 2217-24. | 3.2 | 158 |
| 1547 | A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica, 2002, 87, 804-7. | 1.7 | 8 |
| 1548 | Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 2002, 100, 1590-5. | 0.6 | 62 |

| # | Article | IF | Citations |
|---|---|---|---|
| 1549 | Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica, 2002, 87, 1114-6. | 1.7 | 18 |
| 1550 | Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia. Hematology/Oncology Clinics of North America, 2001, 15, 163-205. | 0.9 | 65 |
| 1551 | Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia. Investigational New Drugs, 2001, 19, 13-20. | 1.2 | 10 |
| 1552 | THE HYPER-CVAD REGIMEN IN ADULT ACUTE LYMPHOCYTIC LEUKEMIA. Hematology/Oncology Clinics of North America, 2000, 14, 1381-1396. | 0.9 | 55 |
| 1553 | Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. , 1999, 60, 130-135. | | 77 |
| 1554 | Colocalization of Tissue Transglutaminase and Stress Fibers in Human Vascular Smooth Muscle Cells and Human Umbilical Vein Endothelial Cells. Experimental Cell Research, 1997, 231, 38-49. | 1.2 | 44 |
| 1555 | Epigenetics of leukemia. , 0, , 239-256. | | 0 |
| 1556 | Myeloid neoplasms with 8q24/ <scp> MYC </scp> rearrangement are frequently associated with myelodysplasia, complex karyotype, <scp> TP53 </scp> alterations, and inferior survival. British Journal of Haematology, 0, , . | 1.2 | 0 |